<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003633.pub3" GROUP_ID="MOVEMENT" ID="032503031700542198" MERGED_FROM="" MODIFIED="2017-12-04 15:12:14 +0000" MODIFIED_BY="Ema Roque" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0"><COVER_SHEET MODIFIED="2017-11-14 18:46:16 +0000" MODIFIED_BY="[Empty name]"><TITLE>Botulinum toxin type A therapy for cervical dystonia</TITLE><CONTACT><PERSON ID="FDF5556E82E26AA201D6C2758D661DA8" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>João</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Costa</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Co-ordinating Editor</POSITION><EMAIL_1>jncosta@medicina.ulisboa.pt</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT><ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION><ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1><ADDRESS_2/><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><REGION/><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+351 217802120</PHONE_1><PHONE_2/><FAX_1>+351 21 7802129</FAX_1><FAX_2/></ADDRESS><FOOTNOTE/></PERSON></CONTACT><CREATORS MODIFIED="2017-11-14 15:14:08 +0000" MODIFIED_BY="Gonçalo Duarte"><PERSON ID="z1309131047147899672215461982225" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Mafalda</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Castelão</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>mcastelao@outlook.com</EMAIL_1><EMAIL_2/><URL>www.medicina.ulisboa.pt</URL><MOBILE_PHONE>+351969668033</MOBILE_PHONE><ADDRESS><DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT><ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION><ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1><ADDRESS_2/><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><REGION/><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE>These authors contributed equally to this work.</FOOTNOTE></PERSON><PERSON ID="z1309131050199323179683584225320" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Raquel</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Marques</LAST_NAME><SUFFIX/><POSITION>Researcher</POSITION><EMAIL_1>amarques5@campus.ul.pt</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT><ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION><ADDRESS_1>Av. Professor Egas Moniz</ADDRESS_1><ADDRESS_2/><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><REGION/><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE>These authors contributed equally to this work.</FOOTNOTE></PERSON><PERSON ID="z1307091141448665579807736261374" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gonçalo</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Duarte</LAST_NAME><SUFFIX/><POSITION>Researcher</POSITION><EMAIL_1>gduarte@campus.ul.pt</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE>+351914662729</MOBILE_PHONE><ADDRESS><DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT><ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION><ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1><ADDRESS_2/><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><REGION>Lisboa</REGION><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+351914662729</PHONE_1><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE>These authors contributed equally to this work.</FOOTNOTE></PERSON><PERSON ID="z1408111518211702342261129499685" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Filipe</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Rodrigues</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Researcher</POSITION><EMAIL_1>filipebrodrigues@gmail.com</EMAIL_1><EMAIL_2>f.rodrigues@ucl.ac.uk</EMAIL_2><URL/><MOBILE_PHONE>00447484169226</MOBILE_PHONE><ADDRESS><DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT><ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION><ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1><ADDRESS_2/><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><REGION/><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE>These authors contributed equally to this work.</FOOTNOTE></PERSON><PERSON ID="6005" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Joaquim</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Ferreira</LAST_NAME><SUFFIX/><POSITION>Director</POSITION><EMAIL_1>joaquimjferreira@gmail.com</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT><ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION><ADDRESS_1>Hospital de Santa Maria</ADDRESS_1><ADDRESS_2>Av. Prof. Egas Moniz</ADDRESS_2><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><REGION/><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+ 351 21 797 3453</PHONE_1><PHONE_2/><FAX_1>+ 351 21 780 2129</FAX_1><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="6111" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Cristina</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Sampaio</LAST_NAME><SUFFIX/><POSITION>Chief Medical Officer</POSITION><EMAIL_1>Cristina.Sampaio@chdifoundation.org</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT/><ORGANISATION>CHDI Foundation</ORGANISATION><ADDRESS_1>155 Village Boulevard</ADDRESS_1><ADDRESS_2>Suite 200</ADDRESS_2><CITY>Princeton</CITY><ZIP>08540</ZIP><REGION>NJ</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="14820" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Austen</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Moore</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION/><EMAIL_1>peter.moore@thewaltoncentre.nhs.uk</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT/><ORGANISATION>The Walton Centre NHS Foundation Trust</ORGANISATION><ADDRESS_1>Lower Lane</ADDRESS_1><ADDRESS_2/><CITY>Liverpool</CITY><ZIP>L9 7LJ</ZIP><REGION/><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+ 44 151 225 3611</PHONE_1><PHONE_2/><FAX_1>+ 44 151 529 4638</FAX_1><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="FDF5556E82E26AA201D6C2758D661DA8" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>João</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Costa</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Co-ordinating Editor</POSITION><EMAIL_1>jncosta@medicina.ulisboa.pt</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT><ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION><ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1><ADDRESS_2/><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><REGION/><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+351 217802120</PHONE_1><PHONE_2/><FAX_1>+351 21 7802129</FAX_1><FAX_2/></ADDRESS><FOOTNOTE/></PERSON></CREATORS><DATES MODIFIED="2017-11-14 18:46:16 +0000" MODIFIED_BY="[Empty name]"><UP_TO_DATE><DATE DAY="6" MONTH="10" YEAR="2016"/></UP_TO_DATE><LAST_SEARCH><DATE DAY="6" MONTH="10" YEAR="2016"/></LAST_SEARCH><NEXT_STAGE><DATE DAY="7" MONTH="12" YEAR="2020"/></NEXT_STAGE><PROTOCOL_PUBLISHED ISSUE="2" YEAR="2002"/><REVIEW_PUBLISHED ISSUE="1" YEAR="2005"/><LAST_CITATION_ISSUE ISSUE="12" YEAR="2017"/></DATES><WHATS_NEW MODIFIED="2017-11-14 15:20:41 +0000" MODIFIED_BY="[Empty name]"><WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-11-14 15:20:41 +0000" MODIFIED_BY="[Empty name]"><DATE DAY="14" MONTH="11" YEAR="2016"/><DESCRIPTION><P>New authorship, accumulation of changes, re-assessment and rewriting according to new quality standards, addition of a 'Summary of findings' table</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-10-16 09:22:09 +0100" MODIFIED_BY="[Empty name]"><DATE DAY="6" MONTH="10" YEAR="2016"/><DESCRIPTION><P>Three new trials enrolling 562 participants overall were included in the meta-analysis and systematic review (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>)</P></DESCRIPTION></WHATS_NEW_ENTRY></WHATS_NEW><HISTORY MODIFIED="2016-05-23 19:47:50 +0100" MODIFIED_BY="[Empty name]"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-05-23 19:47:50 +0100" MODIFIED_BY="[Empty name]"><DATE DAY="6" MONTH="10" YEAR="2008"/><DESCRIPTION><P>Converted to new review format.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS"><DATE DAY="25" MONTH="10" YEAR="2004"/><DESCRIPTION><P>Substantive amendment</P></DESCRIPTION></WHATS_NEW_ENTRY></HISTORY><SOURCES_OF_SUPPORT MODIFIED="2017-11-14 18:31:51 +0000" MODIFIED_BY="[Empty name]"><INTERNAL_SOURCES MODIFIED="2017-11-14 18:31:51 +0000" MODIFIED_BY="[Empty name]"><SOURCE MODIFIED="2017-11-14 18:31:51 +0000" MODIFIED_BY="[Empty name]"><NAME>Cochrane Movement Disorders</NAME><COUNTRY CODE="PT">Portugal</COUNTRY><DESCRIPTION/></SOURCE><SOURCE><NAME>The Walton Centre for Neurology and Neurosurgery</NAME><COUNTRY CODE="GB">UK</COUNTRY><DESCRIPTION/></SOURCE></INTERNAL_SOURCES><EXTERNAL_SOURCES/></SOURCES_OF_SUPPORT><MESH_TERMS VERIFIED="NO"/><KEYWORDS/></COVER_SHEET><MAIN_TEXT MODIFIED="2017-11-14 18:43:23 +0000" MODIFIED_BY="[Empty name]"><SUMMARY MODIFIED="2017-11-14 15:20:41 +0000" MODIFIED_BY="[Empty name]"><TITLE MODIFIED="2016-06-06 18:51:21 +0100" MODIFIED_BY="[Empty name]">Treatment with botulinum toxin type A for people with involuntary posturing of the head, or cervical dystonia</TITLE><SUMMARY_BODY MODIFIED="2017-11-14 15:20:41 +0000" MODIFIED_BY="[Empty name]"><P><B>The review question</B></P><P>We reviewed the evidence about the effect of botulinum toxin type A (BtA) in people with involuntary positioning of the head, or cervical dystonia. This is an update of a previous Cochrane Review and we assessed the effectiveness (reduction in severity, disability and pain) and safety of BtA versus placebo (a pretend medicine) in cervical dystonia.</P><P><B>Background</B></P><P>Cervical dystonia, also called spasmodic torticollis, is a disease that causes undesired, uncontrollable, often painful, abnormal placement of the head. It is a relatively uncommon condition (affecting 57 to 280 people per million) that can be very disabling and can affect a person's quality of life negatively. In most cases the cause is unknown and no cure exists. Since cervical dystonia is normally a long-term disease it requires long-term treatment.</P><P>Botulinum toxin is a powerful, natural chemical that can cause severe paralysis (an inability to move in the part of the body where it is applied) in animals and humans<I>. </I>It can also be used to treat many conditions, in particular those with involuntary muscle contractions, such as cervical dystonia. Botulinum toxin is delivered by injections into the muscles that contract to produce most of the disease symptoms. There are different types of botulinum toxin, not all are available for treating health conditions. BtA is typically considered the first treatment option in cervical dystonia.</P><P><B>Study characteristics </B></P><P>We performed a rigorous search of the medical literature in October 2016 and found eight studies that compared treatment with BtA versus placebo. These studies included a total of 1010 participants, with on average a moderate disease impairment. The participants remained in the majority of studies for a short period of time - between 16 and 20 weeks after the treatment. The average age of people in the studies was 52.3 years, and they had had cervical dystonia for an average of 4.8 to 12.1 years before taking part in the trials. Most, 64%, of the people in the studies were women. Seven of the eight trials were funded by drug manufacturers with possible interests in the results of the studies.</P><P><B>Key results </B></P><P>The results show that a single treatment session improved cervical dystonia symptoms, including pain, and participant's self-evaluations. However, the risk of having an unpleasant or undesirable event, particularly swallowing difficulties and tiredness, was also increased. Only three studies examined the impact of BtA on quality of life, suggesting some benefit from BtA.</P><P><B>Certainty in the evidence </B></P><P>The certainty in the evidence for overall and pain improvement, the risk of undesired events, self-evaluation, the risk of swallowing difficulties, and the risk of participants not tolerating treatment, is moderate.</P><P>Nevertheless, to be included in the studies, participants had to have a history of successful treatment with BtA. People with certain types of cervical dystonia, in particular the types that make the head turn mostly backward or forward, were not allowed to participate in the studies, and it is known that these types respond less to botulinum toxin treatment. Therefore, the conclusions from this review may not apply to all people with cervical dystonia.</P><P>We can draw no conclusions regarding long-term effects of BtA for this condition.</P></SUMMARY_BODY></SUMMARY><ABSTRACT MODIFIED="2017-11-14 18:43:23 +0000" MODIFIED_BY="[Empty name]"><ABS_BACKGROUND MODIFIED="2017-11-14 15:20:41 +0000" MODIFIED_BY="[Empty name]"><P>This is an update of a Cochrane Review first published in 2005. Cervical dystonia is the most common form of focal dystonia and is a highly disabling movement disorder characterised by involuntary, usually painful, head posturing. Currently, botulinum toxin type A (BtA) is considered the first line therapy for this condition.</P></ABS_BACKGROUND><ABS_OBJECTIVES MODIFIED="2016-10-22 22:07:20 +0100" MODIFIED_BY="[Empty name]"><P>To compare the efficacy, safety, and tolerability of botulinum toxin type A (BtA) versus placebo in people with cervical dystonia.</P></ABS_OBJECTIVES><ABS_SEARCH_STRATEGY MODIFIED="2017-11-14 18:42:16 +0000" MODIFIED_BY="[Empty name]"><P>To identify studies for this review we searched Cochrane Movement Disorders' Trials Register, CENTRAL, MEDLINE, Embase, reference lists of articles and conference proceedings. All elements of the search, with no language restrictions, were run in October 2016.</P></ABS_SEARCH_STRATEGY><ABS_SELECTION_CRITERIA MODIFIED="2016-05-22 19:22:35 +0100" MODIFIED_BY="[Empty name]"><P>Double-blind, parallel, randomised, placebo-controlled trials (RCTs) of BtA versus placebo in adults with cervical dystonia.</P></ABS_SELECTION_CRITERIA><ABS_DATA_COLLECTION MODIFIED="2017-11-14 15:20:41 +0000" MODIFIED_BY="[Empty name]"><P>Two review authors independently assessed records, selected included studies, extracted data using a paper pro forma, and evaluated the risk of bias. We resolved disagreements by consensus or by consulting a third review author. We performed meta-analyses using a random-effects model for the comparison of BtA versus placebo to estimate pooled effects and corresponding 95% confidence intervals (95% CI). In addition, we performed preplanned subgroup analyses according to BtA dose used, the BtA formulation used, and the use or not of guidance for BtA injection. The primary efficacy outcome was improvement in cervical dystonia-specific impairment. The primary safety outcome was the proportion of participants with any adverse event.</P></ABS_DATA_COLLECTION><ABS_RESULTS MODIFIED="2017-11-14 18:43:23 +0000" MODIFIED_BY="[Empty name]"><P>We included eight RCTs of moderate overall risk of bias, including 1010 participants with cervical dystonia. Six studies excluded participants with poorer responses to BtA treatment, therefore including an enriched population with a higher probability of benefiting from this therapy. Only one trial was independently funded. All RCTs evaluated the effect of a single BtA treatment session, using doses from 150 U to 236 U of onabotulinumtoxinA (Botox), 120 U to 240 U of incobotulinumtoxinA (Xeomin), and 250 U to 1000 U of abobotulinumtoxinA (Dysport).</P><P>BtA was associated with a moderate-to-large improvement in the participant's baseline clinical status as assessed by investigators, with reduction of 8.06 points in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS total score) at week 4 after injection (95% CI 6.08 to 10.05; I<SUP>2</SUP> = 0%) compared to placebo, corresponding on average to a 18.7% improvement from baseline. The mean difference (MD) in TWSTRS pain subscore at week 4 was 2.11 (95% CI 1.38 to 2.83; I<SUP>2</SUP> = 0%). Overall, both participants and clinicians reported an improvement of subjective clinical status. There were no differences between groups regarding withdrawals due to adverse events. However, BtA treatment was associated with an increased risk of experiencing an adverse event (risk ratio (RR) 1.19; 95% CI 1.03 to 1.36; I<SUP>2</SUP> = 16%). Dysphagia (9%) and diffuse weakness/tiredness (10%) were the most common treatment-related adverse events (dysphagia: RR 3.04; 95% CI 1.68 to 5.50; I<SUP>2</SUP> = 0%; diffuse weakness/tiredness: RR 1.78; 95% CI 1.08 to 2.94; I<SUP>2</SUP> = 0%). Treatment with BtA was associated with a decreased risk of participants withdrawing from trials. We have moderate certainty in the evidence across all of the aforementioned outcomes.</P><P>We found no evidence supporting the existence of a clear dose-response relationship with BtA, nor a difference between BtA formulations, nor a difference with use of EMG-guided injection.</P><P>Due to clinical heterogeneity, we did not pool data regarding health-related quality of life, duration of clinical effect, or the development of secondary non-responsiveness.</P></ABS_RESULTS><ABS_CONCLUSIONS MODIFIED="2017-11-14 15:20:41 +0000" MODIFIED_BY="[Empty name]"><P>We have moderate certainty in the evidence that a single BtA treatment session is associated with a significant and clinically relevant reduction of cervical dystonia-specific impairment, including severity, disability, and pain, and that it is well tolerated, when compared with placebo. There is also moderate certainty in the evidence that people treated with BtA are at an increased risk of developing adverse events, most notably dysphagia and diffuse weakness. There are no data from RCTs evaluating the effectiveness and safety of repeated BtA injection cycles. There is no evidence from RCTs to allow us to draw definitive conclusions on the optimal treatment intervals and doses, usefulness of guidance techniques for injection, the impact on quality of life, or the duration of treatment effect.</P></ABS_CONCLUSIONS></ABSTRACT><BODY MODIFIED="2017-11-14 18:19:19 +0000" MODIFIED_BY="[Empty name]"><BACKGROUND MODIFIED="2017-11-14 15:20:41 +0000" MODIFIED_BY="[Empty name]"><P>This review is an update of a review previously published in the Cochrane Database of Systematic Reviews 2005, Issue 1 (<LINK REF="REF-Costa-2005" TYPE="REFERENCE">Costa 2005</LINK>), evaluating the efficacy and safety of botulinum toxin type A (BtA) versus placebo in the treatment of cervical dystonia.</P><CONDITION MODIFIED="2017-01-24 19:40:36 +0000" MODIFIED_BY="[Empty name]"><P>See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for glossary of terms.</P><P>Dystonia is the third most common movement disorder, after Parkinson&#8217;s disease and essential tremor, with an overall prevalence of 164 per million (<LINK REF="REF-Steeves-2012" TYPE="REFERENCE">Steeves 2012</LINK>). Dystonia syndromes are a group of disabling, painful disorders characterised by involuntary sustained or intermittent muscle contractions causing abnormal, often repetitive, movements or postures of the face, neck, trunk or limbs (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>). Dystonic movements are typically patterned or twisting, and are often initiated or worsened by voluntary action (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>). These neurological disorders can be classified based on topographic distribution, including focal dystonia (one body region, e.g. cervical dystonia and blepharospasm), segmental dystonia (two or more adjacent regions), multifocal dystonia (two or more nonadjacent regions), hemidystonia (ipsilateral regions) and generalised dystonia (trunk and two or more other regions) (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>; <LINK REF="REF-Tarsy-2006" TYPE="REFERENCE">Tarsy 2006</LINK>).</P><P>Focal dystonia is a highly disabling movement disorder, with serious functional and social impairment. Close to half of the patient population quits work by the age of forty or retires early due to dystonia, and 10 years later, only 25% of people are working compared to 62% of the general population (<LINK REF="REF-Zoons-2012" TYPE="REFERENCE">Zoons 2012</LINK>). Moreover, health-related quality of life is significantly diminished, mainly attributable to depression and anxiety, with scores comparable to people with multiple sclerosis, Parkinson&#8217;s disease or stroke (<LINK REF="REF-Zoons-2012" TYPE="REFERENCE">Zoons 2012</LINK>).</P><P>Cervical dystonia, also called spasmodic torticollis, is the most common form of adult-onset focal dystonia, with estimates from population studies ranging from 57 per million in Europe (<LINK REF="REF-ESDE-2000" TYPE="REFERENCE">ESDE 2000</LINK>) to as high as 280 per million in the USA (<LINK REF="REF-Jankovic-2006" TYPE="REFERENCE">Jankovic 2006</LINK>). It typically has its onset in the fifth decade (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>), and affects more women than men (<LINK REF="REF-Defazio-2013" TYPE="REFERENCE">Defazio 2013</LINK>). This condition is characterised by abnormal movements of the head, neck, and shoulder, resulting in posturing of the head away from its normal central position (<LINK REF="REF-Foltz-1959" TYPE="REFERENCE">Foltz 1959</LINK>). It may present predominantly with sustained abnormal posture, spasm, jerks, tremor, or a combination of these features. Neck or shoulder pain, or both, occur in more than 70% of individuals with cervical dystonia (<LINK REF="REF-Chan-1991" TYPE="REFERENCE">Chan 1991</LINK>; <LINK REF="REF-Tarsy-2006" TYPE="REFERENCE">Tarsy 2006</LINK>).</P><P>Cervical dystonia can be classified according to the dominant head position, with the most common type involving horizontal turning, the so-called rotatory (or simple) torticollis (<LINK REF="REF-Chan-1991" TYPE="REFERENCE">Chan 1991</LINK>; <LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>). Other common patterns include laterocollis (tilt to one side), retrocollis (tilt upwards resulting in neck extension) and anterocollis (tilt downwards resulting in neck flexion). Among all forms of cervical dystonia, complex torticollis, a combination of these abnormal patterns, is found relatively frequently in clinical practice.</P><P>The aetiology of most forms of dystonia is still not fully understood, with the exception of early-onset dystonia, for which a hereditary aetiology is common (<LINK REF="REF-Balint-2015" TYPE="REFERENCE">Balint 2015</LINK>). In most cases of focal adult-onset dystonia, such as cervical dystonia, the pathophysiology is generally considered to result from inhibition of the central nervous system (CNS) at multiple levels (<LINK REF="REF-Hallett-1998" TYPE="REFERENCE">Hallett 1998</LINK>) resulting in abnormal sensorimotor integration. Cervical dystonia can also be secondary to brain injury, infections of the CNS, drugs (such as levodopa or antipsychotics), toxics, vascular or neoplastic disorders and may also be psychogenic (i.e. functional) (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>). Although most cases of cervical dystonia are currently classified as idiopathic, it should be observed that some may come to be reclassified as inherited, since new gene discoveries are under investigation (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>; <LINK REF="REF-Balint-2015" TYPE="REFERENCE">Balint 2015</LINK>).</P><P>The natural course of cervical dystonia remains unclear. It usually develops gradually and deteriorates over the initial years. The clinical presentation in adults seldom progresses to generalised dystonia, although it often extends to contiguous body regions. For most individuals, cervical dystonia is a life-long disorder, with only about 10% undergoing spontaneous remissions (<LINK REF="REF-Jahnanshani-1990" TYPE="REFERENCE">Jahnanshani 1990</LINK>).</P><P>To date, no curative or disease-modifying treatments are available for cervical dystonia.</P></CONDITION><INTERVENTION MODIFIED="2017-11-14 15:20:41 +0000" MODIFIED_BY="[Empty name]"><P>Botulinum toxin is a powerful biological toxin produced by <I>Clostridium botulinum</I>. The active form of botulinum toxin is a di-chain polypeptide composed of two chains: a heavy chain (100 kDa) and a light chain (50 kDa), and by associating with certain auxiliary proteins (haemagglutinins and non-haemagglutinins), the toxin forms a non-covalent multimeric complex of variable size (<LINK REF="REF-Simpson-2004" TYPE="REFERENCE">Simpson 2004</LINK>). The nontoxic proteins aid the formation of neutralising antibodies, though beyond this their role is unclear (<LINK REF="REF-Frevert-2010" TYPE="REFERENCE">Frevert 2010</LINK>). Botulinim toxin binds to peripheral cholinergic nerve terminals of the neuromuscular junction as well as sympathetic ganglionic, parasympathetic ganglionic, and postganglionic terminals (<LINK REF="REF-Simpson-2004" TYPE="REFERENCE">Simpson 2004</LINK>). After binding to an acceptor protein, botulinum toxin is endocytosed at the presynaptic membrane of acetylcholine nerve terminals (<LINK REF="REF-Pellizzari-1999" TYPE="REFERENCE">Pellizzari 1999</LINK>). By action of the N-terminal on the heavy chain, a pore is formed on the endocytic membrane, which permits the release of the light chain into the cytosol. This light chain, which is a zinc protease, performs the key-action of the botulinum toxin, by cleaving soluble N-ethylmaleimide-sensitive factor attachment receptor proteins (SNARE proteins) (<LINK REF="REF-Pellizzari-1999" TYPE="REFERENCE">Pellizzari 1999</LINK>).</P><P>SNAREs are docking proteins for acetylcholine vesicles that allow for the release of acetylcholine into the synaptic cleft (<LINK REF="REF-Pellizzari-1999" TYPE="REFERENCE">Pellizzari 1999</LINK>). The overall effect of botulinum toxin is a local chemodenervation by the temporary blockade of acetylcholine release at cholinergic synapses. Temporary synapses are consequently formed via the process of axonal sprouting (<LINK REF="REF-Duchen-1971" TYPE="REFERENCE">Duchen 1971</LINK>; <LINK REF="REF-Holland-1981" TYPE="REFERENCE">Holland 1981</LINK>; <LINK REF="REF-Juzans-1996" TYPE="REFERENCE">Juzans 1996</LINK>).</P><P>There are seven immunologically distinct botulinum toxin serotypes (labelled A to G). These different botulinum toxin serotypes cleave specific SNARE proteins. Serotype A cleaves SNARE protein SNAP 25, located on the inner membrane of nerve cells (<LINK REF="REF-Pellizzari-1999" TYPE="REFERENCE">Pellizzari 1999</LINK>).</P><P>Botulinum toxin is injected into the muscles thought to be involved in dystonia, with or without guidance by either electromyography (EMG) or ultrasound. As a general rule, the number of muscles injected and the number of injection sites per muscle are tailored to the severity of the case in question and the mass of the muscle, respectively. Within roughly three months after injection of botulinum toxin into skeletal muscle, the nerve terminal resumes exocytosis, and the muscle returns to its baseline clinical function, showing a wearing-off response from the botulinum toxin injection (<LINK REF="REF-Jankovic-2004" TYPE="REFERENCE">Jankovic 2004</LINK>). Eventually, the muscle paralysis subsides, and this is associated with the formation of new sprouts capable of neurotransmission. Over time, synaptic activity resumes in the original nerve terminals, leading to sprout regression (<LINK REF="REF-de-Paiva-1999" TYPE="REFERENCE">de Paiva 1999</LINK>).</P><P>Currently there are two commercially available botulinum toxin serotypes - botulinum toxin type A (BtA) and botulinum toxin type B (BtB). The following products are commonly available (three BtA and one BtB): onabotulinumtoxinA (Botox, Allergan Inc., Irvine, CA, USA), abobotulinumtoxinA (Dysport/Reloxin/Azzalure, Ipsen Pharma, Boulogne Billancourt, France), incobotulinumtoxinA (Xeomin/Bocoture Merz GmbH, Frankfurt, Germany), and rimabotulinumtoxinB (Myobloc/Neurobloc, Solstice Neurosciences Inc., Louisville, KY, USA). Other BtA formulations are available in more restricted markets and are yet to receive a generic name: Prosigne/Lantox (Lanzhou Institute of Biological Products, China), PurTox (Mentor Worldwide LLC, Santa Barbara, CA, USA), and Neuronox (Medy-Tox Inc, South Korea) (<LINK REF="REF-Walker-2014" TYPE="REFERENCE">Walker 2014</LINK>).</P></INTERVENTION><THEORY MODIFIED="2017-11-14 15:20:40 +0000" MODIFIED_BY="[Empty name]"><P>The therapeutic potential of all botulinum toxin serotypes derives from their ability to inhibit the release of acetylcholine from the presynaptic nerve terminal into the synaptic cleft, causing local chemodenervation (<LINK REF="REF-Jankovic-2004" TYPE="REFERENCE">Jankovic 2004</LINK>). In addition to this, recent research has also suggested that botulinum toxin is active at multiple levels, namely sensory nerve terminals, and muscle spindles, which leads to a reduction in sensory input and fewer muscle contractions (<LINK REF="REF-Filippi-1993" TYPE="REFERENCE">Filippi 1993</LINK>; <LINK REF="REF-Matak-2014" TYPE="REFERENCE">Matak 2014</LINK>; <LINK REF="REF-Rosales-1996" TYPE="REFERENCE">Rosales 1996</LINK>; <LINK REF="REF-Rosales-2010" TYPE="REFERENCE">Rosales 2010</LINK>).</P><P>It has been further suggested that cortical reorganisation may result from changes in the spinal cord, brainstem, and central nervous pathways (<LINK REF="REF-Palomar-2012" TYPE="REFERENCE">Palomar 2012</LINK>). Animal research has shown the presence of supra-therapeutic levels of botulinum toxin by way of retrograde axonal transport and penetration of the CNS (<LINK REF="REF-Antonucci-2008" TYPE="REFERENCE">Antonucci 2008</LINK>; <LINK REF="REF-Boroff-1975" TYPE="REFERENCE">Boroff 1975</LINK>). However, botulinum toxin has not been shown to penetrate the blood-brain barrier in humans.</P><P>Until recently, SNARE proteins were considered the only target-molecules of botulinum toxin. Thus, it was widely accepted that the therapeutic and toxic actions of botulinum toxin were exclusively mediated by SNARE cleavage preventing the release of synaptic neurotransmitters. However, recent studies have suggested that a number of botulinum toxin actions might not be mediated by SNARE cleavage, specifically regarding neuroexocytosis, cell cycle and apoptosis, neuritogenesis and gene expression (<LINK REF="REF-Matak-2015" TYPE="REFERENCE">Matak 2015</LINK>). The existence of unknown botulinum toxin molecular targets and modulation of unknown signalling pathways is a possibility that may prove to be pharmacologically relevant.</P></THEORY><IMPORTANCE MODIFIED="2017-11-14 15:20:40 +0000" MODIFIED_BY="[Empty name]"><P>BtA is the toxin serotype that has been most intensively studied and approved for the treatment of the large number of focal dystonias. BtA is considered the first line therapy for cervical dystonia (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>), though BtB has been shown to be efficacious, though with a different safety profile (<LINK REF="REF-Marques-2016" TYPE="REFERENCE">Marques 2016</LINK>; <LINK REF="REF-Duarte-2016" TYPE="REFERENCE">Duarte 2016</LINK>).</P><P>This is an update of a Cochrane Systematic Review that previously assessed the efficacy and safety of BtA in comparison to placebo in people with cervical dystonia. Since the release of the original review, three new trials have been published (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>). Furthermore, Cochrane&#8217;s criteria for evaluating studies' risk of bias and the certainty in evidence have evolved and been updated. Therefore, the authors consider it important to update this review.</P></IMPORTANCE></BACKGROUND><OBJECTIVES MODIFIED="2016-10-22 23:54:45 +0100" MODIFIED_BY="[Empty name]"><P>To compare the efficacy, safety, and tolerability of botulinum toxin type A (BtA) versus placebo in people with cervical dystonia.</P></OBJECTIVES><METHODS MODIFIED="2017-11-14 15:33:11 +0000" MODIFIED_BY="[Empty name]"><SELECTION_CRITERIA MODIFIED="2017-11-14 15:20:40 +0000" MODIFIED_BY="[Empty name]"><CRIT_STUDIES MODIFIED="2017-11-14 15:20:40 +0000" MODIFIED_BY="[Empty name]"><P>Randomised controlled trials (RCTs), blinded, single or multiple dose, parallel-designed, of any duration, assessing the efficacy or safety, or both, of BtA treatment versus placebo in people with cervical dystonia were eligible for inclusion in this review. We excluded non-parallel study designs, namely cross-over trials, from this updated version of the review, due to uncertainty about whether this type of study design was appropriate to study people with cervical dystonia, as well as methodological concerns with regards to detection and performance bias.</P></CRIT_STUDIES><CRIT_PARTICIPANTS MODIFIED="2017-11-14 15:20:40 +0000" MODIFIED_BY="[Empty name]"><P>Adults (i.e. 18 years of age or older), in any setting, with a clinical diagnosis made by any physician, specialist or otherwise, of idiopathic cervical dystonia. We allowed trials enrolling participants with any form of cervical dystonia, and additional or more widespread dystonias, for inclusion. Participants could have had prior exposure to BtA or BtB, and could be taking any concomitant medications if on stable regimens.</P><P>There were no restrictions regarding the number of participants recruited to trials, or the number of recruitment centres.</P></CRIT_PARTICIPANTS><CRIT_INTERVENTIONS MODIFIED="2017-11-10 10:09:32 +0000" MODIFIED_BY="[Empty name]"><P>Intramuscular injections of BtA compared to placebo. We allowed all administration schedules and injection techniques, performed with or without guidance by either EMG or ultrasound.</P></CRIT_INTERVENTIONS><CRIT_OUTCOMES MODIFIED="2017-11-14 15:20:40 +0000" MODIFIED_BY="[Empty name]"><CRIT_OUTCOMES_PRIMARY MODIFIED="2017-11-14 15:20:40 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="5">Cervical dystonia-specific improvement</HEADING><P>Overall improvement on any validated symptomatic rating scale, such as Cervical Dystonia Severity Scale (CDSS), Tsui scale, Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), and TWSTRS Severity and Disability subscales scores, measured between weeks 3 and 6.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Adverse events</HEADING><P>The proportion of participants with any adverse event, measured at any point during study follow-up. In this item we also evaluated adverse events of special interest, such as sore throat/dry mouth, neck weakness, dysphagia, injection site pain, voice change, and systemic complaints (e.g. diffuse muscle weakness, malaise, dizziness, and headache), measured at any point during study follow-up.</P></SUBSECTION></CRIT_OUTCOMES_PRIMARY><CRIT_OUTCOMES_SECONDARY MODIFIED="2017-11-14 15:20:40 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="5">Subjective evaluation of clinical status</HEADING><P>Evaluated by either participants, or clinicians, or both, as assessed with validated assessment tools such as Patient Subjective Assessment of Change, Patient Global Assessment of Improvement, Patient Evaluation of Global Response (PEGR), Patient and Physician Global Assessment of Change, Investigator Global Assessment of Efficacy (IGAE), Physician Global Assessment of Change (PGAC), and visual analogue scale (VAS) for symptom severity, measured between weeks 3 and 6.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Pain relief</HEADING><P>As assessed with validated assessment tools such as Patient Assessment of Pain, TWSTRS Pain subscale score, and VAS pain score, measured between weeks 3 and 6.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Health-related quality of life</HEADING><P>As assessed with validated assessment tools such as Short Form 36 (SF-36) Quality-of-Life questionnaire and Cervical Dystonia Impact Profile (CDIP)-58 scale, measured at any point during study follow-up.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Tolerability</HEADING><P>We defined tolerability as the number of participant withdrawals due to adverse events, measured at any point during study follow-up.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Duration of effect</HEADING><P>As assessed by the number of days until need for reinjection or effect waning.</P></SUBSECTION></CRIT_OUTCOMES_SECONDARY></CRIT_OUTCOMES></SELECTION_CRITERIA><SEARCH_METHODS MODIFIED="2017-11-14 15:20:40 +0000" MODIFIED_BY="[Empty name]"><P>For this update, we expanded the search strategy to capture all the search terms for BtA formulations that were currently available. The search strategy was designed to include other botulinum toxin formulations and other dystonic disorders that are also under current revision by our group.</P><ELECTRONIC_SEARCHES MODIFIED="2017-11-14 15:20:40 +0000" MODIFIED_BY="[Empty name]"><P>We ran the final search for the original version of this review in June 2003, based on the search strategy developed for Cochrane Movement Disorders to identify all papers since 1977, the first year that botulinum toxin was used therapeutically in any condition. The search for the current update was run for the last time in October 2016.</P><P>For the identification of studies considered for inclusion in this review, we developed detailed search strategies for each database searched. Please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the Cochrane Central Register of Controlled Trials (CENTRAL) strategy, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for the MEDLINE search strategy, and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> for the Embase strategy.</P><P>We assessed non-English language papers, translated them as necessary and evaluated them for inclusion.</P><P>We did not search trials registries.</P><SUBSECTION><HEADING LEVEL="5">Databases searched</HEADING><UL><LI>Cochrane Movement Disorders' Trials Register (June 2003);</LI><LI>CENTRAL (2016, Issue 11) in the Cochrane Library;</LI><LI>MEDLINE (1977 to 6 October 2016);</LI><LI>Embase (1977 to 6 October 2016).</LI></UL></SUBSECTION></ELECTRONIC_SEARCHES><OTHER_SEARCHES MODIFIED="2017-11-14 15:20:40 +0000" MODIFIED_BY="[Empty name]"><P>The search strategy also included:</P><UL><LI>searches through reference lists of located trials and review articles concerning botulinum toxin;</LI><LI>handsearch of abstracts of international congresses relevant in the fields of movement disorders and botulinum toxins (American Academy of Neurology, Movement Disorders Society, International Association of Parkinsonism and Related Disorders, and International Neurotoxin Association (1985 to October 2016));</LI><LI>personal communication with other researchers in the field;</LI><LI>contact with drug manufacturers;</LI><LI>whenever necessary, we contacted authors of published trials for further information and unpublished data.</LI></UL></OTHER_SEARCHES></SEARCH_METHODS><DATA_COLLECTION MODIFIED="2017-11-14 15:33:11 +0000" MODIFIED_BY="[Empty name]"><STUDY_SELECTION MODIFIED="2017-11-14 15:20:40 +0000" MODIFIED_BY="[Empty name]"><P>Two review authors independently screened all titles and abstracts identified from searches to determine which ones met the inclusion criteria. We retrieved in full text any papers identified as potentially relevant by at least one review author or those without an available abstract. Two review authors independently screened full-text articles, with discrepancies resolved by discussion and by consulting a third review author where necessary to reach consensus. We collated duplicate publications and have presented these by individual study. We have outlined the screening and selection process in a PRISMA flow chart (<LINK REF="REF-Liberati-2009" TYPE="REFERENCE">Liberati 2009</LINK>), see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P></STUDY_SELECTION><DATA_EXTRACTION MODIFIED="2017-11-14 15:20:39 +0000" MODIFIED_BY="[Empty name]"><P>Two review authors extracted data independently from included studies using a piloted data extraction form. We resolved any discrepancies were by discussion until consensus was reached, or through consultation with a third review author where necessary. Data extracted included the following items from each study.</P><UL><LI>Participants: inclusion and exclusion criteria, demographics and clinical baseline characteristics, number and reasons for withdrawals, exclusions and loss to follow-up, if any</LI><LI>Interventions: full description of intervention, duration of treatment period and follow-up, providers, and co-interventions, if any</LI><LI>Comparisons: number of randomised participants to each arm, compliance and dropouts, reasons for dropouts, and ability to perform an intention-to-treat analysis</LI><LI>Outcomes: definition of outcomes, use of validated measurement tools, time-point measurements, change from baseline or post-interventional measures, and missing outcomes, if any</LI><LI>Study design: interventional, randomised, controlled, double-blind.</LI></UL></DATA_EXTRACTION><QUALITY_ASSESSMENT MODIFIED="2017-11-14 15:33:11 +0000" MODIFIED_BY="[Empty name]"><P>We assessed the risk of bias of included studies according to the domains described in the Cochrane tool for assessing risk of bias (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>), and classified the risk of bias for each domain as high, unclear, or low, and the overall assessment as high or low. We assessed two further domains, which are described below: enriched population and independent funding. We used the following definitions for each domain in the 'Risk of bias' assessment.</P><UL><LI>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated).</LI><LI>Allocation concealment (checking for possible selection bias). We assessed the method used to conceal allocation to interventions prior to assignment to determine whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated); high risk of bias (e.g. open list).</LI><LI>Blinding of participants and personnel (checking for possible performance bias). We assessed the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding, such as identical tablets matched in appearance or smell, or a double-dummy technique); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how it was achieved). Studies that are not double-blind will be considered to have high risk of bias.</LI><LI>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study has a clear statement that outcome assessors were unaware of treatment allocation, and ideally describes how this was achieved); unclear risk of bias (study states that outcome assessors were blind to treatment allocation but lacks a clear statement on how it was achieved). We considered studies where outcome assessment is not blinded as having a high risk of bias.</LI><LI>Selective reporting (checking for reporting bias). We assessed whether primary and secondary outcome measures were pre-specified and whether these were consistent with those reported. We assessed selective reporting as: low risk of bias (studies reporting primary and secondary outcomes); high risk of bias (not all pre-specified outcomes reported or only for certain data collection time points).</LI><LI>Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (&lt; 10% of participants did not complete the study and/or used &#8216;baseline observation carried forward&#8217; analysis); unclear risk of bias (used 'last observation carried forward' analysis); high risk of bias (used 'completer' analysis).</LI></UL><P>In addition to these criteria, we considered the implications of baseline imbalances in prognostic factors affecting the trial outcomes, as these may lead to selection bias (<LINK REF="REF-Corbett-2014" TYPE="REFERENCE">Corbett 2014</LINK>).</P><SUBSECTION><HEADING LEVEL="4">For-profit bias</HEADING><P>In order to assess the study source of funding, we added this domain in place of the &#8216;other bias&#8217; domain.</P><UL><LI>Low risk of bias: the trial appears to be free of industry sponsorship or other type of for-profit support that may introduce bias into trial design, conduct, or trial results.</LI><LI>Unclear risk of bias: the trial may or may not be free of for-profit bias as the trial did not provide any information on clinical trial support or sponsorship.</LI><LI>High risk of bias: the trial was sponsored by industry or received other type of for-profit support.</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Enriched population</HEADING><P>Because the clinical effect of botulinum toxin treatment is easily perceived, botulinum toxin-naive participants are likely to recognise the presence or absence of beneficial clinical effects, or frequent adverse events, or both, effectively revealing the respective allocation arm. It is also relevant that, by preferentially including responders to botulinum toxin or excluding non-responders to botulinum toxin, there is an increased likelihood that these participants would respond more favourably to botulinum toxin than a naive population would. We opted to subdivide this domain in two: preferential enrolment of known positive responders to botulinum toxin; and exclusion of known poor responders to botulinum toxin.</P><UL><LI>Low risk of bias: at least 70% of trial participants were naive to treatment with botulinum toxin; the trial did not exclude any particular form of cervical dystonia including those associated with a poorer response to botulinum toxin (such as pure anterocollis and retrocollis).</LI><LI>Unclear risk of bias: the trial did not make explicit the percentage of participants who were known to be botulinum toxin naive.</LI><LI>High risk of bias: arbitrarily defined as more than 30% of participants non-naive to botulinum toxin; explicit exclusion of people with forms of cervical dystonia associated with a poorer response to botulinum toxin.</LI></UL></SUBSECTION></QUALITY_ASSESSMENT><EFFECT_MEASURES MODIFIED="2017-11-14 15:20:39 +0000" MODIFIED_BY="[Empty name]"><P>We compared disease symptoms at baseline to disease symptoms in weeks 2 to 4 post-injection in the BtA and placebo arms. We extracted continuous outcomes whenever possible,, pooled the data from the studies, where adequate, and used them for comparison.</P><SUBSECTION><HEADING LEVEL="4">Dichotomous data</HEADING><P>We based analysis of these data on the number of events and the number of people assessed in the intervention and comparison groups. We used these to calculate the risk ratio (RR) and 95% confidence interval (CI).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Continuous data</HEADING><P>We based analysis of these data on the mean, standard deviation (SD) and number of people assessed for both the intervention and comparison groups to calculate mean difference (MD) and 95% CI. Where the MD was reported without individual group data, we used this to report the study results. If more than one study measured the same outcome using different validated tools, we calculated the standardised mean difference (SMD), namely Hedges&#8217; (adjusted) g (<LINK REF="REF-Hedges-1985" TYPE="REFERENCE">Hedges 1985</LINK>), and 95% CI. For interpretation of effect sizes with SMDs, we used a rule of thumb to define a small effect (SMD = 0.2), a moderate effect (SMD = 0.5), or a large effect (SMD = 0.8) (<LINK REF="REF-Cohen-1988" TYPE="REFERENCE">Cohen 1988</LINK>). If necessary for comparison, we dichotomised rating scales using each study author's own criteria for improvement or no improvement.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Time-to-event data</HEADING><P>We planned to analyse these data based on log hazard ratios (HR) and standard errors obtained from results of Cox proportional hazards regression models. We had planned to use these in order to calculate a HR and 95% CI.</P></SUBSECTION></EFFECT_MEASURES><UNIT_OF_ANALYSIS MODIFIED="2017-11-14 15:20:39 +0000" MODIFIED_BY="[Empty name]"><P>Whenever the included studies had multiple arms with different dosages of botulinum toxin, we combined all groups to create a single pair-wise comparison, using the Review Manager 5 (RevMan 5) calculator (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), according to the methods suggested by Cochrane (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). We also would have opted to create a single, pair-wise comparison in case of multiple treatment groups using different interventions (e.g. onabotulinumtoxinA and abobotulinumtoxinA) if these had been compared to the same comparator.</P><P>This method combined all relevant experimental intervention groups of the study into a single group, and all relevant control intervention groups into a single control group. This approach avoided the duplication of the control group that would happen if multiple comparisons (e.g. BtA dose1 versus placebo; BtA dose2 versus placebo) were included in the meta-analysis, as well as the loss of information if one dosage group was chosen to the detriment of the others. If applicable, we planned to explore the effect of dosage in subgroup analysis.</P><P>For dichotomous outcomes, we planned to sum both the sample sizes and the numbers of people with events across groups. For continuous outcomes, means and standard deviations could be combined using a pooled mean or SD (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>; <LINK REF="REF-Higgins-2011c" TYPE="REFERENCE">Higgins 2011c</LINK>).</P></UNIT_OF_ANALYSIS><MISSING_DATA MODIFIED="2017-11-14 15:20:39 +0000" MODIFIED_BY="[Empty name]"><P>For missing outcome or summary data we used imputation methods to derive the missing data (where possible) and reported any assumptions in the review. In these cases we carried out sensitivity analyses to investigate the effects of any imputed data on pooled effect estimates.</P><P>As a first option we chose to use the available information (e.g. standard error (SE), 95% CI or exact P value) to recover the missing data algebraically (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>; <LINK REF="REF-Higgins-2011c" TYPE="REFERENCE">Higgins 2011c</LINK>; <LINK REF="REF-Wiebe-2006" TYPE="REFERENCE">Wiebe 2006</LINK>). When change from baseline SD was not reported or not possible to extract, we attempted to create a correlation coefficient based on another study in this review, and then used this correlation coefficient to impute a change from baseline SD (<LINK REF="REF-Abrams-2005" TYPE="REFERENCE">Abrams 2005</LINK>; <LINK REF="REF-Follmann-1992" TYPE="REFERENCE">Follmann 1992</LINK>; <LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>).</P><P>If this were to fail, and if there was at least one sufficiently large and similar study, we would use a method of single imputation (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>; <LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>).</P><P>Lastly, if there were a sufficient number of included studies with complete information, we would have used multiple imputation methods to derive missing data (<LINK REF="REF-Carpenter-2013" TYPE="REFERENCE">Carpenter 2013</LINK>; <LINK REF="REF-Rubin-1991" TYPE="REFERENCE">Rubin 1991</LINK>).</P><P>If none of these methods proved successful, we would have conducted a narrative synthesis for the data in question.<BR/></P></MISSING_DATA><HETEROGENEITY_ASSESSMENT MODIFIED="2017-11-14 15:20:39 +0000" MODIFIED_BY="[Empty name]"><P>We assessed whether studies were similar enough to allow pooling of data using meta-analysis. Where data were pooled using meta-analysis, we assessed the degree of heterogeneity by visual inspection of forest plots and by examining the Chi<SUP>2</SUP> test for heterogeneity (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). We quantified heterogeneity using the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We considered an I<SUP>2 </SUP>value of 50% or more to represent substantial levels of heterogeneity, but interpreted this value in light of the size and direction of effects and the strength of the evidence for heterogeneity, based on the P value from the Chi<SUP>2 </SUP>test.</P></HETEROGENEITY_ASSESSMENT><BIAS_ASSESSMENT MODIFIED="2017-11-10 11:40:37 +0000" MODIFIED_BY="[Empty name]"><P>We included too few studies in this review, namely fewer than 10, to allow construction of a funnel plot (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>), and formal testing of asymmetry (<LINK REF="REF-Peters-2006" TYPE="REFERENCE">Peters 2006</LINK>), which may indicate publication bias. Should enough studies be included in future updates of this review, we plan to undertake these analyses.</P></BIAS_ASSESSMENT><DATA_SYNTHESIS MODIFIED="2017-11-14 15:20:39 +0000" MODIFIED_BY="[Empty name]"><P>We performed the analyses with Review Manager 5 (RevMan 5) version 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), Stata version 14 (<LINK REF="REF-Stata-2015" TYPE="REFERENCE">Stata 2015</LINK>) and Trial Sequential Analysis (TSA) (<LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>; <LINK REF="REF-TSA-2011" TYPE="REFERENCE">TSA 2011</LINK>).</P><SUBSECTION><HEADING LEVEL="4">Meta-analysis</HEADING><P>We based the decision whether or not to meta-analyse data on an assessment of whether the interventions in the included trials were similar enough in terms of participants, settings, intervention, comparison and outcome measures to ensure meaningful conclusions from a statistically pooled result. We conducted data synthesis using a random-effects model.</P><P>We pooled effect measures by applying the Mantel-Haenszel method for dichotomous outcomes, and applying the inverse-variance or generic inverse-variance method for continuous outcomes. In addition, we had planned to pool time-to-event data using the generic inverse-variance method. We presented all results with 95% CI.</P><P>We calculated the number of participants needed to treat for an additional beneficial outcome (NNTB) and for an additional harmful outcome (NNTH) from meta-analysis estimates, rather than treating data as if they came from a single trial, as the latter approach is more prone to bias, especially when there are significant imbalances between groups within one or more trials in the meta-analysis (<LINK REF="REF-Altman-2002" TYPE="REFERENCE">Altman 2002</LINK>). However, caution is needed in the interpretation of these findings since they may be misleading because of variation in the event rates in each trial, differences in the outcomes considered, and differences in clinical setting (<LINK REF="REF-Smeeth-1999" TYPE="REFERENCE">Smeeth 1999</LINK>).</P><P>Where there were no data that could be combined into a meta-analysis we undertook a narrative approach to result synthesis.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Trial Sequential Analysis</HEADING><P>In order to explore whether the cumulative data were of adequate power to evaluate the primary outcomes of this review, we performed a Trial Sequential Analysis (TSA) (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>), and calculated a required information size (also known as the 'heterogeneity-adjusted required information size') (<LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). TSA aims to evaluate whether statistically significant results of meta-analysis are reliable by accounting for the required information size (i.e. the number of participants in the meta-analysis required to accept or reject an intervention effect). The technique is analogous to sequential monitoring boundaries in single trials. TSA adjusts the threshold of statistical significance and has been shown to reduce the risk of random errors due to repetitive testing of accumulating data (<LINK REF="REF-Imberger-2016" TYPE="REFERENCE">Imberger 2016</LINK>).</P><P>We calculated the required information size and computed the trial sequential monitoring boundaries using the O&#8217;Brien-Fleming approach (<LINK REF="REF-O_x0027_Brien-1979" TYPE="REFERENCE">O'Brien 1979</LINK>). The required information size was based on the event proportion or standard deviation in the control group; assumption of a plausible relative risk reduction (RRR) of 10%; a 5% risk of type I error; a 20% risk of type II error (power = 80%); and the observed heterogeneity of the meta-analysis (<LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Assessing the certainty in the evidence</HEADING><P>As recommended by the GRADE Working Group methodology (<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>), two review authors independently assessed all of the outcomes in the following domains: study limitations, inconsistency, indirectness, imprecision and publication bias. In case of disagreement the authors attempted to reach consensus, consulting an independent third review author if necessary. For this purpose, we used the GRADEpro GDT software tool (<LINK REF="REF-GRADEpro-GDT-2015" TYPE="REFERENCE">GRADEpro GDT 2015</LINK>), which we then used to export a 'Summary of findings' table for inclusion in the review manuscript.</P><P>To ensure the consistency and reproducibility of GRADE judgements, we applied the following criteria to each domain for all key comparisons of the critical outcomes.</P><UL><LI>Study limitations: we downgraded once if more than 30% of participants were from studies classified as being at a high risk of bias across any domain, with the exception of 'for-profit bias'.</LI><LI>Inconsistency: we downgraded once if heterogeneity was statistically significant or if the I<SUP>2</SUP> value was more than 40%. When we did not perform a meta-analysis we downgraded once if trials did not show effects in the same direction.</LI><LI>Indirectness: we downgraded once if more than 50% of the participants were outside the target group.</LI><LI>Imprecision: we downgraded once if the optimal information size criterion was not met or, alternatively, if it was met but the 95% CI failed to exclude important benefit or important harm (<LINK REF="REF-Guyatt-2011" TYPE="REFERENCE">Guyatt 2011</LINK>).</LI><LI>Publication bias: we downgraded once where there was direct evidence of publication bias or if estimates of effect were based on small scale, industry-sponsored studies that raised a high index of suspicion of publication bias.</LI></UL><P>We applied the following definitions to the certainty in the evidence (<LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>):</P><UL><LI>high certainty: we are very confident that the true effect lies close to that of the estimate of the effect;</LI><LI>moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different;</LI><LI>low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;</LI><LI>very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="3">'Summary of findings' table</HEADING><P>As has become standard practice in Cochrane Reviews, we have included a 'Summary of findings' table to present the main findings of this review in a simple tabular format, based on the results of the GRADE analysis.</P></SUBSECTION></DATA_SYNTHESIS><SUBGROUP_ANALYSIS MODIFIED="2017-11-14 15:20:38 +0000" MODIFIED_BY="[Empty name]"><P>We pre-planned subgroup analyses for the following areas, independently of the presence or not of significant heterogeneity.</P><UL><LI>Different BtA formulations</LI><LI>Different BtA doses: high (Botox/Xeomin &gt; 201 U; Dysport = 1000 U), medium (Botox/Xeomin 101 U to 200 U; Dysport = 500 U), and low (Botox/Xeomin &lt; 100 U; Dysport = 250 U) doses, all defined arbitrarily</LI><LI>EMG-guided versus non-EMG-guided botulinum toxin injection</LI></UL></SUBGROUP_ANALYSIS><SENSITIVITY_ANALYSIS MODIFIED="2017-07-19 20:47:29 +0100" MODIFIED_BY="[Empty name]"><P>We conducted sensitivity analyses for every study where we applied imputation methods.</P></SENSITIVITY_ANALYSIS></DATA_COLLECTION></METHODS><RESULTS MODIFIED="2017-11-14 18:19:19 +0000" MODIFIED_BY="[Empty name]"><STUDY_DESCRIPTION MODIFIED="2017-11-14 18:05:47 +0000" MODIFIED_BY="[Empty name]"><P>We identified three new studies for inclusion in this update: <LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>.</P><P>We identified two studies (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>) as duplicates of two previously included studies (Brashear 1998, Truong 2002, respectively). We chose to replace the original references as the current study reports contain more data. The older references can now be found as secondary references under the new studies.</P><P>Overall, we included eight parallel-designed studies comparing BtA (different total treatment doses) with placebo in this update, with a total of 1010 participants with cervical dystonia.</P><SEARCH_RESULTS MODIFIED="2017-11-14 15:20:38 +0000" MODIFIED_BY="[Empty name]"><P>See: <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, flow diagram of study selection.</P><P>We last ran the electronic search in October 2016. The search returned 1646 records (208 through CENTRAL; 182 though MEDLINE; 1256 through Embase), resulting in 1599 records after removing all duplicates. After title and abstract screening, we assessed 24 articles for full-text screening, with eight being included for both the qualitative and quantitative syntheses.</P><P>We excluded nine trials for having a cross-over design; two due to not being randomised; two for including the wrong population; and another two for studying the wrong outcomes.</P><P>We did not retrieve any unpublished trials.</P><P>For this update, we contacted the author of <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK> and <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK> for clarification of whether the study population was the same in both trials. The author replied and confirmed that these were two different studies.</P></SEARCH_RESULTS><INCLUDED_STUDIES_DESCR MODIFIED="2017-11-14 18:05:47 +0000" MODIFIED_BY="[Empty name]"><P>We have listed all the included studies in this review in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P><P>See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for a summary of the clinical characteristics of included studies.</P><P>The eight included studies enrolled a total of 1010 adult participants, with a mean age of 52.3 years (range 18 to 82), 649 of whom were female (64%). Trial size varied from 55 to 233 participants. Seven studies were performed in a multicenter setting &#8211; two large trials (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>) and one small study (<LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>) in North America, one medium-sized study in the USA and Russia (<LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>), two trials enrolling up to 75 participants each in Europe (<LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>), and one large study enrolling participants at 61 sites in 11 countries (<LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>). The three larger studies (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>) enrolled a total of 616 participants, accounting for 61% of the participants included in this review.</P><P>Participants' baseline characteristics differed between trials. The mean duration of cervical dystonia ranged from 4.8 to 12.1 years, though the distribution was generally equivalent between treatment and placebo arms in each trial, exceeding a three-year difference in one study only (<LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>). The overall disease impairment at baseline was moderate-to-severe in all trials, with scores ranging from 41.8 to 46.2 on the TWSTRS scale, 13.9 to 14.4 on the Tsui scale, and 9.2 to 9.3 on the CDSS.</P><P>Only two studies exclusively enrolled participants who had never been exposed to botulinum toxin (<LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>). For all other trials, between 61% and 100% of participants had received prior treatment with botulinum toxin, with time since last injection before study entry ranging from 10 weeks to 16 weeks. All but one small trial (<LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>) excluded clinical forms of cervical dystonia associated with a poorer response to botulinum toxin, such as pure anterocollis and retrocollis. Overall, we assessed only one study (<LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>) as not having an enriched population. We deemed all other studies to be at high risk of bias for this domain. As a result, the population characteristics across studies did not allow for conducting a subgroup analysis for people naive and non-naive to botulinum toxin.</P><P>The number of dropouts was generally small in most trials, although its interpretation needs to be adjusted to the time point reported in each study. Total dropouts from trials varied from 3% to 6% at week 8 (<LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>), to as high as 21% at week 10 (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>) and 29% at week 12 (<LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>). One study (<LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>), however, showed considerably higher rates of dropouts, ranging from 54% at as early as week 8, to 70% at week 12; reasons for discontinuation in this study were not reported by the trial authors.</P><P>Overall, the number of dropouts was higher among participants allocated to placebo arms: 27% (combined n = 90) of the participants allocated to placebo withdrew, compared to only 12% (combined n = 56) of participants allocated to BtA. In trials that reported the reasons for dropouts, lack of efficacy was the most frequent reason for participant discontinuation from the study, accounting for half (combined n = 45) of total dropouts in placebo arms and for 23% (combined n = 13) in BtA arms. In the intervention arms, adverse events were responsible for 7% (n = 4) of discontinuation across studies, as compared to 0% in the placebo arms (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>).</P><SUBSECTION><HEADING LEVEL="4">Study design and interventions</HEADING><P>Five trials used a fixed dose of 500 U of BtA formulation Dysport to compare with placebo (<LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>; combined n = 515). In the same trial, <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK> further assessed low (250 U) and high (1000 U) doses of Dysport in two different arms (n = 37). Two previously included studies (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>; combined n = 225) compared BtA formulation Botox with placebo, with doses varying from 95 U to 360 U. One new study (n = 233) evaluating the BtA formulation Xeomin versus placebo was identified in this update, using dosages of 120 U and 240 U (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>). All studies were designed to allow one single treatment session.</P><P>Most studies performed BtA injection without EMG guidance (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>). However, for almost half of the participants included across studies (n = 429), EMG guidance was left at the discretion of the investigator performing the injection (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>, <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>, <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>).</P><P>The duration of trials ranged from 8 weeks to 20 weeks post-injection. For most participants, study termination occurred between weeks 8 to 12 (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>), as determined by the clinical need for reinjection, or study dropout.</P><P>All studies except two (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>) assessed efficacy and other primary outcomes using an intent-to-treat (ITT) analysis, which included all participants randomised to treatment. Some of these studies (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>) performed the safety assessment on a per-protocol (PP) population, which included only participants who had received a dose of study medication.</P></SUBSECTION></INCLUDED_STUDIES_DESCR><EXCLUDED_STUDIES_DESCR MODIFIED="2017-11-14 15:20:38 +0000" MODIFIED_BY="[Empty name]"><P>We have listed all the excluded studies in this review, together with reasons for their exclusion, in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P></EXCLUDED_STUDIES_DESCR></STUDY_DESCRIPTION><STUDY_QUALITY MODIFIED="2017-11-14 17:49:04 +0000" MODIFIED_BY="[Empty name]"><P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>: 'Risk of bias' table.</P><P>We evaluated the included studies using a modified version of the Cochrane 'Risk of bias' tool. See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for the 'Risk of bias' summary graphs. These assessments were based on the information available in the primary report data.</P><P>Overall, we considered no studies to be at low risk of bias across all domains. However, the only two domains that we considered to represent a high risk of bias were the 'for-profit bias' and 'enriched population' domains. It is noteworthy that all trials but one had a high risk of both 'for-profit bias' and 'enriched population'.</P><ALLOCATION MODIFIED="2017-11-14 17:20:01 +0000" MODIFIED_BY="[Empty name]"><P>Three studies (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>) clearly described the process of random sequence generation; we assessed the other five studies to be at unclear risk of bias for this criterion. <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>, <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>, and <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK> described an adequate allocation concealment process and we rated them as being at a low risk. All but one of the included trials reported a higher disease impairment at baseline in the control arm although it is unclear whether these differences are either statistically significant or clinically relevant. This leads us to assess the overall risk of selection bias across the included trials to be a serious cause for concern, despite the fact that overall no one trial is uniquely responsible for this assessment.</P></ALLOCATION><BLINDING MODIFIED="2017-11-14 17:36:08 +0000" MODIFIED_BY="[Empty name]"><P>We judged the blinding of participants and personnel involved in the trial to be at a low risk of bias in the majority of studies included in this review; three trials (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>) did not describe enough information to allow for a clear judgment. We considered that only <LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK> had adequately blinded participants and investigators measuring both objective and subjective outcomes. For the assessment of objective outcomes, we also judged <LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK> to be at low risk. We considered that the remaining studies were at an unclear risk of bias across this domain. We judged <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK> at low risk of performance bias, but at an unclear risk of both elements of detection bias. </P></BLINDING><EXCLUSIONS MODIFIED="2017-11-14 17:49:04 +0000" MODIFIED_BY="[Empty name]"><P>Six out of eight studies summarised the reasons for missing data and used appropriate statistical tools to deal with it, and we rated them at low risk of bias. <LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK> reported missing data across the study visits so that we assessed this study at unclear risk of attrition bias. <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK> reported a large number of dropouts in both intervention arms, though this was asymmetrical, with over 60% of participants withdrawing from the placebo arm by week 4. For this reason we rated <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK> at a high risk of attrition bias. </P></EXCLUSIONS><SELECTIVE_REPORTING MODIFIED="2017-01-28 11:58:47 +0000" MODIFIED_BY="[Empty name]"><P>We considered all studies to be at low risk for reporting bias.</P></SELECTIVE_REPORTING><OTHER_BIAS_SOURCES MODIFIED="2017-11-14 15:20:38 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="4">For-profit bias</HEADING><P>All trials but one (<LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>) declared funding or supply of study vials from industry sources, and we rated them at a high risk of bias for funding and potential conflicts of interest.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Enriched population</HEADING><P>Three studies (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>) preferentially enrolled participants known to have previously responded to BtA treatment, and were at high risk of bias for enriched population. On the other hand, all studies except one (<LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>) excluded forms of cervical dystonia known to have a poorer clinical response to BtA injection, and were also considered to be at a high risk of bias for this domain.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Publication bias</HEADING><P>We intended to use funnel plots to explore publication bias. However, due to the small number of included studies, the power of this analysis was considered to be inadequate (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P></SUBSECTION></OTHER_BIAS_SOURCES></STUDY_QUALITY><INTERVENTION_EFFECTS MODIFIED="2017-11-14 18:19:19 +0000" MODIFIED_BY="[Empty name]"><P>The key results of this review can be found in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P><SUBSECTION><HEADING LEVEL="3">Preceding data analysis</HEADING><P>See <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>.</P><P><LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>, <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>, and <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK> reported no SD for the primary outcome, so we opted to impute these values from other studies in this review (<LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>, respectively), which used the same scale, time point and error measurement for assessing the same outcome.</P><P><LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK> did not report the absolute numerical values for the primary outcome at week 4. Therefore, we opted to have two review authors independently extract these data from the graph provided in the report. Since the two review authors reported very similar values, we imputed these data (mean values from the two authors) and used them for analysis.</P><P><LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK> and <LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK> presented data separately for each BtA dose, reporting sample sizes, means and SD for each intervention group. In order to conduct pooled analyses we combined the BtA groups using a pooled SD formula for paired data.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Primary outcomes</HEADING><SUBSECTION><HEADING LEVEL="4">Cervical dystonia-specific improvement</HEADING><P>The included trials assessed the primary outcome at either week 4 (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>) or week 6 (<LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>) following initial injection of study medication. Most trials reported the primary efficacy outcome as the change from baseline measurement using validated scales, namely the CDSS (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>), the Tsui scale (<LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>) and the TWSTRS (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>). <LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK> reported no objective efficacy measurements. The CDSS uses a protractor and wall chart to rate the severity of the head's deviation. The Tsui scale (range, 0 to 25) grades severity of postural deviance, acknowledging the presence of tremor and the pattern of movements; it does not assess disability, pain or other subjective symptoms. TWSTRS (range, 0 to 85) is composed of three subscales that grade severity (range, 0 to 35), disability (range, 0 to 30), and pain (range, 0 to 20). <LINK REF="REF-Tarsy-1997" TYPE="REFERENCE">Tarsy 1997</LINK> demonstrated that Tsui and TWSTRS score reduction rates after botulinum toxin therapy correlate significantly with each other.</P><P>Seven trials (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>; combined n = 833) contributed data for this outcome. Overall, treatment with BtA was associated with a moderate-to-large cervical dystonia-specific improvement (SMD 0.70, 95% CI 0.52 to 0.89; I<SUP>2 </SUP>= 36%; moderate certainty in the evidence; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P><P>Four trials (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; combined n = 522) used the TWSTRS total score to assess cervical dystonia-specific improvement. Overall, treatment with BtA was associated with a MD of 8.06 in TWSTRS total score compared to placebo (95% CI 6.08 to 10.05; I<SUP>2 </SUP>= 0%; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), representing a 18.7% improvement compared to the baseline clinical status (43.55 TWSTRS combined baseline score).</P><P>Three trials (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; combined n = 429) contributed data regarding the TWSTRS subscales. Overall, treatment with BtA was associated with a MD of 3.13 in the TWSTRS severity subscale (95% CI 2.15 to 4.11; I<SUP>2 </SUP>= 0%; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), and 2.52 in the TWSTRS disability subscale (95% CI 1.72 to 3.31; I<SUP>2 </SUP>= 23%; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P><P>For the Trial Sequential Analysis we could not use the results of the overall improvement, since these data were only available as SMD (<LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>). Thus, we opted to use the data from trials that used the TWSTRS scale.</P><P>The required information size was based on the event proportion or standard deviation in the control group; assumption of a plausible relative risk reduction (RRR) of 10%; a 5% risk of type I error; a 20% risk of type II error (power = 80%); and the observed heterogeneity of the meta-analysis. We assumed a baseline TWSTRS of 42 points and an SD of 10. Given these constraints, the cumulative evidence overcame the heterogeneity-adjusted required information size - 180 participants. We are able to conclude that the cumulative evidence is adequately-powered to demonstrate the 8.16 TWSTRS point difference at week 4 between BtA and placebo.</P><SUBSECTION><HEADING LEVEL="5">1.1. Overall improvement with high versus medium versus low dose of BtA subgroup analysis</HEADING><P>We carried out a preplanned subgroup analysis to assess overall improvement according to the BtA dosages used (see <LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>). Considering the current evidence behind the potency equivalence between BtA formulations, we assigned arbitrary thresholds for high, medium, and low doses of BtA. Two trials (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; combined n = 193) contributed data to the high-dose subgroup; six trials (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>; combined n = 545) contributed data to the medium-dose subgroup; and one trial (<LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; n = 39) contributed data to the low-dose subgroup.</P><P>One study (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>) reported a range of BtA injection doses that crossed the arbitrary dose limits we defined. We therefore did not include it in this subgroup meta-analysis.</P><P>All three dosages were efficacious against placebo (high dose: SMD 1.08, 95% CI 0.53 to 1.63; I<SUP>2 </SUP>= 52%; medium dose: SMD 0.76, 95% CI 0.59 to 0.94; I<SUP>2 </SUP>= 0%; low dose: SMD 1.24, 95% CI 0.55 to 1.94), though we did not find a difference in efficacy between the subgroups (P = 0.25; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">1.2. Overall improvement with Botox versus Dysport versus Xeomin subgroup analysis</HEADING><P>We carried out a preplanned subgroup analysis to assess overall improvement according to BtA formulation (see <LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>). One trial (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; n = 170) contributed data to the Botox subgroup; five trials (<LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>; combined n = 430) contributed data to the Dysport subgroup; and one trial (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; n = 233) contributed data to the Xeomin subgroup.</P><P>All three formulation were efficacious against placebo (Botox: SMD 0.38, 95% CI 0.08 to 0.69; Dysport: SMD 0.75, 95% CI 0.54 to 0.96; I<SUP>2 </SUP>= 8%; Xeomin: SMD 0.82, 95% CI 0.53 to 1.10), though we did not find a difference in efficacy between the subgroups (P = 0.08; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">1.3 Overall improvement with EMG-guided versus non-EMG-guided injection subgroup analysis</HEADING><P>We carried out a preplanned subgroup analysis to assess the comparative efficacy of BtA in trials that used EMG versus trials that did not use EMG (see <LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>). Four trials (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; combined n = 522) contributed data to the EMG-guided subgroup; and three trials (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>; combined n = 311) contributed data to the non-EMG-guided subgroup.</P><P>It is important to note that all four trials that contributed data to the EMG-guided subgroup left the use of EMG at the discretion of the investigator.</P><P>Both comparisons were efficacious against placebo (EMG-guided: SMD 0.71, 95% CI 0.52 to 0.89; I<SUP>2 </SUP>= 0%; non-EMG-guided: SMD 0.79; 95% CI 0.27 to 1.31; I<SUP>2 </SUP>= 75%), though we did not find a difference in efficacy between the subgroups (P = 0.76; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Adverse events</HEADING><P>Seven trials (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>: combined n = 952) contributed data for this outcome. Adverse events related to study treatment were reported in 55.3% of participants in the BtA groups, compared to 46.5% of participants in the placebo arms. Overall, treatment with BtA was associated with a 20% increase in the risk of adverse events, when compared with placebo (risk ratio (RR) 1.19; 95% CI 1.03 to 1.36; I<SUP>2 </SUP>= 16%; moderate certainty in the evidence; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). The number needed to treat for an additional harmful outcome (NNTH) with a single BtA treatment was 9 (95% CI 5 to 31).</P><P>Adverse events were measured as the proportion of trial participants who experienced any adverse event during any point in follow-up.</P><P>The required information size was based on the event proportion or standard deviation in the control group; assumption of a plausible relative risk reduction (RRR) of 10%; a 5% risk of type I error; a 20% risk of type II error (power = 80%); and the observed heterogeneity of the meta-analysis. We assumed a control event rate of 46%. Given these constraints, the cumulative evidence overcame the heterogeneity-adjusted required information size - 892 participants. We are able to conclude that the cumulative evidence is adequately-powered to demonstrate the 23% risk difference in adverse events between BtA and placebo.</P><SUBSECTION><HEADING LEVEL="5">2.1 Adverse events with high versus medium versus low dose of BtA subgroup analysis</HEADING><P>We carried out a preplanned subgroup analysis to assess the risk of adverse events according to the BtA dosages used (see <LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>). Considering the current evidence behind the potency equivalence between BtA formulations, we assigned arbitrary thresholds for low, medium, and high doses of BtA. Two trials (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; combined n = 193) contributed data to the high-dose subgroup; six trials (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>; combined n = 664) contributed data to the medium-dose subgroup; and one trial (<LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; n = 39) contributed data to the low-dose subgroup.</P><P>We did not find a difference in the risk of adverse events between the subgroups (P = 0.66; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">2.2 Adverse events with Botox versus Dysport versus Xeomin subgroup analysis</HEADING><P>We carried out a preplanned subgroup analysis to assess the risk of adverse events according to BtA formulation (see <LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>). One trial (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; n = 170) contributed data to the Botox subgroup; five trials (<LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>; n = 549) contributed data to the Dysport subgroup; and one trial (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; n = 233) contributed data to the Xeomin subgroup.</P><P>Overall, we did not find a difference in the risk of adverse events between these subgroups (P = 0.34; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">2.3 Adverse events with EMG-guided versus non-EMG-guided injection subgroup analysis</HEADING><P>We carried out a preplanned subgroup analysis to assess the risk of adverse events in trials that used EMG versus trials that did not use EMG (see <LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>). Four trials (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; n = 640) contributed data to the EMG-guided subgroup; and three trials (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>; n = 312) contributed data to the non-EMG-guided subgroup.</P><P>It is important to note that all four trials that contributed data to the EMG-guided subgroup left the use of EMG at the discretion of the investigator.</P><P>Overall, we did not find a difference in the risk of adverse events between these subgroups (P = 0.52; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">2.4 Adverse events of special interest</HEADING><P>Treatment with BtA was only associated with an increased risk of two adverse events of special interest, namely dysphagia (RR 3.04, 95% CI 1.68 to 5.50; I<SUP>2 </SUP>= 0%; moderate certainty in the evidence; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>), and diffuse weakness/tiredness (RR 1.78, 95% CI 1.08 to 2.94; I<SUP>2 </SUP>= 0%; moderate certainty in the evidence; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). The NNTH with a single BtA treatment for dysphagia was 16 (95% CI 7 to 49) and that for diffuse weakness/tiredness was 21 (95% CI 9 to 208).</P><P>The remaining adverse events that were reported in the included trials included neck weakness (RR 3.23, 95% CI 0.95 to 10.91; I<SUP>2 </SUP>= 23%; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>), voice changes/hoarseness (RR 1.83, 95% CI 0.37 to 8.95; I<SUP>2 </SUP>= 26%; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>), sore throat/dry mouth (RR 1.66, 95% CI 0.78 to 3.51; I<SUP>2 </SUP>= 5%; <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>), vertigo/dizziness (RR 1.47, 95% CI 0.38 to 5.73; I<SUP>2</SUP>=0%; <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>), malaise/upper respiratory infection (RR 1.29, 95% CI 0.63 to 2.64; I<SUP>2 </SUP>= 45%; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>), injection site pain (RR 1.33, 95% CI 0.88 to 2.02; I<SUP>2 </SUP>= 0%; <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>), and headache (RR 1.05, 95% CI 0.59 to 1.86; I<SUP>2 </SUP>= 0%; <LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>), though we did not find a difference between BtA and placebo regarding the risk of each one of these adverse events.</P></SUBSECTION></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Secondary outcomes</HEADING><SUBSECTION><HEADING LEVEL="4">Subjective evaluation of clinical status</HEADING><P>The included trials assessed subjective evaluation of overall improvement by both physicians and participants between weeks 3 to 6 after BtA injection. They used four scales to evaluate the amount of improvement: the Patient Evaluation of Global Response (PEGR), the Global Assessment of Change (GAS), the visual analogue scale (VAS), and the Clinical Global Rating. PERG and GAS (range, -4 to +4) are similar scales ranging from "Very marked worsening" (-4) to "Complete resolution of cervical dystonia symptoms" (+4). VAS (range, 0 mm to 100 mm) assesses the change from baseline in symptom severity, where 0 mm indicates "Much worse", 50 mm "No change", and 100 mm "Symptom-free". The Clinical Global Rating is a scale taking into account 6 grades of efficacy (excellent, good, moderate, slight improvement, no change, condition worse) and 4 grades of adverse events (none, mild, moderate, extreme).</P><P>The trials measured subjective assessments using these validated scales as the change from baseline to weeks 3 to 6.</P><P>We could not combine data from three studies (<LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>; <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>) into the meta-analysis for this outcome. <LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK> reported no data for the control group, <LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK> reported a change from baseline for both study groups but did not report a measure of dispersion, and <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK> did not report the change from baseline.</P><SUBSECTION><HEADING LEVEL="5">3.1. Subjective assessment by clinicians</HEADING><P>Four trials (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>; n = 544) contributed data for this outcome. Treatment with BtA was associated with an increased likelihood of clinical improvement when compared to placebo as assessed by physicians between weeks 4 and 20 after drug injection (RR 1.91, CI 1.47 to 2.49; I<SUP>2 </SUP>= 28%; <LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>). We calculated an NNTB of 3 (95% CI 2 to 6) with a single BtA treatment session.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">3.2. Subjective assessment by participants</HEADING><P>Five trials (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>; n = 624) contributed data for this outcome. Treatment with BtA was associated with an increased likelihood of clinical improvement when compared to placebo as assessed by participants between weeks 4 and 20 after drug injection (RR 2.30, CI 1.83 to 2.90; I<SUP>2 </SUP>= 0%; moderate certainty in the evidence; <LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>). We calculated an NNTB of 3 (95% CI 2 to 5) with a single BtA treatment session.</P><P>Two trials (<LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>) considered only those participants reporting more than a half of improvement from baseline, and therefore these pooled results may underestimate the likelihood of participants reporting a subjective benefit with BtA treatment.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Pain relief</HEADING><P>Six trials (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; <LINK REF="STD-Wissel-2001" TYPE="STUDY">Wissel 2001</LINK>; n = 722) contributed data to this outcome. They measured pain relief with validated pain scales as the change from baseline to weeks 3 to 6. Overall, treatment with BtA was associated with a moderately increased efficacy with regards to pain relief at weeks 4 to 6 (SMD 0.50, 95% CI 0.35 to 0.65; I<SUP>2 </SUP>= 0%; moderate certainty in the evidence; <LINK REF="CMP-001.26" TYPE="ANALYSIS">Analysis 1.26</LINK>).</P><P>Three trials (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; n = 429) contributed data measured on the TWSTRS pain subscale, and for this pooled result we found a MD of 2.11 TWSTRS points favouring participants allocated to BtA (95% CI 1.38 too 2.83; I<SUP>2 </SUP>= 0%; <LINK REF="CMP-001.27" TYPE="ANALYSIS">Analysis 1.27</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Health-related quality of life</HEADING><P>Three studies (<LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK>; <LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>) assessed the impact of BtA on quality of life.</P><P><LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK> (n = 213) used the Cervical Dystonia Impact Profile (CDIP)-58 scale (including eight subscales: head and neck symptoms, pain and discomfort, sleep, upper limb activities, walking, annoyance, mood and psychosocial functioning), and reported a significant improvement in total CDIP-58 score (49.3 in BtA versus 59.4 in placebo; P &lt; 0.0001), as well as in all eight CDIP-58 subscales (P &lt; 0.0003).</P><P><LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK> (n = 80) and <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK> (n = 116) reported an improvement from baseline to week 8 in the physical function domain of the SF-36 (<LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>: odds ratio (OR) 1.60, P = 0.011; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>: MD 10.10, 95% CI 2.95 to 17.25; P = 0.018), but no benefit in social functioning when compared to placebo (<LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK>: OR 0.30, 95% CI 0.23 to 0.82; P = 0.265; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>: MD 6.90, 95% CI 2.16 to 15.96; P = 0.125).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Tolerability</HEADING><P>Adverse drug reactions (ADRs) can be a result of adverse events cause by the intervention (i.e. type A and/or type B ADRs), or lack of efficacy of the treatment (i.e. failure of therapy, a type F ADR) (<LINK REF="REF-Edwards-2000" TYPE="REFERENCE">Edwards 2000</LINK>).</P><P>Four trials (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; n = 574) contributed data to this outcome. Overall, BtA was associated with a decreased likelihood of withdrawal from trials (RR 0.36, 95% CI 0.21 to 0.61; I<SUP>2 </SUP>= 0%; moderate certainty in the evidence; <LINK REF="CMP-001.30" TYPE="ANALYSIS">Analysis 1.30</LINK>).</P><P>Three trials (<LINK REF="STD-Charles-2012" TYPE="STUDY">Charles 2012</LINK>; <LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK>; n = 519) contributed data regarding the withdrawals due to lack of efficacy. Overall, BtA was associated with a decreased likelihood of withdrawal from trials due to this reason (RR 0.30, 95% CI 0.17 to 0.53; I<SUP>2 </SUP>= 0%; <LINK REF="CMP-001.31" TYPE="ANALYSIS">Analysis 1.31</LINK>).</P><P>Two trials (<LINK REF="STD-Comella-2011" TYPE="STUDY">Comella 2011</LINK>; <LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>; n = 288) contributed data regarding the withdrawals due to adverse events. Overall, we did not find a difference between BtA and placebo regarding withdrawals due to adverse events (RR 3.10; 95% CI 0.36 to 26.74; I<SUP>2 </SUP>= 0%; <LINK REF="CMP-001.32" TYPE="ANALYSIS">Analysis 1.32</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Duration of effect</HEADING><P>We did not pool results for this outcome due to the lack of combinable data.</P><P>Most studies assessed duration of effect on participants who showed some level of response to the assigned study treatment, either BtA or placebo. <LINK REF="STD-Poewe-1998" TYPE="STUDY">Poewe 1998</LINK> reported a dose-dependent duration of effect, with request for re-injection occurring at week 8 in 39%, 50% and 94% of participants treated with high-, medium- to low-dose, and placebo, respectively.</P><P><LINK REF="STD-Truong-2005" TYPE="STUDY">Truong 2005</LINK> reported a mean duration of effect of 22.8 weeks (SD = 12.5; range 9 to 46) until recurrence of symptoms, while <LINK REF="STD-Truong-2010" TYPE="STUDY">Truong 2010</LINK> reported a mean time to re-treatment of 14.4 weeks (range 4 to 30).</P><P><LINK REF="STD-Poewe-2016" TYPE="STUDY">Poewe 2016</LINK> evaluated response to BtA over five treatment cycles. It reports that the duration of treatment effect for treatment responders was more than 85 days from cycles 2 to 5, irrespective of the dose used.</P></SUBSECTION></SUBSECTION></INTERVENTION_EFFECTS></RESULTS><DISCUSSION MODIFIED="2017-11-14 15:55:21 +0000" MODIFIED_BY="[Empty name]"><SUMMARY_OF_RESULTS MODIFIED="2017-11-14 15:20:38 +0000" MODIFIED_BY="[Empty name]"><P>This updated review included eight randomised, parallel-designed trials, that enrolled 1010 people with cervical dystonia, of whom 70% had been previously treated with botulinum toxin for their condition.</P><P>As can be seen in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>, in comparison to placebo, BtA was probably more efficacious in reducing cervical dystonia-associated impairment, including disease severity, disability, and associated pain. Treatment with BtA also increased the likelihood that participants and clinicians would detect any form of improvement. Uncertanity remains over the effect of BtA on other domains of people's quality of life, such as social functioning or mental health.</P><P>However, treatment with BtA increased the risk of experiencing an adverse event. In particular, BtA increased in the risk of two specific adverse events of special interest, namely dysphagia and diffuse weakness/tiredness. No fatalities or serious adverse events were considered related to BtA treatment in any trial. Finally, treatment with BtA slightly decreased the risk of withdrawal from the included clinical trials. Data for special subpopulations, such as children and pregnant women, were not available.</P><P>We found low to moderate statistical heterogeneity for most efficacy and safety outcome estimates.</P><SUBSECTION><HEADING LEVEL="3">BtA doses</HEADING><P>All dosages were efficacious against placebo, but we found no clear-cut evidence of a dose-response gradient. It is, however, noteworthy that these trials were not dose-response studies, they were not adequately powered to assess this question, and that we based this conclusion on arbitrarily defined dose-subgroup analyses.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">BtA formulations</HEADING><P>Although none of the trials was designed or powered to evaluate the comparative utility of the three most widely used formulations of BtA (Botox (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), and Xeomin (incobotulinumtoxinA)), we did not find differences between these subgroups in terms of overall efficacy or safety.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Use of EMG</HEADING><P>Although none of the trials was designed to evaluate the comparative utility of injection technique with or without EMG, we did not find differences between trials that allowed and those that did not allow the use of EMG, in terms of overall efficacy or safety.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Duration of effect</HEADING><P>Results from the few studies that addressed the duration of clinical effect of a treatment cycle in this review were not conclusive, with time to re-treatment ranging greatly, from 1 to 11 months. We could not adequately evaluate long-term duration of effect as all trials but one evaluated only a single treatment session.</P></SUBSECTION></SUMMARY_OF_RESULTS><APPLICABILITY_OF_FINDINGS MODIFIED="2017-11-14 15:20:38 +0000" MODIFIED_BY="[Empty name]"><P>All included trials addressed the primary research question directly, using similar and validated assessment tools. However, they did not fully report data for all outcomes, and in some cases we could not pool results and compare them across studies. This limited the amount of data available and, consequently, the confidence in overall conclusions.</P><P>The participants included in the trials were not fully representative of the overall population of people with cervical dystonia. The effects of population enrichment and the moderate overall disease impairment (as assessed by the baseline TWSTRS scores) preclude definite conclusions concerning all people with this condition.</P><P>Four noteworthy factors challenge the implementation of the evidence in this review. Firstly, there was a considerably heterogeneous regional distribution, with most trials being conducted in North America and Europe. Differences in clinical practice, training of experts, and local guidelines in other regions of the world may present an obstacle to the application of the evidence here demonstrated. Secondly, sample size across included trials was relatively small and many subgroup analyses addressing clinically relevant questions for the main outcomes were underpowered. More studies are needed to provide robust evidence for these questions. Thirdly, the use of enriched populations in clinical trials limits applicability of results into clinical practice, as complex and potentially poorer responders are usually excluded in these trials. The fact that such individuals are common in clinical practice further complicates issues of generalisation. Fourthly, it is common for people with cervical dystonia to have concomitant medications for their condition, such as muscle relaxants and benzodiazepines. Reasonably, participants in trials are required to be on a stable dose of these medications for many weeks to avoid confounding factors. As a result, little is known at present about the impact of these drug regimens with regard to implementation of the evidence in this review.</P></APPLICABILITY_OF_FINDINGS><QUALITY_OF_EVIDENCE MODIFIED="2017-11-14 15:55:21 +0000" MODIFIED_BY="[Empty name]"><P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, 'Risk of bias' tables, 'Risk of bias' summary tables (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>), and <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P><P>We considered all included trials but one to be at a high risk for both 'for-profit bias' and having an enriched population. Only three of the included studies adequately described the randomisation or allocation methods, or both, with the remaining trials being assessed at an unclear risk of bias for these items. We considered most studies to be appropriately blinded in general. However, only a single trial provided a satisfactory description of blinding of objective outcome assessment, and we considered all but one possibly biased regarding subjective outcome assessment, as most studies predominantly enrolled participants with previous exposure to botulinum toxin. This represents a major methodological limitation that may have resulted in a biased assessment of the intervention effect, particularly with regards to subjective outcomes, namely pain assessment, subjective assessment by participants and clinicians, and quality of life assessments, which are highly susceptible to biased estimations.</P><P>We could not compare some outcomes across studies, as some studies did not report relevant data. We were unable to impute values for missing data due to imbalances between baseline characteristics of the participants and incomplete description of the variables, further reducing the amount of combinable data, and therefore our confidence in the results.</P><P>The included trials each enrolled between 55 and 233 participants, and although individually some of these trials were underpowered, the pooling of the trials permitted an adequate sample size for the majority of efficacy outcomes.</P><P>Taken together, as can be seen in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>, we consider that there is moderate certainty in the evidence that a single treatment session of BtA improves cervical dystonia-associated impairment in certain types of cervical dystonia, including severity, disability, and pain. The certainty in the evidence supporting the higher occurrence of any adverse event, as well diffuse weakness/tiredness and dysphagia is moderate. The certainty in the evidence assessing the change in subjective evaluation of clinical status evaluated by participants is moderate. Finally, we have moderate certainty in the evidence that treatment with BtA increases the likelihood of participants not dropping out of clinical trials.</P></QUALITY_OF_EVIDENCE><POTENTIAL_BIASES MODIFIED="2017-11-14 15:20:37 +0000" MODIFIED_BY="[Empty name]"><P>Although we followed the methods recommended by Cochrane in order to minimise bias in the review process, certain areas do deserve attention. In particular, we have not searched clinical trials registries. Although this opens the current review to the potential bias of having missed trials, we consider this possibility highly unlikely because we have extensively contacted other experts in this field and US and European trials in this area are well-known.</P><P>An additional bias was that we could not obtain data for all outcomes in the included trials. A further limitation of this review is the small number of participants contributing data to each outcome, although Trial Sequential Analysis showed that both the primary efficacy and safety outcomes were adequately powered to demonstrate the difference that we observed.</P></POTENTIAL_BIASES><AGREEMENT MODIFIED="2017-11-14 15:20:37 +0000" MODIFIED_BY="[Empty name]"><P>Overall, the results of this updated review are in agreement with the conclusions of earlier versions (<LINK REF="REF-Costa-2005" TYPE="REFERENCE">Costa 2005</LINK>). The current clinical practice guidelines of the American Academy of Neurology and the European Academy of Neurology agree that BtA is "established as safe and effective for cervical dystonia treatment" (<LINK REF="REF-Simpson-2016" TYPE="REFERENCE">Simpson 2016</LINK>) and that it is considered an "effective and safe treatment for cervical dystonia" (<LINK REF="REF-Albanese-2011" TYPE="REFERENCE">Albanese 2011</LINK>). We now conclude that no claims can be made regarding a clear dose-response relationship for efficacy outcomes. On the other hand, a clear relationship exists for the increased risk of treatment-related adverse events of special interest, namely dysphagia and diffuse weakness/tiredness.</P></AGREEMENT></DISCUSSION><CONCLUSIONS MODIFIED="2017-11-14 15:20:37 +0000" MODIFIED_BY="[Empty name]"><IMPLICATIONS_PRACTICE MODIFIED="2017-11-14 15:20:37 +0000" MODIFIED_BY="[Empty name]"><P>In this updated Cochrane Review we found that a single treatment session of botulinum toxin type A (BtA) is effective and well-tolerated in the treatment of moderately-impaired adults with certain types of cervical dystonia. The clinical benefit includes moderate to large improvements across several objective disease domains, namely severity, disability, and pain. The benefit is also meaningful when subjectively assessed by patients. The evidence is less robust regarding health-related quality of life improvements. Adverse events are frequent, but are not commonly associated with treatment discontinuation. In fact, since withdrawals were less frequent in the BtA group, we can assume that people with cervical dystonia find the risk-benefit profile of BtA highly favourable. Dysphagia and diffuse weakness/tiredness are the most frequent treatment-related adverse events of special interest. We are moderately certain about the conclusions based on the evidence.</P><P>The available evidence does not allow for firm conclusions regarding the existence of a clear dose-benefit response, nor to support or not support routine use of EMG-guided BtA injection. The current evidence does not allow conclusions regarding the comparative risk-benefit profiles of the different BtA formulations available.</P><P>We can draw no conclusions regarding people with pure retrocollis or anterocollis, as these were predominantly excluded in the clinical trials.</P></IMPLICATIONS_PRACTICE><IMPLICATIONS_RESEARCH MODIFIED="2017-11-14 15:20:37 +0000" MODIFIED_BY="[Empty name]"><P>We have had access only to published research data from trials of BtA versus placebo in adults with certain types of cervical dystonia. The net benefit of a single BtA injection in the treatment of cervical dystonia has been clearly established in the published trials, making it difficult to determine which and how many resources should be invested in future research.</P><P>Nonetheless, further studies are needed to establish the relative effectiveness of different doses of BtA, assessing efficacy, safety, duration of effect, and quality of life across regimes, with repeated BtA treatment sessions, and assessed under conditions more closely resembling clinical practice (pragmatic clinical trials). Because therapy typically requires optimising a dose for each patient rather than administering a fixed dose of botulinum toxin, such a line of research would be important to support physicians' management of doses and allow for a more solid and safe individualisation of patient treatment. Also to be determined is the added value, if any, of guidance methods (e.g. EMG) in injecting botulinum toxin into the cervical muscles.</P><P>Future research concerning all formulations of botulinum neurotoxin should endeavour to establish clinical effectiveness not only based on changes from baseline, but also, preferably, based on validated measures of Minimal Clinically Important Difference/Change (<LINK REF="REF-Bro_x017c_ek-2006" TYPE="REFERENCE">Bro&#380;ek 2006</LINK>). Research is required in order to establish such a parameter for the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), currently the most widely used and disseminated clinical scale in the field. We are, however, aware of an effort to create a new clinical scale in dystonia - the Comprehensive Cervical Dystonia Rating Scale (<LINK REF="REF-Comella-2015" TYPE="REFERENCE">Comella 2015</LINK>), which will include a revision of the TWSTRS, to be named TWSTRS-2, with a Minimal Clinically Important Change validation being planned.</P><P>It is currently uncertain whether or not the clinical effectiveness of botulinum toxin decays over time, with repeated treatment sessions, and whether a possible loss of effectiveness occurs in all clinical domains. Future studies comparing any form of BtA should address the comparative proportion of participants who develop secondary non-responsiveness to treatment.</P><P>Finally, in conducting this systematic review we were faced with the fact that there is no defined core outcome set in cervical dystonia research, as there are for other areas (<LINK REF="REF-Tugwell-2007" TYPE="REFERENCE">Tugwell 2007</LINK>). The definition of a set of core outcome measures to be included in future research, via well-established methodology to determine the inclusion of patient-reported outcomes (<LINK REF="REF-Macefield-2014" TYPE="REFERENCE">Macefield 2014</LINK>), would be relevant to promote research in this field, as well as to support the clinical effectiveness of botulinum toxin.</P><P>Given the high degree of certainty in the results, and that the outcomes are mostly adequately-powered and provide robust evidence of efficacy, future efforts to update this review may not be justified, unless Cochrane methodology changes or some of the research suggestions are published.</P></IMPLICATIONS_RESEARCH></CONCLUSIONS></BODY><ACKNOWLEDGEMENTS MODIFIED="2017-11-14 15:20:37 +0000" MODIFIED_BY="[Empty name]"><P>We would like to thank Ema Roque (Cochrane Movement Disorders) and Daisy Abreu (Clinical Pharmacology Unit, Faculty of Medicine, University of Lisbon) sincerely for their contributions to this review.</P></ACKNOWLEDGEMENTS><CONFLICT_OF_INTEREST MODIFIED="2017-11-14 15:20:37 +0000" MODIFIED_BY="[Empty name]"><P>JC, JJF, and CS were investigators in clinical trials in botulinum toxin A and B use in dystonia sponsored by Elan (manufacturer of botulinum toxin type B), Allergan (manufacturer of botulinum toxin type A), and Ipsen (manufacturer of botulinum toxin type A). Searching for studies, selection of studies, data extraction and analysis (including risk of bias), and GRADE assessment were performed by authors (FBR, GSD, MC, REM) who were not trialists. JJF and CS were speakers in symposiums promoted by Elan, Allergan, and Ipsen.<BR/>APM has received royalties from Ipsen for the use 'LIVEchart' scoring system for botulinum toxin treatment efficacy. He has additionally received consulting fees from Ipsen, Merz (manufacturer of botulinum toxin type A), Eisai (manufacturer of botulinum toxin type B), and Allergan. The same companies have provided for support for travel to meetings for studies or other purposes.</P></CONFLICT_OF_INTEREST><CONTRIBUTIONS MODIFIED="2017-11-14 16:01:26 +0000" MODIFIED_BY="[Empty name]"><P>Austen P Moore - APM; Cristina Sampaio - CS; Filipe Brogueira Rodrigues - FBR; Gonçalo S Duarte - GSD; João Costa - JC; Joaquim Ferreira - JJF; Mafalda Castelão - MC; Raquel E Marques - REM.</P><P>Concieving the review - APM, CS, JC, JJF</P><P>Designing the review - APM, CS, JC, JJF</P><P>Co-ordinating the review - JC</P><P>Designing search strategies &#8211; FBR, GSD, JC</P><P>Undertaking searches &#8211; FBR, GSD</P><P>Screening search results &#8211; FRB, GSD, MC, REM</P><P>Organising retrieval of papers - FRB, GSD, JC, MF, REM</P><P>Screening retrieved papers against eligibility criteria - FRB, GSD, MC, REM</P><P>Appraising quality of papers - FRB, GSD, MC, REM</P><P>Extracting data from papers - FRB, GSD, MC, REM</P><P>Writing to authors of papers for additional information &#8211; GSD, JC, REM</P><P>Data management for the review &#8211; FRB, GSD, MC, REM</P><P>Entering data into Review Manager 5 - FRB, GSD, MC, REM</P><P>Analysis of data - FRB, GSD, MC, REM</P><P>Interpretation of data - APM, CS, FRB, GSD, JC, JJF, MC, REM</P><P>Writing the review - FRB, GSD, JC, MC, REM</P><P>GRADE assessment - GSD, FBR</P><P>Providing general advice on the review &#8211; APM, CS, JC, JJF</P><P>Performing previous work that was the foundation of the current review &#8211; Ana Borges, Claudia Espírito Santo, Miguel Coelho.</P></CONTRIBUTIONS><PRO_REV_DIFF MODIFIED="2017-11-14 15:20:37 +0000" MODIFIED_BY="[Empty name]"><P>For this updated review the study designs accepted were restricted to parallel-group studies, and we opted not to exclude based on allocation concealment. No changes were made in the type of participants included or in the interventions allowed.</P><P>Adverse events, which were originally a secondary outcome, were included in this updated review as a primary safety outcome. Also, in this safety analysis we considered the proportion of participants with the most frequent adverse events, which was not stated in the original protocol. An assessment of the duration of effect was included as a new secondary outcome measure.</P><P>We no longer consider immunogenicity to be an outcome to be studied in this systematic review, as we believe it does not enhance patient's, physician's, or policymaker's ability to make decisions regarding question of this review. At most, it is an inadequate surrogate measure of the risk of developing clinical non-responsiveness.</P><P>We used new approaches to deal with missing data and unit of analysis issues.</P><P>We used the latest recommended Cochrane tool for assessing risk of bias in this review, which was expanded to include two additional criteria, added by the review authors. We opted to include the enriched population domains, since a known positive response to botulinum toxin type A and certain disease subtype are known to influence the magnitude of response to the intervention. As has been verified in a recent Cochrane methodology systematic review (<LINK REF="REF-Lundh-2017" TYPE="REFERENCE">Lundh 2017</LINK>), industry-sponsored trials display "the existence of an industry bias that cannot be explained by standard 'Risk of bias' assessments". We analysed blinding of outcome assessment in two new subcategories: subjective and objective assessment and also added a &#8216;Summary of findings' table. The search strategy was prolonged to October 2016.</P><P>Trial Sequential Analysis was not in the original review protocol.</P></PRO_REV_DIFF><PUBLIC_NOTES/></MAIN_TEXT><STUDIES_AND_REFERENCES MODIFIED="2017-12-04 15:12:14 +0000" MODIFIED_BY="Ema Roque">
<STUDIES MODIFIED="2017-11-14 17:21:18 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2017-11-14 17:21:18 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Charles-2012" MODIFIED="2017-11-14 17:17:54 +0000" MODIFIED_BY="[Empty name]" NAME="Charles 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-11-14 17:17:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brashear A, Truong D, Charles D, Comella C, Hauser RA, Tsui J</AU>
<TI>A randomized double-blind, placebo-controlled study of intramuscular Botox for the treatment of cervical dystonia (CD)</TI>
<SO>Movement Disorders</SO>
<YR>1998</YR>
<VL>13 Suppl 2</VL>
<PG>276 (P4.243)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291077"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:17:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF; CD 140 Study Group</AU>
<TI>Efficacy, tolerability, and immunogenicity of onabotulinumtoxinA in a randomized, double-blind, placebo-controlled trial for cervical dystonia</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2012</YR>
<VL>35</VL>
<NO>5</NO>
<PG>208-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291078"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:17:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Comella C</AU>
<TI>Botox for cervical dystonia</TI>
<SO>Toxins'99 (www.wemove.org)</SO>
<YR>1999</YR>
<PG>8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291079"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:17:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hauser RA, Comella C, Brashear A, Truong D, Charles PD, Tsui J</AU>
<TI>A randomized, multicenter, placebo-controlled study of original otox (botulinum toxin type A) purified neurotoxin complex for the treatment of cervical dystonia</TI>
<SO>Movement Disorders</SO>
<YR>2000</YR>
<VL>15 Suppl 2</VL>
<PG>30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291080"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-11-17 14:48:17 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291076"/><IDENTIFIER MODIFIED="2014-11-17 14:48:17 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1097/WNF.0b013e31826538c7"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Comella-2011" MODIFIED="2017-11-14 17:17:27 +0000" MODIFIED_BY="[Empty name]" NAME="Comella 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-11-14 17:17:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafeon S; on behalf of the U.S. Xeomin Cervical Dystonia Study Group</AU>
<TI>Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinumneurotoxin type A, without accessory proteins) in patients with cervical dystonia</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2011</YR>
<VL>308</VL>
<NO>1-2</NO>
<PG>103-9</PG>
<IDENTIFIERS MODIFIED="2014-10-05 13:39:18 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291082"/><IDENTIFIER MODIFIED="2014-10-05 13:39:14 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.jns.2011.05.041."/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-13 12:05:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coulonn J-M
</AU>
<TI>Incobotulinumtoxin A (Xeomin) injected with flexible intervals is a well-tolerated long-term treatment of cervical dystonia</TI>
<SO>Annals of Physical and Rehabilitation Medicine</SO>
<YR>2013</YR>
<VL>56</VL>
<PG>e398</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291083"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:17:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evidente VG, Brashear A, Comella CL, Fernandez H, Grafe S, LeDoux MS et al</AU>
<TI>IncobotulinumtoxinA (Xeomin; botulinumneurotoxin type A, free from accessory proteins): flexibility of dosing and injection intervals in cervical dystonia</TI>
<SO>PM&amp;R</SO>
<YR>2011</YR>
<VL>3</VL>
<NO>10S1</NO>
<PG>S215 (P131)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291084"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:17:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evidente VG, Truong D, Jankovic J, Comella CL, Grafe S, Hanschmann A</AU>
<TI>IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2014</YR>
<VL>346</VL>
<NO>1-2</NO>
<PG>116-20</PG>
<IDENTIFIERS MODIFIED="2015-02-02 22:26:23 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291085"/><IDENTIFIER MODIFIED="2015-02-02 22:26:10 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.jns.2014.08.004"/><IDENTIFIER MODIFIED="2015-02-02 22:26:23 +0000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="25186131"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-05 14:14:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez H, Truong D, Asmus F, Hanschmann A, LeDoux M</AU>
<TI>IncobotulinumtoxinA (Xeomin®) remains well tolerated across flexible inter-injection intervals of 6-20 weeks in the treatment of cervical dystonia</TI>
<SO>Neurology</SO>
<YR>2012</YR>
<VL>78</VL>
<NO>Meeting Abstracts 1</NO>
<PG>P01.219</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291086"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:17:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez HH, Evidente VG, Truong D, Brodsky M, Hanschmann A, Comella CL et al</AU>
<TI>Long-term treatment of blepharospasm and cervical dystonia: incobotulinum toxin A is well tolerated when injected at flexible intervals based on patient needs</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2013</YR>
<VL>333</VL>
<PG>109-51 (P1070)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291087"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:17:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez HH, Pappert EJ, Comella CL, Evidente VG, Truong DD, Verma A et al</AU>
<TI>Efficacy and safety of incobotulinumtoxinA in subjects previously treated with botulinum toxin versus toxin-naïve subjects with cervical dystonia</TI>
<SO>Tremor and Other Hyperkinetic Movements</SO>
<YR>2013</YR>
<VL>3</VL>
<PG>1-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291088"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:16:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grafe S, Comella C, Hanschmann A, Jankovic J, Truong D</AU>
<TI>Efficacy and safety of NT 201 (botulinum neurotoxin free from complexing proteins) in cervical dystonia</TI>
<SO>PM&amp;R</SO>
<YR>2010</YR>
<VL>2</VL>
<NO>9S</NO>
<PG>S29 (P49)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291089"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:15:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singer C, Pappert E, Hanschmann A, Fernandez H</AU>
<TI>IncobotulinumtoxinA (NT 201, Xeomin) administered at flexible intervals of 6-20 weeks in subjects with cervical dystonia</TI>
<SO>Movement Disorders</SO>
<YR>2012</YR>
<VL>27 Suppl.1</VL>
<PG>S365 (P1105)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291090"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-05 13:53:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Truong D, Fernandez H, Grafe S</AU>
<TI>IncobotulinumtoxinA (NT-201) injections are safe and effective in adult subjects with cervical dystonia across dosing intervals in a repeated dose-study</TI>
<SO>Movement Disorders</SO>
<YR>2011</YR>
<VL>26 Suppl.2</VL>
<PG>S211 (P625)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291091"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-10-05 13:36:38 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291081"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greene-1990" MODIFIED="2017-11-14 17:16:14 +0000" MODIFIED_BY="[Empty name]" NAME="Greene 1990" YEAR="1990">
<REFERENCE MODIFIED="2017-11-14 17:16:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E</AU>
<TI>Double-blind, placebo-controlled study of botulinum toxin injection for torticollis</TI>
<SO>Neurology</SO>
<YR>1988</YR>
<VL>38 Suppl 1</VL>
<PG>244</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291093"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E</AU>
<TI>Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis</TI>
<SO>Neurology</SO>
<YR>1990</YR>
<VL>40(8)</VL>
<PG>1213-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291094"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291092"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poewe-1998" MODIFIED="2017-11-14 17:20:01 +0000" MODIFIED_BY="[Empty name]" NAME="Poewe 1998" YEAR="1998">
<REFERENCE MODIFIED="2017-11-14 17:14:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poewe W, Brans J, Kessler K, Kanovsky P, Odergren T, Aramideh M et al</AU>
<TI>Dysport for cervical dystonia</TI>
<SO>Movement Disorders</SO>
<YR>2000</YR>
<VL>15 Suppl 2</VL>
<PG>7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7215410"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:16:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R et al</AU>
<TI>What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1998</YR>
<VL>64</VL>
<NO>1</NO>
<PG>13-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7215411"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-23 09:43:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Poewe W</AU>
<TI>Dysport for Cervical Dystonia</TI>
<SO>Toxins'99 (www.wemove.org)</SO>
<YR>1999</YR>
<PG>10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7215412"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7215409"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poewe-2016" MODIFIED="2017-11-14 17:21:18 +0000" MODIFIED_BY="[Empty name]" NAME="Poewe 2016" YEAR="2015">
<REFERENCE MODIFIED="2017-11-14 17:21:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Poewe W, Burbaud P, Castelnovo G, Jost WH, Ceballos-Baumann AO, Banach M et al</AU>
<TI>Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: a randomized-controlled trial</TI>
<SO>Movement Disorders</SO>
<YR>2016 [Epub ahead of print]</YR>
<VL>21</VL>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7215414"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-10-15 09:21:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7215413"/><IDENTIFIER MODIFIED="2016-10-15 09:21:55 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/mds.26760"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Truong-2005" MODIFIED="2017-11-14 17:13:40 +0000" MODIFIED_BY="[Empty name]" NAME="Truong 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-10-05 18:09:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coleman CM, Chang SF, Copley-Merriman C, Hubble J, Masaquel C</AU>
<TI>Health-related quality of life improvements with dysport in cervical dystonia</TI>
<SO>PM&amp;R</SO>
<YR>2011</YR>
<VL>3 Suppl.1</VL>
<NO>10</NO>
<PG>S190 (P41)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291103"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:13:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hauser RA, Truong D, Hubble J, Coleman C, Beffy JL, Chang S, Picaut P</AU>
<TI>AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies</TI>
<SO>Journal of Neural Transmission</SO>
<YR>2013</YR>
<VL>120</VL>
<NO>2</NO>
<PG>299-307</PG>
<IDENTIFIERS MODIFIED="2015-02-02 22:54:10 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291104"/><IDENTIFIER MODIFIED="2015-02-02 22:54:04 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/s00702-012-0872-1"/><IDENTIFIER MODIFIED="2015-02-02 22:54:10 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22878514"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:12:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jen M, Kurth H, Iheanacho I, Dinet J, Gabriel S, Wasiak R et al</AU>
<TI>Improvement of SF-36 scores in cervical dystonia patients - is there a treatment effect when evaluating subscales?</TI>
<SO>Basal Ganglia</SO>
<YR>2014</YR>
<VL>126</VL>
<PG>1-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291105"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:12:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL et al</AU>
<TI>Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study</TI>
<SO>Movement Disorders</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>7</NO>
<PG>783-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291106"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:13:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Truong DD, Duane DD, Jankovic J, Singer C, Comella CL</AU>
<TI>The efficacy and safety of Dysport (botulinumtype A toxin) in cervical dystonia: results of the first US study</TI>
<SO>Movement Disorders</SO>
<YR>2002</YR>
<VL>17 Suppl 5</VL>
<PG>S306 (P1007)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291107"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291102"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Truong-2010" MODIFIED="2017-11-14 17:12:02 +0000" MODIFIED_BY="[Empty name]" NAME="Truong 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-11-13 12:23:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mordin M, Masaquel C, Abbott C, Copley-Merriman C
</AU>
<TI>Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study
</TI>
<SO>BMJ Open</SO>
<YR>2014</YR>
<VL>4</VL>
<NO>10</NO>
<PG>e005150</PG>
<IDENTIFIERS MODIFIED="2014-12-26 17:31:35 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291110"/><IDENTIFIER MODIFIED="2014-12-26 17:31:12 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/bmjopen-2014-005150"/><IDENTIFIER MODIFIED="2014-12-26 17:31:35 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25324317"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-14 17:12:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E et al; Global Dysport Cervical Dystonia Study Group</AU>
<TI>Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia</TI>
<SO>Parkinsonism &amp; Related Disorders</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>5</NO>
<PG>316-23</PG>
<IDENTIFIERS MODIFIED="2014-12-23 16:06:37 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291111"/><IDENTIFIER MODIFIED="2014-12-23 16:06:26 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.parkreldis.2010.03.002"/><IDENTIFIER MODIFIED="2014-12-23 16:06:37 +0000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20359934"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291108"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wissel-2001" MODIFIED="2017-11-13 12:28:16 +0000" MODIFIED_BY="[Empty name]" NAME="Wissel 2001" YEAR="2001">
<REFERENCE MODIFIED="2017-11-13 12:27:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kanovsky P, Ruzicka E, Jech R, Roth J, Schnider P, Auff E et al</AU>
<TI>Standardized dose of 500 Mu of Dysport for 
cervical 
dystonia: 
results of a prospective, randomized, double-blind, placebo-controlled study</TI>
<SO>Movement Disorders</SO>
<YR>2000</YR>
<VL>15 Suppl 2</VL>
<PG>31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291113"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-13 12:27:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Poewe W, Brans J, Kessler K, Kanovsky P, Odergren T, Aramideh M et al</AU>
<TI>Dysport for 
cervical 
dystonia</TI>
<SO>Movement Disorders</SO>
<YR>2000</YR>
<VL>15 Suppl 2</VL>
<PG>7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291114"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-13 12:27:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Poewe W</AU>
<TI>Dysport for 
cervical 
cystonia</TI>
<SO>Toxins'99 (www.wemove.org)</SO>
<YR>1999</YR>
<PG>10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291115"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-13 12:28:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wissel J, Kanovsky P, Ruzicka E, Bares M, Hortova H, Streitova H et al</AU>
<TI>Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study</TI>
<SO>Journal of Neurology</SO>
<YR>2001</YR>
<VL>248
</VL>
<NO>12</NO>
<PG>1073-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291116"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291112"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-11-14 15:23:48 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Blackie-1990" MODIFIED="2017-11-13 12:36:28 +0000" MODIFIED_BY="[Empty name]" NAME="Blackie 1990" YEAR="1990">
<REFERENCE MODIFIED="2017-11-13 12:36:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blackie JD, Lees AJ</AU>
<TI>Botulinum toxin treatment in spasmodic torticollis</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1990</YR>
<VL>53
</VL>
<NO>8</NO>
<PG>640-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291118"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-23 09:48:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Turjanski N, Blackie J, Purves A, Hambleton P, Lees AJ</AU>
<TI>Botulinus toxin in the treatment of spasmodic torticollis long-term results</TI>
<SO>Journal of Neurology</SO>
<YR>1990</YR>
<CY>2nd Congress of European Neurological Society</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291119"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291117"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buchman-1994" MODIFIED="2017-11-13 12:34:13 +0000" MODIFIED_BY="[Empty name]" NAME="Buchman 1994" YEAR="1994">
<REFERENCE MODIFIED="2017-11-13 12:34:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buchman AS, Comella CL, Stebbins GT, Weinstein SL</AU>
<TI>Determining a 
dose-
effect 
curve for 
botulinum 
toxin in the 
sternocleidomastoid 
muscle in 
cervical 
dystonia</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>2</NO>
<PG>188-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291121"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291120"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gelb-1989" MODIFIED="2017-11-13 12:36:18 +0000" MODIFIED_BY="[Empty name]" NAME="Gelb 1989" YEAR="1989">
<REFERENCE MODIFIED="2017-11-13 12:34:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gelb DJ, Arbor A, Don M, Yoshimura RKO, Lowenstein DH, Aminoff MJ</AU>
<TI>Change in 
pattern of 
muscle 
activity 
following 
botulinum 
toxin 
injections for 
torticollis</TI>
<SO>Neurology</SO>
<YR>1989</YR>
<VL>39 Suppl 1</VL>
<PG>320</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291123"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-13 12:35:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gelb DJ, Lowenstein DH, Aminoff MJ</AU>
<TI>Botulinum 
toxin in the 
treatment of 
spasmodic 
torticollis</TI>
<SO>Neurology</SO>
<YR>1988</YR>
<VL>38 Suppl 2</VL>
<PG>244</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291124"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-13 12:36:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gelb DJ, Lowenstein DH, Aminoff MJ</AU>
<TI>Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis</TI>
<SO>Neurology</SO>
<YR>1989</YR>
<VL>39
</VL>
<NO>1</NO>
<PG>80-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291125"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291122"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koller-1990" MODIFIED="2017-11-13 12:36:13 +0000" MODIFIED_BY="[Empty name]" NAME="Koller 1990" YEAR="1990">
<REFERENCE MODIFIED="2017-11-13 12:36:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Koller W, Vetere-Overfield B, Gray C, Dubinsky R</AU>
<TI>Failure of fixed-dose, fixed muscle injection of botulinum toxin in torticollis</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1990</YR>
<VL>13
</VL>
<NO>4</NO>
<PG>355-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291127"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291126"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lange-1991" MODIFIED="2017-11-13 12:36:37 +0000" MODIFIED_BY="[Empty name]" NAME="Lange 1991" YEAR="1991">
<REFERENCE MODIFIED="2017-11-13 12:36:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lange DJ, Rubin M, Greene PE, Kang J, Moskowitz CB, Brin MF et al</AU>
<TI>Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes</TI>
<SO>Muscle and Nerve</SO>
<YR>1991</YR>
<VL>14</VL>
<PG>672-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291129"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291128"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lorentz-1991" MODIFIED="2017-11-13 12:36:42 +0000" MODIFIED_BY="[Empty name]" NAME="Lorentz 1991" YEAR="1991">
<REFERENCE MODIFIED="2017-11-13 12:36:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lorentz IT, Subramaniam SS, Yiannikas C</AU>
<TI>Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients</TI>
<SO>Movement Disorders</SO>
<YR>1991</YR>
<VL>6
</VL>
<NO>2</NO>
<PG>145-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291131"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291130"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-1995" MODIFIED="2017-11-13 12:36:47 +0000" MODIFIED_BY="[Empty name]" NAME="Lu 1995" YEAR="1995">
<REFERENCE MODIFIED="2017-11-13 12:36:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu CS, Chen RS, Tsai CH</AU>
<TI>Double-blind, placebo-controlled study of botulinum toxin injections in the treatment of cervical dystonia</TI>
<SO>Journal of the Formosan Medical Association</SO>
<YR>1995</YR>
<VL>94
</VL>
<NO>4</NO>
<PG>189-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291133"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291132"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maurri-1990" MODIFIED="2017-11-14 15:23:48 +0000" MODIFIED_BY="[Empty name]" NAME="Maurri 1990" YEAR="1990">
<REFERENCE MODIFIED="2017-11-14 15:23:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maurri S, Brogelli S</AU>
<TI>Botulinum toxin therapy for blepharospasm, hemifacial spasm and spasmodic torticollis: clinical studies with a follow-up of 40 months</TI>
<SO>Movement Disorders</SO>
<YR>1990</YR>
<VL>5 Suppl 1</VL>
<PG>73 (P262)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291135"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291134"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-1991" MODIFIED="2016-08-23 09:47:30 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-12-21 20:30:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moore AP, Blumhardt LD</AU>
<TI>A double blind trial of botulinum toxin "A" in torticollis, with one year follow up</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1991</YR>
<VL>54(9)</VL>
<PG>813-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291137"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-23 09:47:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore AP, Blumhardt LD</AU>
<TI>Double blind study of botulinum toxin A in torticollis</TI>
<SO>Journal of Neurology</SO>
<YR>1991</YR>
<VL>54</VL>
<NO>9</NO>
<PG>813-6</PG>
<CY>2nd Congress of European Neurological Society</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291138"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291136"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ostergaard-1994" MODIFIED="2017-11-13 12:38:14 +0000" MODIFIED_BY="[Empty name]" NAME="Ostergaard 1994" YEAR="1994">
<REFERENCE MODIFIED="2017-11-13 12:38:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ostergaard L, Fuglsang-Frederiksen A, Werdelin L, Sjo O, Winkel H</AU>
<TI>Quantitative EMG in botulinum toxin treatment of cervical dystonia. A double-blind, placebo-controlled study</TI>
<SO>Electroencephalography and Clinical Neurophysiology</SO>
<YR>1994</YR>
<VL>93(6)</VL>
<PG>434-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291140"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291139"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perlmutter-1989" MODIFIED="2017-11-14 15:23:43 +0000" MODIFIED_BY="[Empty name]" NAME="Perlmutter 1989" YEAR="1989">
<REFERENCE MODIFIED="2017-11-14 15:23:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perlmutter JS, Tempel LW, Burde R</AU>
<TI>Double-blind, placebo-controlled, crossover trial of botulinum-A toxin for torticollis</TI>
<SO>Neurology</SO>
<YR>1989</YR>
<VL>39 Suppl 1</VL>
<PG>352</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291142"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291141"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Relja-1993" NAME="Relja 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Relja M, Petravic D</AU>
<TI>Botulinum toxin type A injections for cervical dystonia: a double-blind, placebo controlled study</TI>
<SO>The Canadian Journal of Neurological Sciences</SO>
<YR>1993</YR>
<VL>20 Suppl 4</VL>
<PG>S185 (6-17-01)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291144"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291143"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsui-1986" MODIFIED="2017-11-13 12:43:59 +0000" MODIFIED_BY="[Empty name]" NAME="Tsui 1986" YEAR="1986">
<REFERENCE MODIFIED="2017-11-13 12:43:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB</AU>
<TI>Double-blind study of botulinum toxin in spasmodic torticollis</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>2
</VL>
<NO>2</NO>
<PG>245-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7215416"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7215415"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsui-1988" MODIFIED="2017-11-14 15:23:35 +0000" MODIFIED_BY="[Empty name]" NAME="Tsui 1988" YEAR="1988">
<REFERENCE MODIFIED="2017-11-14 15:23:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Tsui J, Eisen A, Calne DB</AU>
<TI>Botulinum toxin in spasmodic torticollis</TI>
<SO>Advances in Neurology</SO>
<YR>1988</YR>
<VL>50: Dystonia 2</VL>
<PG>593-7</PG>
<EN>Stanley Fahn et al</EN>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7215418"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7215417"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshimura-1990" MODIFIED="2017-11-14 15:23:28 +0000" MODIFIED_BY="[Empty name]" NAME="Yoshimura 1990" YEAR="1990">
<REFERENCE MODIFIED="2017-11-14 15:23:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshimura D, Aminoff M, Gelb D</AU>
<TI>Long term follow-up of patients treated with botulinum toxin for spasmodic torticollis</TI>
<SO>Movement Disorders</SO>
<YR>1990</YR>
<VL>5 (Suppl 1)</VL>
<PG>75 (P268)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3291150"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3291149"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-11-14 18:31:30 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2017-11-14 18:31:30 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abrams-2005" MODIFIED="2016-05-23 07:40:10 +0100" MODIFIED_BY="[Empty name]" NAME="Abrams 2005" TYPE="JOURNAL_ARTICLE">
<AU>Abrams KR, Gillies CL, Lambert PC</AU>
<TI>Meta-analysis of heterogeneously reported trials assessing change from baseline</TI>
<SO>Statistics in Medicine</SO>
<YR>2005</YR>
<VL>24</VL>
<PG>3823-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Albanese-2011" MODIFIED="2017-04-06 18:33:30 +0100" MODIFIED_BY="[Empty name]" NAME="Albanese 2011" TYPE="JOURNAL_ARTICLE">
<AU>Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G et al</AU>
<TI>EFNS guidelines on diagnosis and treatment of primary dystonias</TI>
<SO>European Journal of Neurology</SO>
<YR>2011</YR>
<VL>18</VL>
<PG>5-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Albanese-2013" MODIFIED="2017-11-13 12:46:54 +0000" MODIFIED_BY="[Empty name]" NAME="Albanese 2013" TYPE="JOURNAL_ARTICLE">
<AU>Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS
 et al</AU>
<TI>Phenomenology and classification of dystonia: a consensus update</TI>
<SO>Movement Disorders</SO>
<YR>2013</YR>
<VL>28</VL>
<NO>7</NO>
<PG>863-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-2002" MODIFIED="2016-05-23 07:40:10 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Deeks JJ</AU>
<TI>Meta-analysis, Simpson's paradox, and the number needed to treat</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>1</NO>
<PG>3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Antonucci-2008" MODIFIED="2016-05-23 19:41:58 +0100" MODIFIED_BY="[Empty name]" NAME="Antonucci 2008" TYPE="JOURNAL_ARTICLE">
<AU>Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M</AU>
<TI>Long-distance retrograde effects of botulinum neurotoxin</TI>
<SO>Journal of Neuroscience</SO>
<YR>2008</YR>
<VL>28</VL>
<PG>3689&#8211;96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balint-2015" MODIFIED="2016-05-23 07:40:10 +0100" MODIFIED_BY="[Empty name]" NAME="Balint 2015" TYPE="JOURNAL_ARTICLE">
<AU>Balint B, Bhatia KP</AU>
<TI>Isolated and combined dystonia syndromes - an update on new genes and their phenotypes</TI>
<SO>European Journal of Neurology</SO>
<YR>2015</YR>
<VL>22</VL>
<NO>4</NO>
<PG>610-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balshem-2011" MODIFIED="2016-08-23 09:25:37 +0100" MODIFIED_BY="[Empty name]" NAME="Balshem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 3. Rating the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>401-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boroff-1975" MODIFIED="2017-11-13 12:48:04 +0000" MODIFIED_BY="[Empty name]" NAME="Boroff 1975" TYPE="JOURNAL_ARTICLE">
<AU>Boroff DA, Chen GS</AU>
<TI>On the question of permeability of the blood&#8211;brain barrier to botulinum toxin</TI>
<SO>International Archives of Allergy and Applied Immunology</SO>
<YR>1975</YR>
<VL>48</VL>
<PG>495&#8211;504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bro_x017c_ek-2006" MODIFIED="2016-06-06 11:11:39 +0100" MODIFIED_BY="[Empty name]" NAME="Bro&#380;ek 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bro&#380;ek JL, Guyatt GH, Schünemann HJ</AU>
<TI>How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure</TI>
<SO>Health and Quality of Life Outcomes</SO>
<YR>2006</YR>
<VL>4</VL>
<PG>69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-2013" MODIFIED="2016-09-08 18:46:41 +0100" MODIFIED_BY="[Empty name]" NAME="Carpenter 2013" TYPE="BOOK">
<AU>Carpenter J, Kenward M</AU>
<SO>Multiple Imputation and its Application</SO>
<YR>2013</YR>
<PB>Wiley</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-1991" NAME="Chan 1991" TYPE="JOURNAL_ARTICLE">
<AU>Chan J, Brin MF, Fanh S</AU>
<TI>Idiopathic cervical dystonia: clinical characteristics</TI>
<SO>Movement Disorders</SO>
<YR>1991</YR>
<VL>6</VL>
<PG>119-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1988" MODIFIED="2017-11-13 12:50:46 +0000" MODIFIED_BY="[Empty name]" NAME="Cohen 1988" TYPE="BOOK">
<AU>Cohen J</AU>
<SO>Statistical Power Analysis in the Behavioral Sciences</SO>
<YR>1988</YR>
<EN>2nd</EN>
<PB>Lawrence Erlbaum Associates, Inc
</PB>
<CY>Hillsdale (NJ)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Comella-2015" MODIFIED="2017-11-14 18:25:48 +0000" MODIFIED_BY="[Empty name]" NAME="Comella 2015" TYPE="JOURNAL_ARTICLE">
<AU>Comella CL, Fox SH, Bhatia KP, Perlmutter JS, Jinnah HA, Zurowski M et al</AU>
<TI>Development of the comprehensive cervical dystonia rating scale: methodology</TI>
<SO>Movement Disorders</SO>
<YR>2015</YR>
<VL>2</VL>
<NO>2</NO>
<PG>135-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corbett-2014" MODIFIED="2017-11-13 12:51:56 +0000" MODIFIED_BY="[Empty name]" NAME="Corbett 2014" TYPE="JOURNAL_ARTICLE">
<AU>Corbett MS, Higgins JP, Woolacott NF</AU>
<TI>Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool</TI>
<SO>Research 
Synthesis 
Methods</SO>
<YR>2014</YR>
<VL>5</VL>
<NO>1</NO>
<PG>79-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Paiva-1999" MODIFIED="2017-11-13 12:52:36 +0000" MODIFIED_BY="[Empty name]" NAME="de Paiva 1999" TYPE="JOURNAL_ARTICLE">
<AU>de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO</AU>
<TI>Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1999</YR>
<VL>96</VL>
<PG>3200&#8211;5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2017-11-14 15:23:02 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Defazio-2013" MODIFIED="2017-11-13 12:53:26 +0000" MODIFIED_BY="[Empty name]" NAME="Defazio 2013" TYPE="JOURNAL_ARTICLE">
<AU>Defazio G, Jankovic J, Giel JL, Papapetropoulos S</AU>
<TI>Descriptive epidemiology of cervical dystonia</TI>
<SO>Tremor and Other Hyperkinetic Movements</SO>
<YR>2013</YR>
<VL>3</VL>
<PG>tre-03-193-4374-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duarte-2016" MODIFIED="2016-10-26 21:44:44 +0100" MODIFIED_BY="[Empty name]" NAME="Duarte 2016" TYPE="COCHRANE_REVIEW">
<AU>Duarte GS, Castelão M, Rodrigues FB, Marques RE, Ferreira J, Sampaio C, et al</AU>
<TI>Botulinum toxin type A versus botulinum toxin type B for cervical dystonia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2016</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2016-10-26 21:44:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-26 21:44:35 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004314.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duchen-1971" MODIFIED="2017-11-13 12:54:48 +0000" MODIFIED_BY="[Empty name]" NAME="Duchen 1971" TYPE="JOURNAL_ARTICLE">
<AU>Duchen LW</AU>
<TI>An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1971</YR>
<VL>14</VL>
<PG>47-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edwards-2000" MODIFIED="2015-04-13 17:56:30 +0100" MODIFIED_BY="[Empty name]" NAME="Edwards 2000" TYPE="JOURNAL_ARTICLE">
<AU>Edwards IR, Aronson JK</AU>
<TI>Adverse drug reactions: definitions, diagnosis, and management</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<NO>9237</NO>
<PG>1255-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESDE-2000" MODIFIED="2017-01-24 19:38:24 +0000" MODIFIED_BY="[Empty name]" NAME="ESDE 2000" TYPE="JOURNAL_ARTICLE">
<AU>Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group</AU>
<TI>A prevalence study of primary dystonia in eight European countries</TI>
<SO>Journal of Neurology</SO>
<YR>2000</YR>
<VL>247</VL>
<PG>787-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Filippi-1993" MODIFIED="2017-11-13 12:55:58 +0000" MODIFIED_BY="[Empty name]" NAME="Filippi 1993" TYPE="JOURNAL_ARTICLE">
<AU>Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E</AU>
<TI>Botulinum A toxin effects on rat jaw muscle spindles</TI>
<SO>Acta Oto-laryngologica</SO>
<YR>1993</YR>
<VL>113</VL>
<PG>400&#8211;4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Follmann-1992" MODIFIED="2016-05-23 19:41:58 +0100" MODIFIED_BY="[Empty name]" NAME="Follmann 1992" TYPE="JOURNAL_ARTICLE">
<AU>Follmann D, Elliott P, Suh I, Cutler J</AU>
<TI>Variance imputation for overviews of clinical trials with continuous response</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1992</YR>
<VL>45</VL>
<PG>769-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foltz-1959" NAME="Foltz 1959" TYPE="JOURNAL_ARTICLE">
<AU>Foltz EL, Knopp LM, Ward AA</AU>
<TI>Experimental spasmodic torticollis</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1959</YR>
<VL>16</VL>
<PG>55-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frevert-2010" MODIFIED="2016-05-23 19:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Frevert 2010" TYPE="JOURNAL_ARTICLE">
<AU>Frevert J, Dressler D</AU>
<TI>Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?</TI>
<SO>Biologics: Targets &amp; Therapy</SO>
<YR>2010</YR>
<VL>4</VL>
<PG>325-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2016-09-08 18:22:37 +0100" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>1</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-GDT-2015" MODIFIED="2017-11-14 15:34:56 +0000" MODIFIED_BY="[Empty name]" NAME="GRADEpro GDT 2015" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro GDT</TI>
<YR>2015</YR>
<EN>assessed 3 January 2017</EN>
<PB>McMaster University (developed by Evidence Prime)</PB>
<CY>Hamilton (ON)</CY>
<MD>Available at gradepro.org</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011" MODIFIED="2016-08-25 23:56:03 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D et al</AU>
<TI>GRADE guidelines 6. Rating the quality of evidence-imprecision</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1283-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hallett-1998" MODIFIED="2017-11-13 12:57:30 +0000" MODIFIED_BY="[Empty name]" NAME="Hallett 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hallett M</AU>
<TI>The neurophysiology of dystonia</TI>
<SO>Archives of Neurology</SO>
<YR>1998</YR>
<VL>55</VL>
<NO>5</NO>
<PG>601-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hedges-1985" MODIFIED="2017-11-14 18:26:42 +0000" MODIFIED_BY="[Empty name]" NAME="Hedges 1985" TYPE="BOOK">
<AU>Hedges LV, Olkin I</AU>
<SO>Statistical Methods for Meta-Analysis</SO>
<YR>1985</YR>
<PB>Academic Press, Inc</PB>
<CY>San Diego, California</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2016-05-23 07:40:10 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2017-11-14 18:26:56 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2017-11-14 18:27:05 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG (editors)</AU>
<TI>Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011c" MODIFIED="2017-11-14 18:27:12 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011c" TYPE="OTHER">
<AU>Higgins JPT, and Deeks JJ (editors)</AU>
<TI>Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holland-1981" MODIFIED="2017-11-13 12:59:23 +0000" MODIFIED_BY="[Empty name]" NAME="Holland 1981" TYPE="JOURNAL_ARTICLE">
<AU>Holland RL, Brown MC</AU>
<TI>Nerve growth in botulinum toxin poisoned muscles</TI>
<SO>Neuroscience
</SO>
<YR>1981</YR>
<VL>6</VL>
<PG>1167&#8211;79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imberger-2016" MODIFIED="2017-11-14 18:27:16 +0000" MODIFIED_BY="[Empty name]" NAME="Imberger 2016" TYPE="JOURNAL_ARTICLE">
<AU>Imberger G, Thorlund K, Gluud C, Wetterslev J</AU>
<TI>False-positive findings in Cochrane meta-analyses with and without application of Trial Sequential Analysis: an empirical review</TI>
<SO>BMJ Open</SO>
<YR>2016</YR>
<VL>6</VL>
<NO>8</NO>
<PG>e011890</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jahnanshani-1990" MODIFIED="2016-08-23 09:41:22 +0100" MODIFIED_BY="[Empty name]" NAME="Jahnanshani 1990" TYPE="JOURNAL_ARTICLE">
<AU>Jahnanshani M, Marion M-H, Marsden CD</AU>
<TI>Natural history of adult-onset idiopathic torticollis</TI>
<SO>Archives of Neurology</SO>
<YR>1990</YR>
<VL>47</VL>
<PG>548-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jakobsen-2014" MODIFIED="2016-09-08 18:21:06 +0100" MODIFIED_BY="[Empty name]" NAME="Jakobsen 2014" TYPE="JOURNAL_ARTICLE">
<AU>Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C</AU>
<TI>Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2014</YR>
<VL>14</VL>
<NO>1</NO>
<PG>120</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jankovic-2004" MODIFIED="2017-11-13 13:01:23 +0000" MODIFIED_BY="[Empty name]" NAME="Jankovic 2004" TYPE="JOURNAL_ARTICLE">
<AU>Jankovic J</AU>
<TI>Botulinum toxin in clinical practice</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2004</YR>
<VL>75</VL>
<PG>951&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jankovic-2006" MODIFIED="2015-04-13 18:02:45 +0100" MODIFIED_BY="[Empty name]" NAME="Jankovic 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jankovic J, Tsui J, Bergeron C</AU>
<TI>Prevalence of cervical dystonia and spasmodic torticollis in the United States general population</TI>
<SO>Parkinsonism &amp; Related Disorders</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>7</NO>
<PG>411&#8211;6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juzans-1996" MODIFIED="2017-11-13 13:02:00 +0000" MODIFIED_BY="[Empty name]" NAME="Juzans 1996" TYPE="JOURNAL_ARTICLE">
<AU>Juzans P, Comella J, Molgo J, Faille L, Angaut-Petit D</AU>
<TI>Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle</TI>
<SO>Neuromuscular Disorders : NMD</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>3</NO>
<PG>177-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liberati-2009" MODIFIED="2016-08-23 09:24:17 +0100" MODIFIED_BY="[Empty name]" NAME="Liberati 2009" TYPE="JOURNAL_ARTICLE">
<AU>Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al</AU>
<TI>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration</TI>
<SO>PLoS Medicine</SO>
<YR>2009</YR>
<VL>6</VL>
<PG>e1000100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lundh-2017" MODIFIED="2017-04-06 18:39:26 +0100" MODIFIED_BY="[Empty name]" NAME="Lundh 2017" TYPE="COCHRANE_REVIEW">
<AU>Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L</AU>
<TI>Industry sponsorship and research outcome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2017</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2017-04-06 18:39:26 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-04-06 18:39:26 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.MR000033.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Macefield-2014" MODIFIED="2017-11-14 18:31:30 +0000" MODIFIED_BY="[Empty name]" NAME="Macefield 2014" TYPE="JOURNAL_ARTICLE">
<AU>Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST et al</AU>
<TI>Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs)</TI>
<SO>Trials</SO>
<YR>2014</YR>
<VL>15</VL>
<PG>49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marques-2016" MODIFIED="2017-11-14 18:31:10 +0000" MODIFIED_BY="[Empty name]" NAME="Marques 2016" TYPE="COCHRANE_REVIEW">
<AU>Marques RE, Duarte GS, Rodrigues FB, Castelão M, Ferreira J, Sampaio C et al</AU>
<TI>Botulinum toxin type B for cervical dystonia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2016</YR>
<VL>13</VL>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2016-10-16 09:33:23 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-16 09:33:23 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004315.pub3"/><IDENTIFIER TYPE="PUBMED" VALUE="27176573"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Matak-2014" MODIFIED="2017-11-13 14:42:27 +0000" MODIFIED_BY="[Empty name]" NAME="Matak 2014" TYPE="JOURNAL_ARTICLE">
<AU>Matak I, Lackovi&#263; Z</AU>
<TI>Botulinum toxin A, brain and pain</TI>
<SO>Progress in Neurobiology</SO>
<YR>2014</YR>
<VL>119-120</VL>
<PG>39&#8211;59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matak-2015" MODIFIED="2017-11-14 18:31:05 +0000" MODIFIED_BY="[Empty name]" NAME="Matak 2015" TYPE="JOURNAL_ARTICLE">
<AU>Matak I, Lackovi&#263; Z</AU>
<TI>Botulinum neurotoxin type A: actions beyond SNAP-25?</TI>
<SO>Toxicology</SO>
<YR>2015</YR>
<VL>335</VL>
<PG>79-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-1979" MODIFIED="2016-09-08 18:23:05 +0100" MODIFIED_BY="[Empty name]" NAME="O'Brien 1979" TYPE="JOURNAL_ARTICLE">
<AU>O&#8217;Brien PC, Fleming TR</AU>
<TI>A multiple testing procedure for clinical trials</TI>
<SO>Biometrics</SO>
<YR>1979</YR>
<VL>35</VL>
<PG>549-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palomar-2012" MODIFIED="2017-11-13 14:43:40 +0000" MODIFIED_BY="[Empty name]" NAME="Palomar 2012" TYPE="JOURNAL_ARTICLE">
<AU>Palomar FJ, Mir P</AU>
<TI>Neurophysiological changes after intramuscular injection of botulinum toxin</TI>
<SO>Clinical Neurophysiology</SO>
<YR>2012</YR>
<VL>123</VL>
<NO>23</NO>
<PG>54&#8211;60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pellizzari-1999" MODIFIED="2017-11-13 14:44:09 +0000" MODIFIED_BY="[Empty name]" NAME="Pellizzari 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pellizzari R, Rossetto O, Schiavo G, Montecucco C</AU>
<TI>Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses</TI>
<SO>Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>259&#8211;68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peters-2006" MODIFIED="2015-04-13 18:04:22 +0100" MODIFIED_BY="[Empty name]" NAME="Peters 2006" TYPE="JOURNAL_ARTICLE">
<AU>Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L</AU>
<TI>Comparison of two methods to detect publication bias in meta-analysis</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<NO>6</NO>
<PG>676-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2017-11-14 18:28:11 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager 5 (RevMan 5)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>Nordic Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosales-1996" MODIFIED="2017-11-13 14:44:45 +0000" MODIFIED_BY="[Empty name]" NAME="Rosales 1996" TYPE="JOURNAL_ARTICLE">
<AU>Rosales RL, Arimura K, Takenaka S, Osame M</AU>
<TI>Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1996</YR>
<VL>19</VL>
<PG>488&#8211;96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosales-2010" MODIFIED="2017-11-13 14:45:10 +0000" MODIFIED_BY="[Empty name]" NAME="Rosales 2010" TYPE="JOURNAL_ARTICLE">
<AU>Rosales RL, Dressler D</AU>
<TI>On muscle spindles, dystonia and botulinum toxin</TI>
<SO>European Journal of Neurology</SO>
<YR>2010</YR>
<VL>17</VL>
<PG>71&#8211;80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rubin-1991" MODIFIED="2016-09-08 18:34:28 +0100" MODIFIED_BY="[Empty name]" NAME="Rubin 1991" TYPE="JOURNAL_ARTICLE">
<AU>Rubin DB, Schenker N</AU>
<TI>Multiple imputation in health-care databases: an overview and some applications</TI>
<SO>Statistics in Medicine</SO>
<YR>1991</YR>
<VL>10</VL>
<PG>585&#8211;98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2017-11-14 18:28:02 +0000" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and &#8216;Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-2004" MODIFIED="2017-11-13 14:46:23 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Simpson LL</AU>
<TI>Identification of the major steps in botulinum toxin action</TI>
<SO>Annual Review of Pharmacology and Toxicology</SO>
<YR>2004</YR>
<VL>44</VL>
<PG>167-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-2016" MODIFIED="2017-11-14 18:29:01 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 2016" TYPE="JOURNAL_ARTICLE">
<AU>Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS et al</AU>
<TI>Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology</TI>
<SO>Neurology</SO>
<YR>2016</YR>
<VL>10</VL>
<PG>1818-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smeeth-1999" MODIFIED="2017-11-14 18:27:51 +0000" MODIFIED_BY="[Empty name]" NAME="Smeeth 1999" TYPE="JOURNAL_ARTICLE">
<AU>Smeeth L, Haines A, Ebrahim S</AU>
<TI>Numbers needed to treat derived from meta-analysis - sometimes informative, usually misleading</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>318</VL>
<NO>7197</NO>
<PG>1548-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stata-2015" MODIFIED="2017-11-14 18:27:44 +0000" MODIFIED_BY="[Empty name]" NAME="Stata 2015" TYPE="COMPUTER_PROGRAM">
<AU>StataCorp</AU>
<TI>Stata Statistical Software: release 14</TI>
<YR>2015</YR>
<EN>accessed 3 January 2017</EN>
<PB>StataCorp</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steeves-2012" MODIFIED="2017-11-14 18:29:11 +0000" MODIFIED_BY="[Empty name]" NAME="Steeves 2012" TYPE="JOURNAL_ARTICLE">
<AU>Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T</AU>
<TI>The prevalence of primary dystonia: a systematic review and meta&#8208;analysis</TI>
<SO>Movement Disorders</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>14</NO>
<PG>1789-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" MODIFIED="2017-11-13 14:50:49 +0000" MODIFIED_BY="[Empty name]" NAME="Sterne 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Egger M</AU>
<TI>Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>10</NO>
<PG>1046-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2017-11-14 15:22:44 +0000" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="OTHER">
<AU>Sterne JAC, Egger M, Moher D (editors)</AU>
<TI>Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tarsy-1997" NAME="Tarsy 1997" TYPE="JOURNAL_ARTICLE">
<AU>Tarsy D</AU>
<TI>Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin</TI>
<SO>Movement Disorders</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>1</NO>
<PG>100-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tarsy-2006" MODIFIED="2017-11-13 14:51:27 +0000" MODIFIED_BY="[Empty name]" NAME="Tarsy 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tarsy D, Simon DK</AU>
<TI>Dystonia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<PG>818-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2017-11-13 14:51:46 +0000" MODIFIED_BY="[Empty name]" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual for 
Trial 
Sequential 
Analysis (TSA)</TI>
<SO>ctu.dk/tsa/files/tsa &#775;manual.pdf 2011</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TSA-2011" MODIFIED="2017-11-14 18:28:30 +0000" MODIFIED_BY="[Empty name]" NAME="TSA 2011" TYPE="COMPUTER_PROGRAM">
<AU>Copenhagen Trial Unit</AU>
<TI>Trial Sequential Analysis. Version 0.9 Beta</TI>
<YR>2011</YR>
<EN>accessed 3 January 2017</EN>
<PB>Copenhagen Trial Unit</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tugwell-2007" MODIFIED="2016-06-06 11:11:39 +0100" MODIFIED_BY="[Empty name]" NAME="Tugwell 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L</AU>
<TI>OMERACT: an international initiative to improve outcome measurement in rheumatology</TI>
<SO>Trials</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walker-2014" MODIFIED="2017-11-14 18:28:42 +0000" MODIFIED_BY="[Empty name]" NAME="Walker 2014" TYPE="JOURNAL_ARTICLE">
<AU>Walker TJ, Dayan SH</AU>
<TI>Comparison and overview of currently available neurotoxins</TI>
<SO>Journal of Clinical and Aesthetic Dermatology</SO>
<YR>2014</YR>
<VL>7</VL>
<NO>2</NO>
<PG>31-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2017-11-14 18:28:47 +0000" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<PG>64-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2016-09-08 18:23:30 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in random-effects model meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiebe-2006" MODIFIED="2016-09-08 18:26:03 +0100" MODIFIED_BY="[Empty name]" NAME="Wiebe 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ</AU>
<TI>A systematic review identifies a lack of standardization in methods for handling missing variance data</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>4</NO>
<PG>342-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zoons-2012" MODIFIED="2017-11-14 15:22:32 +0000" MODIFIED_BY="[Empty name]" NAME="Zoons 2012" TYPE="JOURNAL_ARTICLE">
<AU>Zoons E, Dijkgraaf MG, Dijk JM, Van Schaik IN, Tijssen MA</AU>
<TI>Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value</TI>
<SO>Journal of Neurology</SO>
<YR>2012</YR>
<VL>259</VL>
<NO>12</NO>
<PG>2519-26</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-11-14 15:22:22 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Costa-2000" NAME="Costa 2000" TYPE="JOURNAL_ARTICLE">
<AU>Costa J, Ferreira JJ, Sampaio C</AU>
<TI>Botulinum toxin type A for the treatment of cervical dystonia: a systematic review</TI>
<SO>Movement Disorders</SO>
<YR>2000</YR>
<VL>15 Suppl 3</VL>
<PG>29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Costa-2005" MODIFIED="2017-11-14 15:22:22 +0000" MODIFIED_BY="[Empty name]" NAME="Costa 2005" TYPE="COCHRANE_REVIEW">
<AU>Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P et al</AU>
<TI>Botulinum toxin type A therapy for cervical dystonia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2016-08-23 09:49:26 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-08-23 09:49:26 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003633.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ferreira-1999" NAME="Ferreira 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ferreira JJ, Costa J, Sampaio C</AU>
<TI>Botulinum toxin type A for the treatment of cervical dystonia: a systematic review</TI>
<SO>European Journal of Neurology</SO>
<YR>1999</YR>
<VL>6 Suppl 3</VL>
<PG>76</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES><CHARACTERISTICS_OF_STUDIES MODIFIED="2017-11-14 17:46:32 +0000" MODIFIED_BY="[Empty name]"><CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-11-14 17:46:32 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><INCLUDED_CHAR MODIFIED="2017-11-14 16:44:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Charles-2012"><CHAR_METHODS MODIFIED="2017-11-14 15:20:37 +0000" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel design</P><P><B>Randomisation:</B> carried out in blocks of four; method not described</P><P><B>Setting:</B> multicentre (22 centres in the USA, 1 in Canada)</P><P><B>Duration: </B>10 weeks</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:20:36 +0000" MODIFIED_BY="[Empty name]"><P>170 participants enrolled (BtA group = 88; placebo group = 82)</P><P><B>% Female: </B>BtA: 70%; placebo: 80%</P><P><B>Mean age, range: </B>BtA: 55 years; placebo: 55 years</P><P><B>Mean CD duration: </B>BtA: 11.2 years; placebo: 9.1 years</P><P><B>Mean CD severity, SD (CDSS): </B>BtA: 9.2, 4.8; placebo: 9.3, 4.2</P><P><B>Inclusion criteria:</B></P><UL><LI>21-75 years of age</LI><LI>idiopathic CD with a minimum score of 4 on the CDSS</LI><LI>&#8805; 2 previous successful treatments with &#8804; 360 U of Botox administered at 12- to 16-week intervals</LI></UL><P><B>Exclusion criteria:</B></P><UL><LI>previous treatment with onabotulinumtoxinA for any other indication</LI><LI>pure anterocollis or isolated head shift</LI><LI>pregnancy</LI><LI>profound atrophy of cervical musculature</LI><LI>medical conditions or treatments known to be contraindicated for the injection of onabotulinumtoxinA</LI></UL></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 15:20:36 +0000" MODIFIED_BY="[Empty name]"><P><B>BtA: </B>Botox (onabotulinumtoxinA); 25 ng of neurotoxin complex protein per 100 U, diluted with 1 mL sterile solution</P><P><B>Placebo: </B>0.5 mg of human serum albumin and 0.9 mg of sodium chloride</P><P><B>Study drug preparation: </B>BtA provided in vials by Allergan</P><P><B>Muscles injected:</B> the doses and muscles injected were determined by the physician based on clinical assessment</P><P><B>EMG guidance: </B>no</P><P><B>BtA dose per participant: </B>maximum: 360 U; mean, range: 236 U, 91 U-360 U</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 16:44:44 +0000" MODIFIED_BY="[Empty name]"><P><B>Primary outcomes:</B></P><UL><LI>CDSS (range, 0-54) at week 4</LI><LI>Physician GAS (range, -4 to +4; -4: very marked worsening, +4: complete remission) at week 6</LI></UL><P><B>Secondary outcomes:</B></P><UL><LI>Functional disability (range, 0-4; 0: no disability, 4: extreme disability)</LI><LI>Range of cervical motion</LI><LI>Participant assessment of pain (5-point scale for both frequency and intensity)</LI><LI>Frequency of pain (range, 0-4; 0: never, 4: constant)</LI><LI>Intensity of pain (range, 0-4; 0: none, 4: very severity)</LI><LI>Participant GAS (range, -4 to +4; -4: very marked worsening, +4: complete remission)</LI><LI>Adverse events</LI><LI>Time to treatment failure</LI><LI>Plasma neutralising antibodies</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-14 15:20:36 +0000" MODIFIED_BY="[Empty name]"><P>This was a 2-period clinical trial consisting of a 10-week open-label period followed by a 10-week double-blind period, with up to 6 weeks between periods. Participants who successfully completed the open phase (i.e. responded to BtA and were compliant with the study protocol) were enrolled into the blinded phase. 214 participants were enrolled in Period I, of whom 170 continued into Period II. We only considered the results of the blinded phase in this review.</P><P><B>Study discontinuations, reasons:</B></P><P>BtA: n = 11 (13%), lack of efficacy: n = 8, unrelated reasons: n = 3</P><P>Placebo: n = 24 (29%), lack of efficacy: n = 19, unrelated reasons: n = 5</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 16:40:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Comella-2011"><CHAR_METHODS MODIFIED="2017-11-14 15:20:35 +0000" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel design</P><P><B>Randomisation: </B>block-wise randomisation using a software-generated code</P><P><B>Setting: </B>multicentre (37 centres in the USA)</P><P><B>Duration: </B>8 weeks, follow-up up to 20 weeks</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 16:40:04 +0000" MODIFIED_BY="[Empty name]"><P>233 participants enrolled (BtA 120 U group = 78; BtA 240 U group = 81; placebo group = 74)</P><P><B>% Female: </B>BtA 120 U: 51%; BtA 240 U: 54%; placebo: 49%</P><P><B>Mean age, SD: </B>BtA 120 U: 52.8 years, 11.5; BtA 240 U: 53.2 years, 12.2; placebo: 52.4 years, 10.8</P><P><B>Mean CD duration: </B>BtA 120 U: 9.3 years, 8.4; BtA 240U: 9.7 years, 9.0; placebo: 10.8 years, 9.0</P><P><B>Mean CD severity, SD (TWSTRS total): </B>BtA 120 U: 42.6, 9.7; BtA 240 U: 42.1, 9.3; placebo: 41.8, 7.9</P><P><B>Inclusion criteria:</B></P><UL><LI>18-75 years of age</LI><LI>primary CD with predominantly rotational form</LI><LI>TWSTRS total score &#8805; 20</LI></UL><P><B>Exclusion criteria: </B></P><UL><LI>predominant anterocollis or retrocollis</LI><LI>prior CD surgery</LI><LI>previous treatment with Bt injections in the last 10 weeks</LI><LI>concomitant treatment with phenol, alcohol injections or local anaesthetics in the affected area</LI><LI>intrathecal baclofen in the last 2 weeks</LI><LI>parenteral use of tubocurarines, barbiturates, aminoglycosides or aminoquinolones</LI></UL><P>Other medications for focal dystonia were required to be on a stable dose for at least 3 months</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 15:20:35 +0000" MODIFIED_BY="[Empty name]"><P><B>BtA: </B>Xeomin (incobotulinumtoxinA); 120 U or 240 U, diluted in 4.8 mL</P><P><B>Placebo: </B>reconstitution of powder with 0.9% NaCl diluted in 4.8 mL</P><P><B>Study drug preparation:</B> vials and providers not mentioned</P><P><B>Muscles injected:</B> the number of injection sites per muscle and the volume injected into each muscle were determined at the discretion of the investigator</P><P><B>EMG guidance:</B> left at discretion of the investigator</P><P><B>BtA dose per participant: </B>120 U or 240 U</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 15:20:35 +0000" MODIFIED_BY="[Empty name]"><P><B>Primary outcomes:</B></P><UL><LI>TWSTRS total (range, 0-85) at week 4</LI></UL><P><B>Secondary outcomes:</B></P><UL><LI>TWSTRS total and TWSTRS subscales at weeks 4, 8 and final visit</LI><LI>PEGR (range, -4 to +4; -4: marked worsening, +4 complete remission)</LI><LI>IGAE (4-point scale; poor, moderate, good, very good)</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-14 15:20:35 +0000" MODIFIED_BY="[Empty name]"><P><B>Study discontinuations (at week 8), reasons:</B></P><P>BtA 120 U: n = 3 (4%), adverse events: n = 1, consent withdrawal: n = 1, lost to F/U: n = 1</P><P>BtA 240 U: n = 5 (6%), adverse events: n = 2, consent withdrawal: n = 1, lost to F/U: n = 1, unrelated reasons: n = 1</P><P>Placebo: n = 6 (8%), lack of efficacy: n = 3, consent withdrawal: n = 1, lost to F/U: n = 1, unrelated reasons: n = 1</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greene-1990"><CHAR_METHODS MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel design</P><P><B>Randomisation: </B>stratified by CD classification; method not described</P><P><B>Setting:</B> single-centre (USA)</P><P><B>Duration: </B>12 weeks</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]"><P>55 participants enrolled (BtA group = 28; placebo group = 27)</P><P><B>% Female: </B>BtA: 61%; placebo: 67%</P><P><B>Mean age: </B>BtA: 46.8 years; placebo: 52.6 years</P><P><B>Mean CD duration: </B>BtA: 6.6 years; placebo: 9.8 years</P><P><B>CD severity: </B>BtA: 7% mild, 71% moderate, 21% severe; placebo: 11% mild, 48% moderate, 41% severe</P><P><B>Inclusion criteria:</B></P><UL><LI>Idiopathic CD non-responder to at least 2 drug trials including at least 1 trial of anticholinergics</LI></UL><P><B>Exclusion criteria: </B></P><UL><LI>Known or suspected cause for CD</LI><LI>prior thalamotomy or peripheral surgery</LI><LI>previous treatment with Bt</LI></UL></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]"><P><B>BtA: </B>Botox (onabotulinumtoxinA); diluted in saline solution to a concentration of 25 U per 1 mL</P><P><B>Placebo: </B>saline solution</P><P><B>Study drug preparation: </B>BtA provided in vials by Smith-Kettlewell Eye Research Institute (USA)</P><P><B>Muscles injected: t</B>he doses, muscles, and number of injected sites per muscle were determined by the physician based on clinical assessment and classification of CD</P><P><B>EMG guidance:</B> no</P><P><B>BtA dose per participant: </B>150 U, rotational torticollis and torticollis plus retrocollis; 165 U, head tilt</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]"><P><B>Primary outcomes:</B></P><UL><LI>Patient Subjective Assessment of Change - 3 scales: Res Scale (results of injection: marked, moderate, slight improvement, no change, slight and definitely worse); Cap Scale (functional capability; 0%: completely disable, 100%: fully functional); Pain scale (0%: no difference, 100%: complete relieve)</LI></UL><P><B>Secondary outcomes:</B></P><UL><LI>Columbia Torticollis Rating Scale (objective video records rating)</LI><LI>Time course of benefit</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]"><P><B>Study discontinuations, reasons:</B></P><P>BtA: n = 3 (11%), adverse events: n = 1, unrelated reasons: n = 2</P><P>Placebo: n = 0</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poewe-1998"><CHAR_METHODS MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel design</P><P><B>Randomisation:</B> not described</P><P><B>Setting: </B>multicentre (Germany and Austria)</P><P><B>Duration: </B>8 weeks</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]"><P>75 participants enrolled (BtA 250 U group = 19; BtA 500 U group = 18; BtA 1000 U group = 18; placebo group = 20).</P><P><B>% Female: </B>all groups: 48%</P><P><B>Mean age, SD: </B>all groups: 47 years, 11.5</P><P><B>Mean CD duration, SD: </B>all groups: 7.4 years, 6.7</P><P><B>CD severity (Tsui modified scale): </B>BtA 250 U: 14.3; BtA 500 U: 13.1; BtA 1000 U: 14.5; placebo: 14.4</P><P><B>Inclusion criteria: </B></P><UL><LI>Rotational CD with hyperactivity clinically confined to one splenius capitis muscle and the contralateral sternocleidomastoid muscle</LI><LI>previously untreated with Bt</LI></UL><P><B>Exclusion criteria: </B></P><UL><LI>not mentioned</LI></UL></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]"><P><B>BtA: </B>Dysport (abobotulinumtoxinA); vials of 500 U, diluted with 1 mL sterile solution</P><P><B>Placebo:</B> 0.125 mg of human serum albumin and 2.5 mg of lactose, diluted with 1 mL sterile solution</P><P><B>Study drug preparation: </B>BtA provided in vials by Speywood Pharmaceuticals</P><P><B>Muscles injected:</B> a total of 2.5 mL of the study drug or placebo was injected in each participant (0.75 mL into 2 sites in the sternocleidomastoid muscle, and 1.75 mL into 2 sites in the splenius capitis muscle)</P><P><B>EMG guidance: </B>no</P><P><B>BtA dose per participant: </B>250 U, 500 U, or 1000 U</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 15:20:32 +0000" MODIFIED_BY="[Empty name]"><P><B>Primary outcomes:</B></P><UL><LI>Modified Tsui Scale score</LI></UL><P><B>Secondary outcomes:</B></P><UL><LI>Physician Global Assessment of Improvement (5-point scale: worse, no improvement, improvement &lt; 50%, improvement &gt; 50%, remission)</LI><LI>Patient Global Assessment of Improvement (5-point scale: worse, no improvement, improvement &lt; 50%, improvement &gt; 50%, remission)</LI><LI>Assessment of Swallowing Difficulties (5-point scale: none, mild, moderate, severe, swallowing not possible)</LI><LI>Adverse events</LI><LI>Clinical Global Rating (taking into account efficacy and safety)</LI><LI>Need for retreatment</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-14 15:20:32 +0000" MODIFIED_BY="[Empty name]"><P><B>Study discontinuations, reasons:</B></P><P>BtA 250 U: n = 0</P><P>BtA 500 U: n = 2 (11%), lost to F/U: n = 2</P><P>BtA 1000 U: n = 0</P><P>Placebo: n = 0</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 15:20:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poewe-2016"><CHAR_METHODS MODIFIED="2017-11-14 15:20:29 +0000" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel design</P><P><B>Randomisation: </B>not adequately described</P><P><B>Setting:</B> multicentre (61 centres in 11 countries)</P><P><B>Duration: </B>12 weeks</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:20:29 +0000" MODIFIED_BY="[Empty name]"><P>369 participants enrolled overall</P><P>213 participants enrolled with data contributing to the current review (BtA group = 159; placebo group = 54)</P><P><B>% Female: </B>BtA: 64%; placebo: 63%</P><P><B>Mean age: </B>BtA: 49 years; placebo: 50 years</P><P><B>Mean CD duration: </B>BtA: 7 years; placebo: 6 years</P><P><B>Mean CD severity, SD (TWSTRS-total): </B>BtA: 46, 9; placebo: 47, 9</P><P><B>Inclusion criteria: </B></P><UL><LI>&#8805; 18 years old</LI><LI>diagnosed with CD &#8805; 18 months before trial enrolment</LI><LI>untreated with BtA or BtB in the prior 14 weeks</LI><LI>TWSTRS total score at baseline &#8805; 30 with subscale scores for severity &#8805; 15, disability &#8805; 3, and pain &#8805; 2</LI></UL><P><B>Exclusion criteria: </B></P><UL><LI>known hypersensitivity to BtA, BtB, or related compounds or components in the study drug formulations</LI><LI>diagnosis of isolated anterocollis or retrocollis</LI><LI>previous poor response to BtA</LI><LI>known requirement for &#8805; 300 U of onabotulinumtoxinA injected into the neck muscles, &#8805; 12,500 U of BtB or &#8805;1000 U of abobotulinumtoxinA</LI><LI>requirement for injections at body sites other than the neck</LI><LI>swallowing or respiratory abnormalities</LI><LI>defective neuromuscular transmission or persistent neuromuscular weakness or any condition interfering with TWSTRS scoring</LI><LI>a body weight &lt; 45.4 kg</LI><LI>previous phenol or alcohol injections into the neck muscles</LI><LI>previous myotomy or denervation surgery to the neck/shoulder region</LI><LI>limited passive range of motion in the neck region</LI><LI>pregnancy</LI></UL></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 15:20:29 +0000" MODIFIED_BY="[Empty name]"><P><B>BtA: </B>Dysport (abobotulinumtoxinA)</P><P><B>Placebo:</B> supplied in a 1-mL prefilled syringe indistinguishable from the active products</P><P><B>Study drug preparation:</B> provided as a freeze-dried powder containing 500 U of BtA haemagglutinin complex together with 125 µg of human albumin and 2.5 mg of lactose. The powder was reconstituted with 1.1 mL sodium chloride for injection using a glass syringe</P><P><B>Muscles injected: </B>administered into 2-4 neck muscles (levator scapulae, trapezius, sternocleidomastoid, splenius capitis, scalenus (medius and anterior), semispinalis capitis, or longissimus capitis) in a single dosing session according to the physicians&#8217; clinical judgment of the individual&#8217;s pattern of dystonic activity</P><P><B>EMG guidance:</B> left at discretion of the investigator</P><P><B>BtA dose per patient: </B>500 U</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 15:20:29 +0000" MODIFIED_BY="[Empty name]"><P><B>Primary outcome:</B></P><UL><LI>TWSTRS total score at week 4</LI></UL><P><B>Secondary outcomes: </B></P><UL><LI>TWSTRS total and TWSTRS subscales at weeks 4 and 8</LI><LI>Investigator&#8217;s and patient's VAS on symptoms</LI><LI>Investigator&#8217;s overall treatment success</LI><LI>VAS for pain at week 4</LI><LI>CD Impact Profile-58 score at week 4</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 17:43:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Truong-2005"><CHAR_METHODS MODIFIED="2017-11-14 15:20:28 +0000" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel design</P><P><B>Randomisation: </B>Block-wise randomisation using a software-generated code, stratification by centre</P><P><B>Setting: </B>multicentre (16 centres in USA)</P><P><B>Duration: </B>4 weeks, follow-up up to 20 weeks</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:20:28 +0000" MODIFIED_BY="[Empty name]"><P>80 participants enrolled (BtA group = 37; placebo group = 43)</P><P><B>% Female: </B>BtA: 62%; placebo: 63%</P><P><B>Mean age, SD: </B>BtA: 53.4 years, 11.6; placebo: 53.6 years, 12.1</P><P><B>Mean CD duration, SD: </B>BtA: 7.1 years, 7.1; placebo: 5.7 years, 5.2</P><P><B>Mean CD severity, SD (TWSTRS total): </B>BtA: 45.1, 8.7; placebo: 46.2, 9.4</P><P><B>Inclusion criteria:</B></P><UL><LI>&#8805; 18 months since cervical dystonia diagnosis</LI><LI>TWSTRS total score of &#8805; 30</LI><LI>de novo or previously treated with Bt &#8805; 16 weeks prior to enrolment</LI></UL><P><B>Exclusion criteria: </B></P><UL><LI>suspected secondary non-responsiveness</LI><LI>prior CD surgery or phenol injections</LI><LI>participants believed to require a Botox dose &lt; 80 U or &gt; 250 U</LI><LI>pure retrocollis forms</LI></UL><P>Medications such as muscle relaxants and benzodiazepines were required to be on a stable dose for &#8805; 6 weeks</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 15:20:28 +0000" MODIFIED_BY="[Empty name]"><P><B>BtA: </B>Dysport (abobotulinumtoxinA); 500 U</P><P><B>Placebo: </B>0.125 mg of human serum albumin and 2.5 mg of lactose</P><P><B>Study drug preparation: </B>BtA provided in vials by Ipsen Ltd</P><P><B>Muscles injected: t</B>he doses and number of injection sites per muscle were determined at the discretion of the investigator.</P><P><B>EMG guidance: </B>left at discretion of the investigator</P><P><B>BtA dose per participant: </B>500 U</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 15:20:28 +0000" MODIFIED_BY="[Empty name]"><P><B>Primary outcome:</B></P><UL><LI>TWSTRS total and TWSTRS subscales at week 4</LI></UL><P><B>Secondary outcomes:</B></P><UL><LI>TWSTRS total and TWSTRS subscales at weeks 8 and 12</LI><LI>Participant assessment of pain using a VAS (range, 0-100; 0 mm: least possible pain, 100 mm: worst possible pain)</LI><LI>Investigator assessment of change using a VAS (range, 0-100; 0 mm: much worse, 50 mm: no change, 100 mm: symptom-free)</LI><LI>Participant assessment of change using a VAS (range, 0-100; 0 mm: much worse, 50 mm: no change, 100 mm: symptom-free)</LI><LI>Adverse events</LI><LI>Plasma neutralising antibodies</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-14 17:43:22 +0000" MODIFIED_BY="[Empty name]"><P>Participants who showed no benefit at week 4 were terminated from the study. Those who had evidence of response at week 4 continued in the study until additional injections were needed.</P><P><B>Study discontinuations (at week 4), reasons:</B></P><P>BtA: n = 15 (41%), reasons not described</P><P>Placebo: n = 27 (63%), reasons not described</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 17:22:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Truong-2010"><CHAR_METHODS MODIFIED="2017-11-14 15:20:27 +0000" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel design</P><P><B>Randomisation: </B>pre-generated randomisation code</P><P><B>Setting: </B>multicentre (16 centres in USA, 4 in Russia)</P><P><B>Duration: </B>12 weeks</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 17:22:05 +0000" MODIFIED_BY="[Empty name]"><P>116 participants enrolled (BtA group = 55; placebo group = 61)</P><P><B>% Female: </B>BtA: 67%; placebo: 62%</P><P><B>Mean age, SD: </B>BtA: 51.9, 13.4; placebo: 53.9, 12.5</P><P><B>Mean CD duration, SD: </B>BtA: 12.0 years, 8.8; placebo: 11.8 years, 8.8</P><P><B>Mean CD severity, SD (TWSTRS total): </B>BtA: 43.8, 8.0; placebo: 45.8, 8.8</P><P><B>Inclusion criteria: </B></P><UL><LI>reported symptoms for &#8805; 18 months</LI><LI>TWSTRS total score &#8805; 30, TWSTRS severity subscale score &#8805; 15, and TWSTRS disability subscale score &#8805; 3</LI><LI>previously untreated with Bt, or previously treated with Bt with a minimum interval of 16 weeks since the last injection or a return to pre-treatment status</LI></UL><P><B>Exclusion criteria: </B></P><UL><LI>pure anterocollis or retrocollis</LI><LI>apparent symptom remission at screening</LI><LI>previous poor response to Bt</LI><LI>current treatment with BtB due to lack of efficacy of BtA or the presence of neutralising antibodies to BtA</LI><LI>myasthenia gravis, other disease of the neuromuscular junction, or symptoms that could interfere with TWSTRS scoring</LI><LI>use of muscle relaxants and benzodiazepines if not on a stable dosage for 6 weeks prior to study treatment</LI><LI>known hypersensitivity to Bt or related compounds; total body weight &lt; 100 lbs (45.4 kg)</LI><LI>pregnant or lactation</LI><LI>previous phenol injections to the neck muscles, myotomy or denervation surgery involving the neck or shoulder region</LI><LI>cervical contracture that limited passive range of motion</LI></UL></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 15:20:27 +0000" MODIFIED_BY="[Empty name]"><P><B>BtA: </B>Dysport (abobotulinumtoxinA)</P><P><B>Placebo: </B>not described</P><P><B>Study drug preparation:</B> BtA provided in vials by Ipsen</P><P><B>Muscles injected:</B> the doses and number of injection sites per muscle were determined at the discretion of the investigator</P><P><B>EMG guidance: </B>left at discretion of the investigator</P><P><B>BtA dose per participant:</B> 500 U</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-14 15:20:25 +0000" MODIFIED_BY="[Empty name]"><P><B>Primary outcome:</B></P><UL><LI>TWSTRS total score at week 4</LI></UL><P><B>Secondary outcomes:</B></P><UL><LI>TWSTRS total and subtotal scores at weeks 8 and 12</LI><LI>Investigator assessment of symptom severity using a VAS, participant Assessment of Symptom Severity using a VAS</LI><LI>Pain VAS scores</LI><LI>Short Form 36 quality-of-life questionnaire scores</LI><LI>Investigator Assessment of Overall Treatment Successes (Global Assessment of Efficacy ratings of &#8216;better&#8217; or &#8216;much better&#8217;, and a Global Safety Assessment of no worse than 'Moderate')</LI><LI>Adverse events</LI><LI>Plasma neutralising antibodies</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-14 15:20:25 +0000" MODIFIED_BY="[Empty name]"><P><B>Study discontinuations, reasons:</B></P><P>BtA: n = 10 (18%), lack of efficacy: n = 5, consent withdrawal: n = 2, lost to F/U: n = 1, unrelated reasons: n = 2</P><P>Placebo: n = 23 (38%), lack of efficacy: n = 23</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-14 15:20:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wissel-2001"><CHAR_METHODS MODIFIED="2017-11-14 15:20:25 +0000" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel design</P><P><B>Randomisation: </B>method not described</P><P><B>Setting: </B>multicentre (Austria and Czech Republic)</P><P><B>Duration: </B>4 weeks, follow-up up to 16 weeks</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:20:25 +0000" MODIFIED_BY="[Empty name]"><P>68 participants enrolled (BtA group = 35; placebo group = 33)</P><P><B>% Female: </B>BtA: 46%; placebo: 56%</P><P><B>Mean age, SD: </B>BtA: 45.8 years, 13.2; placebo: 49.7 years, 9.6</P><P><B>Mean CD duration, SD: </B>BtA: 6.5 years, 8.0; placebo: 4.8 years, 4.4</P><P><B>Mean CD severity, SD (Tsui scale): </B>BtA: 11.1, 1.7; placebo: 11.5, 1.8</P><P><B>Inclusion criteria: </B></P><UL><LI>moderate or severe CD (Tsui score &#8805; 9)</LI></UL><P><B>Exclusion criteria:</B></P><UL><LI>pure anterocollis</LI><LI>treatment with BtA in the last 12 weeks</LI><LI>last BtA dose &gt; 750 U (Dysport) or &lt; 250 U (Dysport)</LI><LI>lack of response to previous BtA treatments</LI><LI>complex pattern of CD requiring EMG assistance or injection of &gt; 3 muscles</LI></UL></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]"><P><B>BtA:</B> Dysport (abobotulinumtoxinA); 500 U, diluted with 1 mL 0.9% saline solution</P><P><B>Placebo: </B>0.125 mg of human serum albumin and 2.5 mg of lactose, diluted with 1 mL 0.9% saline solution</P><P><B>Study drug preparation: </B>BtA and placebo provided in vials by Ipsen</P><P><B>Muscles injected: </B>based on clinical assessment 2 or 3 muscles were selected for injection: sternocleidomastoid (100 U-200 U), splenius capitis (250 U-350 U), trapezius (100 U-200 U), and levator scapulae (100 U-200 U). Each muscle was injected in 2 sites</P><P><B>EMG guidance: </B>no</P><P><B>BtA dose per participant: </B>500 U</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-13 16:06:10 +0000" MODIFIED_BY="[Empty name]"><P><B>Primary outcome:</B></P><UL><LI>Tsui Scale score</LI></UL><P><B>Secondary outcomes:</B></P><UL><LI>Pain Assessment (4-point scale: none, mild, moderate, severe)</LI><LI>Physician Global Assessment of Change (5-point scale: worse, no improvement, improvement &lt; 50%, improvement &gt; 50%, symptom free)</LI><LI>Patient Global Assessment of Change (5-point scale: worse, no improvement, improvement &lt; 50%, improvement &gt; 50%, symptom free)</LI><LI>Clinical Global Assessment (taking into account efficacy and safety)</LI><LI>Adverse effects</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]"><P>Participants were withdrawn from the study if they were considered non-responders at week 4. Participants with an ongoing response at weeks 4 and 8 continued until re-treatment was required.</P><P><B>Study discontinuations (at week 4), reasons:</B></P><P>BtA: n = 0</P><P>Placebo: n = 0</P></CHAR_NOTES></INCLUDED_CHAR><FOOTNOTES><P>Bt: botulinum toxin<BR/>BtA: botulinum toxin type A<BR/>CD: cervical dystonia<BR/>CDSS: Cervical Dystonia Severity Scale<BR/>F/U: follow-up<BR/>GAS: Global Assessment Scale<BR/>IGAE: Investigator Global Assessment of Efficacy<BR/>PEGR: Patient Evaluation of Global Response<BR/>TWSTRS: Toronto Western Spasmodic Torticollis Rating Scale<BR/>VAS: visual analogue scale<BR/></P></FOOTNOTES></CHARACTERISTICS_OF_INCLUDED_STUDIES><CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY"><EXCLUDED_CHAR MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blackie-1990"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]"><P>Cross-over design</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-06 19:09:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buchman-1994"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-06 19:09:41 +0100" MODIFIED_BY="[Empty name]"><P>The primary outcome was not clinical; pharmacokinetic study</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gelb-1989"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]"><P>Cross-over design</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koller-1990"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]"><P>Cross-over design</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lange-1991"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]"><P>This study has recruited part of the same population from <LINK REF="STD-Greene-1990" TYPE="STUDY">Greene 1990</LINK>; the primary outcome was not clinical</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lorentz-1991"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]"><P>Cross-over design</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-1995"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]"><P>Cross-over design</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-06 19:09:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maurri-1990"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-06 19:09:53 +0100" MODIFIED_BY="[Empty name]"><P>Not randomised</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moore-1991"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]"><P>Cross-over design</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ostergaard-1994"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]"><P>Cross-over design</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perlmutter-1989"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]"><P>Cross-over design</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-06 19:10:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Relja-1993"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-06 19:10:02 +0100" MODIFIED_BY="[Empty name]"><P>Not randomised</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsui-1986"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]"><P>Cross-over design</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-06 19:10:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsui-1988"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-06 19:10:06 +0100" MODIFIED_BY="[Empty name]"><P>The primary outcome was not clinical</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-06 19:10:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yoshimura-1990"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-06 19:10:15 +0100" MODIFIED_BY="[Empty name]"><P>This study has recruited part of the same population from <LINK REF="STD-Gelb-1989" TYPE="STUDY">Gelb 1989</LINK><BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><FOOTNOTES/></CHARACTERISTICS_OF_EXCLUDED_STUDIES><CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><FOOTNOTES/></CHARACTERISTICS_OF_AWAITING_STUDIES><CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><FOOTNOTES/></CHARACTERISTICS_OF_ONGOING_STUDIES></CHARACTERISTICS_OF_STUDIES><QUALITY_ITEMS MODIFIED="2017-11-14 17:46:32 +0000" MODIFIED_BY="[Empty name]"><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-11-14 16:56:27 +0000" MODIFIED_BY="[Empty name]" NO="1"><NAME>Random sequence generation (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Charles-2012"><DESCRIPTION><P>Comment: method of randomisation not specified</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:34:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comella-2011"><DESCRIPTION><P>Quote: "Randomization was performed using RANCODE version 3.6 (IDV, Gauting). Block-wise randomization by previous treatment with botulinum toxin ensured a balanced treatment assignment for each center for pretreated and treatment-naïve patients"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greene-1990"><DESCRIPTION><P>Quote: "They were divided into 3 cells (A, pure rotational torticollis; B, torticollis plus retrocollis; and C, head tilt with or without torticollis and retrocollis). In order to ensure reasonable balance of Botox and placebo injections in each cell, randomization was stratified by cell type, which was completed for blocks of 4 sequentially enrolled patients in each cell type"</P><P>Comment: insufficient information about the method of randomisation to permit judgement of low or high risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 16:56:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poewe-1998"><DESCRIPTION><P>Quote: "Patients were randomly assigned to receive treatment with placebo or total dose of 250, 500, or 1000 Dysport units of botulinum toxin type A in a double blind prospective study design"<BR/>Comment: insufficient information about the sequence generation process to permit judgement of &#8216;low risk or high risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poewe-2016"><DESCRIPTION><P>Insufficient information about the sequence generation process to permit judgement of low or high risk<BR/></P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:43:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Truong-2005"><DESCRIPTION><P>Quote: "Randomization was in blocks of four and was stratified by center and according to whether or not the patient had been treated previously with botulinum toxin"</P><P>Quote: "All patients were randomly assigned to treatment using a randomization code generated before the study"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:46:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Truong-2010"><DESCRIPTION><P>Quote: "In the double-blind treatment phase, patients were randomized using a pre-generated randomization code to receive intramuscular injection of either 500 units Dysport or placebo (1:1)"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wissel-2001"><DESCRIPTION><P>Quote: "Patients were randomly assigned to receive either placebo or 500 units of Dysport"<BR/>Comment: insufficient information about the method of randomisation to permit judgement of low risk or high risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-11-14 15:20:36 +0000" MODIFIED_BY="[Empty name]" NO="2"><NAME>Allocation concealment (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Charles-2012"><DESCRIPTION><P>Comment: method of concealment not specified</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:34:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Comella-2011"><DESCRIPTION><P>Comment: method of concealment not specified</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greene-1990"><DESCRIPTION><P>Comment: method of concealment not specified</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poewe-1998"><DESCRIPTION><P>Comment: sequentially numbered drug containers of identical appearance</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 10:13:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poewe-2016"><DESCRIPTION><P>Participants and investigators enrolling participants could not foresee assignment</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:43:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Truong-2005"><DESCRIPTION><P>Quote: "Dysport was provided in a clear glass vial as a freeze dried white pellet (&#8230;). Placebo was provided in identical clear glass vials (&#8230;)"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Truong-2010"><DESCRIPTION><P>Comment: method of concealment not specified</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wissel-2001"><DESCRIPTION><P>Comment: insufficient information to permit judgement of low risk or high risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-08-11 17:54:18 +0100" MODIFIED_BY="[Empty name]" NO="3"><NAME>Blinding (performance bias and detection bias)</NAME><DESCRIPTION><P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2017-11-14 17:32:29 +0000" MODIFIED_BY="[Empty name]" NO="7"><NAME>Blinding of participants and personnel (performance bias)</NAME><DESCRIPTION><P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-14 15:20:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Charles-2012"><DESCRIPTION><P>Comment: blinding not specified although study described as double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-15 09:34:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comella-2011"><DESCRIPTION><P>Quote: "Subjects, investigators, medical staff, (&#8230;) data managers and monitors were blind to subjects' treatment group"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-15 09:36:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greene-1990"><DESCRIPTION><P>Quote: "The blinded physicians then injected them with Botox or saline, using syringes filled by the unblinded physicians according to the protocol"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-14 17:32:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poewe-1998"><DESCRIPTION><P>Quote: "Patients were randomly assigned to receive treatment with placebo or total dose of 250, 500, or 1000 Dysport units of botulinum toxin type A in a double blind prospective study design"</P><P>Quote: "All three vials were identical in appearance"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-15 09:54:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poewe-2016"><DESCRIPTION><P>Quote: "To maintain blinding, all study treatments were identical in appearance and smell. All injections during the double-blind phase were prepared by dedicated and trained site personnel who were independent from investigators and had no contact with the investigators performing study assessment or the trial patients"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-15 09:43:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Truong-2005"><DESCRIPTION><P>Quote: "Placebo was provided in identical clear glass vials (&#8230;). Study medication was supplied in individual patient boxes, containing one vial of either Dysport or placebo. Subjects, investigators, medical staff, (&#8230;) data managers and monitors were blind to subjects' treatment group"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-11-14 15:20:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Truong-2010"><DESCRIPTION><P>Comment: blinding not specified although study described as double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-15 09:48:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wissel-2001"><DESCRIPTION><P>Quote: "Blinded study medication was supplied (...) as identical vials containing either Dysport (...) or placebo"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-11-14 15:20:36 +0000" MODIFIED_BY="[Empty name]" NO="8"><NAME>Blinding of outcome assessment (detection bias)</NAME><DESCRIPTION><P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2"><NAME>Subjective outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1"><NAME>Objective outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 15:20:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Charles-2012"><DESCRIPTION><P>Comment: blinding not specified although study described as double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2017-11-14 15:20:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Charles-2012"><DESCRIPTION><P>Comment: blinding not specified although study described as double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-15 09:34:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comella-2011"><DESCRIPTION><P>Quote: "Subjects, investigators, medical staff, biostatisticians responsible for data analysis, data managers and monitors were blind to subjects' treatment group"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2017-11-14 15:20:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Comella-2011"><DESCRIPTION><P>Comment: although placebo was identical to intervention, the fact that most of the participants had previously been treated with Bt could have led to a degree of bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-15 09:36:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greene-1990"><DESCRIPTION><P>Quote: "Two blinded physicians gave the injections, determined the degree of head turning and disability, and videotaped the patients; but they did not examine the strength or size of the neck muscles, so that the presence of muscle atrophy would not identify patients receiving active injection. Videotapes of each patient visit were rated by the 2 blinded observers independently"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-15 09:36:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greene-1990"><DESCRIPTION><P>Quote: "Patients previously treated with Botox were excluded from the trial"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 15:20:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poewe-1998"><DESCRIPTION><P>Comment: insufficient information to permit judgement of low risk or high risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2017-11-14 15:20:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poewe-1998"><DESCRIPTION><P>Comment: insufficient information to permit judgement of low risk or high risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-15 09:55:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poewe-2016"><DESCRIPTION><P>Quote: "To maintain blinding, all study treatments were identical in appearance and smell. All injections during the double-blind phase were prepared by dedicated and trained site personnel who were independent from investigators and had no contact with the investigators performing study assessment or the trial patients"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-15 09:56:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poewe-2016"><DESCRIPTION><P>Inclusion of a considerable proportion of non-naive participants, meaning they may have been able to foresee group allocation </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 15:20:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Truong-2005"><DESCRIPTION><P>Quote: "Whenever possible, an investigator or research nurse other than the one performing the TWSTRS assessment who was blind to treatment condition performed the assessment for adverse events. All sites were asked to achieve as much consistency as possible with respect to assessors"</P><P>Comment: insufficient information to permit judgement of low risk or high risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2017-11-14 15:20:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Truong-2005"><DESCRIPTION><P>Quote: "At each post-treatment visit, patients and investigators independently assessed the change from baseline"</P><P>Comment: insufficient information to permit judgement of low risk or high risk. Although placebo was identical to intervention, the fact that most of the participants had previously been treated with Botox could have led to a degree of bias</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 15:20:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Truong-2010"><DESCRIPTION><P>Comment: blinding not specified although study described as double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2017-11-14 15:20:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Truong-2010"><DESCRIPTION><P>Comment: blinding not specified although study described as double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wissel-2001"><DESCRIPTION><P>Comment: insufficient information to permit judgement of low or high risk</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wissel-2001"><DESCRIPTION><P>Comment: although placebo was identical to intervention, the fact that most of the participants had previously been treated with Bt could have led to a degree of bias.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-11-14 17:46:32 +0000" MODIFIED_BY="[Empty name]" NO="4"><NAME>Incomplete outcome data (attrition bias)</NAME><DESCRIPTION><P>Attrition bias due to amount, nature or handling of incomplete outcome data</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 15:20:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Charles-2012"><DESCRIPTION><P>Comment: post-randomisation exclusions were described as related to lack of efficacy or administrative reasons</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 15:20:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comella-2011"><DESCRIPTION><P>Quote: "Missing subject data was provided and their absence was regarded according to an ITT protocol"</P><P>Comment: post-randomisation exclusions were low and roughly distributed evenly between groups (BtA 120 U group = 3; BtA 240 U group = 5; Placebo group = 6). The reasons for exclusions were described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greene-1990"><DESCRIPTION><P>Comment: the study authors stated that some data were lost, accounting for up to 13% of total data, and it is unclear whether this had an impact on the overall results.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 15:20:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poewe-1998"><DESCRIPTION><P>Quote: "One patient in the 500 unit group was lost to follow up and had to be excluded from result analysis. A further case of 500 unit group had missed one follow up visit and was excluded from efficacy analysis but included in analysis of adverse events"<BR/>Comment: reasons for missing outcome data unlikely to be related to true outcome</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-15 09:56:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poewe-2016"><DESCRIPTION><P>Reasons for missing outcome data unlikely to be related to true outcome<BR/></P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 17:46:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Truong-2005"><DESCRIPTION><P>Comment: post-randomisation exclusions at week 4 were high in both intervention arms, though this difference was asymmetrical, with more dropouts happening in the placebo arm</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 15:20:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Truong-2010"><DESCRIPTION><P>Quote: "Efficacy variables were assessed using intent-to-treat (ITT) analysis"</P><P>Quote: "Safety assessments were based on the safety population, which included all patients who received at least one dose of study medication"</P><P>Comment: the reasons for discontinuation were described</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-15 09:48:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wissel-2001"><DESCRIPTION><P>Quote: "In order to remove the bias created by the withdrawal of the majority of placebo patients at week 4, a last observation carried forward technique was used for the week 8 analyses"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-11-14 15:20:35 +0000" MODIFIED_BY="[Empty name]" NO="5"><NAME>Selective reporting (reporting bias)</NAME><DESCRIPTION><P>Reporting bias due to selective outcome reporting</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Charles-2012"><DESCRIPTION><P>Comment: the expected outcomes that are usually evaluated in intervention trials for this condition were reported in this study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comella-2011"><DESCRIPTION><P>Comment: the outcomes mentioned in the study protocol matched the outcomes reported in the study.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greene-1990"><DESCRIPTION><P>Comment: the expected outcomes that are usually evaluated in intervention trials for this condition were reported in this study.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poewe-1998"><DESCRIPTION><P>Comment: the expected outcomes that are usually evaluated in intervention trials for this condition were reported in this study.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:56:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poewe-2016"><DESCRIPTION><P>The study protocol is not available but it is clear that the published reports include all expected outcomes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Truong-2005"><DESCRIPTION><P>Comment: the outcomes mentioned in the study protocol matched the outcomes reported in the study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Truong-2010"><DESCRIPTION><P>Comment: the expected outcomes that are usually evaluated in intervention trials for this condition were reported in this study.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wissel-2001"><DESCRIPTION><P>Comment: the expected outcomes that are usually evaluated in intervention trials for this condition were reported in this study.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2017-11-14 15:20:34 +0000" MODIFIED_BY="[Empty name]" NO="10"><NAME>For-profit bias</NAME><DESCRIPTION/><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-30 23:01:47 +0000" MODIFIED_BY="Ana Raquel Marques" RESULT="NO" STUDY_ID="STD-Charles-2012"><DESCRIPTION><P>The study was supported by Allergan.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Comella-2011"><DESCRIPTION><P>Comment: study funded by Merz Pharmaceuticals GmbH, Frankfurt</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-06 21:58:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greene-1990"><DESCRIPTION><P>Study drug was provided by Dr. A. Scott, from Smith-Kettlewell Eye Research Institute (USA).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:40:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poewe-1998"><DESCRIPTION><P>Quote: "Toxin and placebo preparations was supplied by Speywood Pharmaceuticals Ltd"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:57:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poewe-2016"><DESCRIPTION><P>Quote: "This study was sponsored by Ipsen"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Truong-2005"><DESCRIPTION><P>Comment: study funded by Beauford Ipsen</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:47:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Truong-2010"><DESCRIPTION><P>Quote: "This study was supported by the Ipsen Group. Editorial assistance for the preparation of this manuscript was provided by Ogilvy Healthworld Medical Education; funding was provided by Ipsen Limited, Slough, UK"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:48:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wissel-2001"><DESCRIPTION><P>Quote: "Blinded study medication was supplied by Ipsen Ltd"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2017-11-14 15:20:35 +0000" MODIFIED_BY="[Empty name]" NO="9"><NAME>Enriched population &#8211; preferential enrolment of positive responders</NAME><DESCRIPTION/><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Charles-2012"><DESCRIPTION><P>Comment: to enrol in the study, participants had to have had at least 2 previous successful treatments with &#8804; 360 U of Botox administered at 12- to 16-week intervals. Also, all participants enrolled in phase II were compliant to treatment during phase I trial.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:34:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Comella-2011"><DESCRIPTION><P>Quote: "A total of 233 subjects were randomized (...) Of these, 143 were previously treated with botulinum toxin"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greene-1990"><DESCRIPTION><P>Comment: participants who had previously received Botox injections were excluded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poewe-1998"><DESCRIPTION><P>Comment: all participants were previously untreated with botulinum toxin type A</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:58:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poewe-2016"><DESCRIPTION><P>Inclusion of a considerable proportion of non-naive participants, meaning they may have been able to foresee group allocation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-13 10:31:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Truong-2005"><DESCRIPTION><P>Comment: out of the 80 participants enrolled, 21 were de novo</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Truong-2010"><DESCRIPTION><P>Quote: "Patients were excluded if they had a (...) previous poor response to BoNT-A or BoNT-B treatments; current treatment with BoNT-B due to lack of efficacy of BoNT-A or the presence of neutralising antibodies to BoNT-A"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-08 17:09:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wissel-2001"><DESCRIPTION><P>Comment: out of the 68 participants enrolled, 47 had received BtA injections previously</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]" NO="11"><NAME>Enriched population &#8211; exclusion of poor responders</NAME><DESCRIPTION/><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 10:07:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Charles-2012"><DESCRIPTION><P>Quote: "Pure anterocollis and isolated head shift was exclusionary"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:34:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Comella-2011"><DESCRIPTION><P>Quote: "Subjects were excluded if they had (&#8230;) predominant anterocollis or retrocollis"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greene-1990"><DESCRIPTION><P>Comment: Exclusion criteria did not include forms of dystonia known to have poorer response to treatment</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:40:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poewe-1998"><DESCRIPTION><P>Quote: "Seventy five patients (...) with rotational torticollis and hyperactivity clinically confined to one splenius capitis and the contralateral sternomastoid muscles"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-14 15:20:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poewe-2016"><DESCRIPTION><P>Exclusion of nonresponsive phenotypes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:43:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Truong-2005"><DESCRIPTION><P>Quote: "Patients with pure retrocollis were not permitted to participate"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:47:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Truong-2010"><DESCRIPTION><P>Quote: "Patients were excluded if they had a diagnosis of pure anterocollis or retrocollis"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-15 09:48:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wissel-2001"><DESCRIPTION><P>Quote: "Patients with pure anterocollis were excluded"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-10-04 23:10:16 +0100" MODIFIED_BY="[Empty name]" NO="6"><NAME>Other bias</NAME><DESCRIPTION><P>Bias due to problems not covered elsewhere in the table</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM></QUALITY_ITEMS><SOF_TABLES MODIFIED="2017-11-14 18:36:39 +0000" MODIFIED_BY="[Empty name]"><SOF_TABLE ID="SOF-01" MODIFIED="2017-11-14 18:36:39 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES"><TITLE MODIFIED="2016-10-24 21:55:23 +0100" MODIFIED_BY="GDT">Botulinum toxin type A compared to placebo for cervical dystonia</TITLE><TABLE COLS="7" ROWS="13"><TR><TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP"><P><B>Botulinum toxin type A compared to placebo for cervical dystonia</B></P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP"><P><B>Patient or population: </B>adults with cervical dystonia<BR/><B>Setting: </B>hospital-based, movement disorders clinics<BR/><B>Intervention: </B>botulinum toxin type A<BR/><B>Comparison: </B>placebo</P></TD></TR><TR><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Outcomes</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Relative effect<BR/>(95% CI)</P></TH><TH ALIGN="LEFT" COLSPAN="3" ROWSPAN="1" VALIGN="TOP"><P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Certainty in the evidence<BR/>(GRADE)</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>What happens</P></TH></TR><TR><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>With placebo</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>With botulinum toxin type A</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>Difference</P></TH></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P><B>Cervical dystonia-specific impairment</B><BR/>Number of participants: 522 (4 RCTs)</P><P>Assessed 3 to 6 weeks post-injection using TWSTRS total score</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>3.9 TWSTRS units decrease</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>12.45 TWSTRS units decrease</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>The mean change from baseline was 8.06 TWSTRS units higher (6.08 higher to 10.05 higher) in the BtA group compared to the placebo group</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>a</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>BtA treatment probably improves cervical dystonia-specific impairment</P><P/></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P><B>Adverse events</B><BR/>Number of participants: 952 (7 RCTs)</P><P>Assessed at any point during follow-up</P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P><B>RR 1.19</B><BR/>(1.03 to 1.36)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>46.5%</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>55.3%<BR/>(47.9 to 63.2)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>8.8% more<BR/>(1.4 more to 16.7 more)</P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>a</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P>BtA treatment probably increases the risk of adverse events</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P><B>Subjective participant assessment</B><BR/>Number of participants: 624 (5 RCTs)</P><P>Assessed 3 to 6 weeks post-injection</P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P><B>RR 2.30</B><BR/>(1.83 to 2.90)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>24.2%</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>55.7%<BR/>(44.3 to 70.2)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>31.5% more<BR/>(20.1 more to 46 more)</P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>a</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P>BtA treatment probably increases the likelihood that patients will detect any form of improvement</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P><B>Pain relief</B><BR/>Number of participants: 429 (3 RCTs)</P><P>Assessed 3 to 6 weeks post-injection using TWSTRS pain subscore</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>-<SUP>b</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>-<SUP>b</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>-<SUP>b</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>The mean change from baseline was 2.11 TWSTRS units higher (1.38 higher to 2.83 higher) in the BtA group compared to the placebo group</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>a</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>BtA treatment probably improves cervical dystonia-related pain</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P><B>Tolerability</B><BR/>Number of participants: 574 (4 RCTs)</P><P>Assessed at any point during follow-up</P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P><B>RR 0.38</B><BR/>(0.23 to 0.62)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>20.5%</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>7.8%</P><P>(4.7 to 12.7)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>12.7% fewer</P><P>(15.8 to 7.8)</P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>a</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P>BtA treatment probably slightly decreases the risk of withdrawal of clinical trials</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P><B>Dysphagia</B><BR/>Number of participants: 1007 (8 RCTs)</P><P>Assessed at any point during follow-up</P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P><B>RR 3.04</B><BR/>(1.68 to 5.50)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>3.0%</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>9.2%<BR/>(5.1 to 16.7)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>6.2% more<BR/>(2.1 more to 13.7 more)</P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>a</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P>BtA treatment probably increases the risk of dysphagia</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P><B>Diffuse weakness/tiredness</B><BR/>Number of participants: 823 (6 RCTs)</P><P>Assessed at any point during follow-up</P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P><B>RR 1.78</B><BR/>(1.08 to 2.94)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>5.6%</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>10.1%<BR/>(6.1 to 16.6)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>4.4% more<BR/>(0.5 more to 11 more)</P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>a</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P>BtA treatment probably increases the risk of diffuse weakness/tiredness</P></TD></TR><TR><TD COLSPAN="7"><P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/><BR/>BtA: botulinum toxin type A; <B>CI:</B> confidence interval; <B>RCT</B>: randomised controlled trial; <B>RR:</B> risk ratio; TWSTRS: Toronto Western Spasmodic Torticollis Rating Scale</P></TD></TR><TR><TD COLSPAN="7"><P><B>GRADE Working Group grades of evidence</B><BR/><B>High certainty:</B> we are very confident that the true effect lies close to that of the estimate of the effect<BR/><B>Moderate certainty:</B> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/><B>Low certainty:</B> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<BR/><B>Very low certainty:</B> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect</P></TD></TR></TABLE><FOOTNOTES><P><SUP>a</SUP> Downgraded one level due to serious study limitations, namely concerns with randomisation procedures and other biases such as 'for-profit' bias.<BR/><SUP>b</SUP> Data were only available as between-group differences.</P></FOOTNOTES></SOF_TABLE></SOF_TABLES><ADDITIONAL_TABLES MODIFIED="2017-11-14 17:22:44 +0000" MODIFIED_BY="[Empty name]"><ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2017-11-14 15:20:23 +0000" MODIFIED_BY="[Empty name]" NO="1"><TITLE MODIFIED="2016-05-22 19:29:27 +0100" MODIFIED_BY="[Empty name]">Glossary of terms</TITLE><TABLE COLS="2" ROWS="8"><TR><TH><P><B>Term</B></P></TH><TH><P><B>Definition</B></P></TH></TR><TR><TH><P><B>BtA-non-responsive</B></P></TH><TD><P>People who do not experience the expected benefit from treatment with botulinum toxin type A</P></TD></TR><TR><TH><P><B>Cervical dystonia or spasmodic torticollis</B></P></TH><TD><P>A common movement disorder in which people have abnormal movements or postures of the head and neck that they cannot control. It is frequently accompanied by social embarrassment and pain.</P></TD></TR><TR><TH><P><B>Chemodenervation</B></P></TH><TD><P>The process by which botulinum toxin causes muscular paralysis. Although all the anatomical elements necessary for muscular control are intact (i.e. nerve, synapse and muscle), there is a chemical process that disables the transmission of the electrical signal from the nerve to the muscle.</P></TD></TR><TR><TH><P><B>Dysphagia</B></P></TH><TD><P>A discomfort or difficulty when swallowing.</P></TD></TR><TR><TH><P><B>Electromyography</B></P></TH><TD><P>An examination that displays the electrical activity of muscles using pieces of metal attached to the skin or inserted into the muscle.</P></TD></TR><TR><TH><P><B>Non-naive</B></P></TH><TD><P>People who have been treated in the past with botulinum toxin.</P></TD></TR><TR><TH><P><B>Voluntary action</B></P></TH><TD><P>Movements that people are able to control, start and stop when they want to.</P></TD></TR></TABLE><FOOTNOTES/></ADDITIONAL_TABLE><ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2017-11-14 17:22:44 +0000" MODIFIED_BY="[Empty name]" NO="2"><TITLE MODIFIED="2017-11-14 17:21:30 +0000" MODIFIED_BY="[Empty name]">Summary of included studies - participants and drug administration</TITLE><TABLE COLS="10" ROWS="9"><TR><TH><P>Study ID</P></TH><TH><P>Number of participants</P></TH><TH><P>Total dropouts</P></TH><TH><P>Age mean, range (years)</P></TH><TH><P>Baseline CD impairment BtA/placebo</P></TH><TH><P>% participants naive to Bt</P></TH><TH><P>BtA formulation</P></TH><TH><P>Total dose per participant</P></TH><TH><P>EMG-guidance</P></TH><TH><P>Study duration (weeks)</P></TH></TR><TR><TH><P><B>Charles 2012</B></P></TH><TD><P>170</P></TD><TD><P>35</P><P>(11 in BtA)</P></TD><TD><P>55,</P><P>31-76</P></TD><TD><P>9.2/9.3</P><P>(CDSS)</P></TD><TD><P>0</P></TD><TD><P><B>Botox (OnaBtA)</B></P></TD><TD><P>236</P></TD><TD><P>No</P></TD><TD><P>10</P></TD></TR><TR><TH><P><B>Comella 2011</B></P></TH><TD><P>233</P></TD><TD><P>14</P><P>(8 in BtA)</P></TD><TD><P>53</P></TD><TD><P>42.4/41.8</P><P>(TWSTRS)</P></TD><TD><P>39</P></TD><TD><P><B>Xeomin (IncoBtA)</B></P></TD><TD><P>120 or 240</P></TD><TD><P>At discretion</P></TD><TD><P>20</P></TD></TR><TR><TH><P><B>Greene 1990</B></P></TH><TD><P>55</P></TD><TD><P>3</P><P>(3 in BtA)</P></TD><TD><P>50</P></TD><TD><P>21% severe/</P><P>41% severe</P></TD><TD><P>100</P></TD><TD><P><B>Botox (OnaBtA)</B></P></TD><TD><P>150 to 165</P></TD><TD><P>No</P></TD><TD><P>12</P></TD></TR><TR><TH><P><B>Poewe 1998</B></P></TH><TD><P>75</P></TD><TD><P>2</P><P>(2 in BtA)</P></TD><TD><P>47,</P><P>26-82</P></TD><TD><P>13.9/14.4</P><P>(Tsui scale)</P></TD><TD><P>100</P></TD><TD><P><B>Dysport (AboBtA)</B></P></TD><TD><P>250, 500</P><P>or 1000</P></TD><TD><P>No</P></TD><TD><P>8</P></TD></TR><TR><TH><P>Poewe 2016</P></TH><TD><P>213</P></TD><TD><P>N/A</P></TD><TD><P>49</P></TD><TD><P>46/47</P><P>(TWSTRS)</P></TD><TD><P>10</P></TD><TD><P><B>Dysport (AboBtA)</B></P></TD><TD><P>500</P></TD><TD><P>N/A</P></TD><TD><P>12</P></TD></TR><TR><TH><P><B>Truong 2005</B></P></TH><TD><P>80</P></TD><TD><P>56</P><P>(22 in BtA)</P></TD><TD><P>54,</P><P>27-78</P></TD><TD><P>45.1/46.2</P><P>(TWSTRS)</P></TD><TD><P>26</P></TD><TD><P><B>Dysport (AboBtA)</B></P></TD><TD><P>500</P></TD><TD><P>At discretion</P></TD><TD><P>20</P></TD></TR><TR><TH><P><B>Truong 2010</B></P></TH><TD><P>116</P></TD><TD><P>33</P><P>(10 in BtA)</P></TD><TD><P>53,</P><P>20-79</P></TD><TD><P>43.8/45.8</P><P>(TWSTRS)</P></TD><TD><P>17</P></TD><TD><P><B>Dysport (AboBtA)</B></P></TD><TD><P>500</P></TD><TD><P>At discretion</P></TD><TD><P>12</P></TD></TR><TR><TH><P><B>Wissel 2001</B></P></TH><TD><P>68</P></TD><TD><P>0</P></TD><TD><P>48,</P><P>18-75</P></TD><TD><P>11.1/11.5</P><P>(Tsui scale)</P></TD><TD><P>31</P></TD><TD><P><B>Dysport (AboBtA)</B></P></TD><TD><P>500</P></TD><TD><P>No</P></TD><TD><P>16</P></TD></TR></TABLE><FOOTNOTES><P>Bt: botulinum toxin; CD: cervical dystonia; CDSS: Cervical Dystonia Severity Scale; EMG: electromyography; TWSTRS: Toronto Western Spasmodic Torticollis Rating Scale</P></FOOTNOTES></ADDITIONAL_TABLE></ADDITIONAL_TABLES><ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-11-14 17:08:20 +0000" MODIFIED_BY="[Empty name]"><COMPARISON ID="CMP-001" MODIFIED="2017-11-14 17:08:20 +0000" MODIFIED_BY="[Empty name]" NO="1"><NAME>Botulinum toxin type A versus placebo</NAME><IV_OUTCOME CHI2="9.3217921989242" CI_END="0.8857653334258756" CI_START="0.5154830498277688" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.7006241916268222" ESTIMABLE="YES" I2="35.63469478870767" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.052681320886281136" LOG_CI_START="-0.28778561066619623" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.1545148711452877" MODIFIED="2016-10-23 08:40:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.15627316722463136" P_Q="1.0" P_Z="1.1977201890563075E-13" Q="0.0" RANDOM="YES" SCALE="1.89" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.021710642099560428" TOTALS="YES" TOTAL_1="473" TOTAL_2="360" WEIGHT="99.99999999999999" Z="7.417034209373564"><NAME>Cervical dystonia-specific improvement</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE><IV_DATA CI_END="0.6878984212052544" CI_START="0.08070157879474554" EFFECT_SIZE="0.3843" ESTIMABLE="YES" ESTIMATE="0.3843" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-23 17:57:20 +0000" MODIFIED_BY="[Empty name]" ORDER="779" SE="0.1549" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" WEIGHT="19.523122801976577"><FOOTNOTE>CDSS, week 4, mean and SD obtained from graph</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.10206274894594" CI_START="0.53053725105406" EFFECT_SIZE="0.8163" ESTIMABLE="YES" ESTIMATE="0.8163" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-23 18:07:27 +0000" MODIFIED_BY="[Empty name]" ORDER="780" SE="0.1458" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" WEIGHT="20.76642332346033"><FOOTNOTE>TWSTRS, week 4, combined groups method</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.7969738112263811" CI_START="0.6880261887736187" EFFECT_SIZE="1.2425" ESTIMABLE="YES" ESTIMATE="1.2425" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-08 14:25:00 +0000" MODIFIED_BY="[Empty name]" ORDER="781" SE="0.2829" STUDY_ID="STD-Poewe-1998" TOTAL_1="53" TOTAL_2="20" WEIGHT="8.77010780734373"><FOOTNOTE>Tsui (computed from baseline value and % of change), week 4, appropriated SD from Wissel 2001</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.0868563143008476" CI_START="0.2503436856991524" EFFECT_SIZE="0.6686" ESTIMABLE="YES" ESTIMATE="0.6686" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-10-15 17:51:53 +0100" MODIFIED_BY="[Empty name]" ORDER="324" SE="0.2134" STUDY_ID="STD-Poewe-2016" TOTAL_1="46" TOTAL_2="47" WEIGHT="13.268324967118089"><FOOTNOTE>TWSTRS, week 4, appropriated SD from Truong 2010</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.1149676948349365" CI_START="0.2110323051650635" EFFECT_SIZE="0.663" ESTIMABLE="YES" ESTIMATE="0.663" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-08 13:35:53 +0000" MODIFIED_BY="[Empty name]" ORDER="782" SE="0.2306" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" WEIGHT="11.915252454291696"><FOOTNOTE>TWSTRS, week 4, appropriated SD from Truong 2010</FOOTNOTE></IV_DATA><IV_DATA CI_END="0.9518971606641563" CI_START="0.20750283933584368" EFFECT_SIZE="0.5797" ESTIMABLE="YES" ESTIMATE="0.5797" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-23 18:12:23 +0000" MODIFIED_BY="[Empty name]" ORDER="783" SE="0.1899" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" WEIGHT="15.444981373256429"><FOOTNOTE>TWSTRS, week 4</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.3705068304638979" CI_START="0.37249316953610223" EFFECT_SIZE="0.8715" ESTIMABLE="YES" ESTIMATE="0.8715" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-23 18:23:49 +0000" MODIFIED_BY="[Empty name]" ORDER="784" SE="0.2546" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" WEIGHT="10.311787272553145"><FOOTNOTE>Tsui, week 4, pooled SD</FOOTNOTE></IV_DATA></IV_OUTCOME><CONT_OUTCOME CHI2="0.821021840552878" CI_END="10.049643291325802" CI_START="6.075473567283077" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="8.06255842930444" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2016-10-23 08:39:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8444326224779108" P_Q="1.0" P_Z="1.827612296155769E-15" Q="0.0" RANDOM="YES" SCALE="19.06" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="297" TOTAL_2="225" UNITS="" WEIGHT="99.99999999999999" Z="7.952515993006767"><NAME>Cervical dystonia-specific improvement - TWSTRS subgroup analysis</NAME><GROUP_LABEL_1>Experimental</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><CONT_DATA CI_END="10.275677796736804" CI_START="5.456322203263196" EFFECT_SIZE="7.8660000000000005" ESTIMABLE="YES" MEAN_1="10.066" MEAN_2="2.2" MODIFIED="2016-10-15 16:27:20 +0100" MODIFIED_BY="[Empty name]" ORDER="272" SD_1="11.2176" SD_2="7.3" SE="1.2294500387476688" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" WEIGHT="68.00093397495893"/><CONT_DATA CI_END="16.18991890995704" CI_START="3.81008109004296" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="5.0" MODIFIED="2016-10-15 17:45:14 +0100" MODIFIED_BY="[Empty name]" ORDER="160" SD_1="14.8324" SD_2="15.6205" SE="3.1581799251324667" STUDY_ID="STD-Poewe-2016" TOTAL_1="46" TOTAL_2="47" WEIGHT="10.305353893276331"><FOOTNOTE>appropriated SD from Truong 2010 (same scale and week 4)</FOOTNOTE></CONT_DATA><CONT_DATA CI_END="12.78125460005852" CI_START="-0.5812546000585197" EFFECT_SIZE="6.1000000000000005" ESTIMABLE="YES" MEAN_1="9.9" MEAN_2="3.8" MODIFIED="2016-10-15 17:45:22 +0100" MODIFIED_BY="[Empty name]" ORDER="273" SD_1="14.8324" SD_2="15.6205" SE="3.4088660060896037" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" WEIGHT="8.84538593644733"><FOOTNOTE>appropriated SD from Truong 2010 (same scale and week 4)</FOOTNOTE></CONT_DATA><CONT_DATA CI_END="14.443615977866086" CI_START="3.356384022133911" EFFECT_SIZE="8.899999999999999" ESTIMABLE="YES" MEAN_1="15.6" MEAN_2="6.7" MODIFIED="2016-10-15 16:27:38 +0100" MODIFIED_BY="[Empty name]" ORDER="274" SD_1="14.8324" SD_2="15.6205" SE="2.8284274719298024" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" WEIGHT="12.8483261953174"/></CONT_OUTCOME><CONT_OUTCOME CHI2="0.883009111049039" CI_END="4.113452167723166" CI_START="2.1460119494531384" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="3.1297320585881523" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2017-11-13 15:05:58 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6430681853183928" P_Q="1.0" P_Z="4.4982473383751765E-10" Q="0.0" RANDOM="YES" SCALE="12.2" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="251" TOTAL_2="178" UNITS="" WEIGHT="100.0" Z="6.235678277926998"><NAME>Cervical dystonia-specific severity - as assessed with TWSTRS subscale</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><CONT_DATA CI_END="4.041571846847242" CI_START="1.5886281531527566" EFFECT_SIZE="2.8150999999999997" ESTIMABLE="YES" MEAN_1="4.7151" MEAN_2="1.9" MODIFIED="2016-10-15 16:28:50 +0100" MODIFIED_BY="[Empty name]" ORDER="514" SD_1="5.2804" SD_2="4.0" SE="0.6257624408006965" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" WEIGHT="64.33213007374427"/><CONT_DATA CI_END="8.357904700696164" CI_START="-3.357904700696164" EFFECT_SIZE="2.4999999999999996" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="2.1" MODIFIED="2015-01-07 20:31:36 +0000" MODIFIED_BY="[Empty name]" ORDER="1608" SD_1="4.002" SD_2="19.118" SE="2.98878180767737" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" WEIGHT="2.8200609473492833"><FOOTNOTE>TWSTRS, week 4, appropriated SD from Truong 2010 (same scale, measurement error and week 4)</FOOTNOTE></CONT_DATA><CONT_DATA CI_END="5.51639936845703" CI_START="2.0836006315429705" EFFECT_SIZE="3.8000000000000003" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="2.4" MODIFIED="2016-10-15 16:28:46 +0100" MODIFIED_BY="[Empty name]" ORDER="351" SD_1="5.4" SD_2="3.8" SE="0.8757300552437538" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" WEIGHT="32.847808978906464"/></CONT_OUTCOME><CONT_OUTCOME CHI2="2.6136094629249236" CI_END="3.309728584090514" CI_START="1.7203583635381192" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.5150434738143166" ESTIMABLE="YES" I2="23.477473265582127" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2017-11-13 15:06:04 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.27068372706972754" P_Q="1.0" P_Z="5.541328660467385E-10" Q="0.0" RANDOM="YES" SCALE="10.08" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.11799610200508222" TOTALS="YES" TOTAL_1="251" TOTAL_2="178" UNITS="" WEIGHT="100.0" Z="6.202953301233149"><NAME>Cervical dystonia-specific disability - as assessed with TWSTRS subscale</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><CONT_DATA CI_END="4.194850908171099" CI_START="2.0995490918289015" EFFECT_SIZE="3.1472" ESTIMABLE="YES" MEAN_1="3.1472" MEAN_2="0.0" MODIFIED="2016-10-15 16:28:57 +0100" MODIFIED_BY="[Empty name]" ORDER="516" SD_1="4.5377" SD_2="3.4" SE="0.5345255915082294" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" WEIGHT="40.72119099440322"/><CONT_DATA CI_END="3.0024669909929425" CI_START="0.7975330090070574" EFFECT_SIZE="1.9" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="0.6" MODIFIED="2016-10-15 16:29:14 +0100" MODIFIED_BY="[Empty name]" ORDER="1609" SD_1="3.15" SD_2="1.44" SE="0.5624934946198304" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" WEIGHT="37.845053059172905"><FOOTNOTE>appropriated SD from Truong 2010</FOOTNOTE></CONT_DATA><CONT_DATA CI_END="3.978962934827208" CI_START="0.8210370651727916" EFFECT_SIZE="2.4" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="1.5" MODIFIED="2016-10-15 16:29:02 +0100" MODIFIED_BY="[Empty name]" ORDER="352" SD_1="4.9" SD_2="3.6" SE="0.805608137334087" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" WEIGHT="21.433755946423876"/></CONT_OUTCOME><IV_OUTCOME CHI2="9.146098947679548" CI_END="1.0037209140699204" CI_START="0.6820344890478394" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_SIZE="0.8428777015588799" ESTIMABLE="YES" I2="12.53101408847456" I2_Q="27.318146648551924" ID="CMP-001.05" LOG_CI_END="0.001612973437963749" LOG_CI_START="-0.16619366343084777" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.07423543532926312" MODIFIED="2017-11-14 17:08:20 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.33012171341965346" P_Q="0.25262267629842927" P_Z="9.52782119319901E-25" Q="2.751718493375696" RANDOM="YES" SCALE="2.65" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.007589680440051208" TOTALS="YES" TOTAL_1="385" TOTAL_2="392" WEIGHT="99.99999999999999" Z="10.270933492539566"><NAME>Cervical dystonia-specific improvement - 
doses subgroup analysis</NAME><GROUP_LABEL_1>Experimental</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="0.0" CI_END="1.9359632829410933" CI_START="0.5518367170589068" DF="0" EFFECT_SIZE="1.2439" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.2868971163157177" LOG_CI_START="-0.2581894066376047" LOG_EFFECT_SIZE="0.09478546781955836" MODIFIED="2017-11-14 17:08:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="4.2701656525273655E-4" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="5.091553030710462" Z="3.522798074199943"><NAME>Low 
dose</NAME><IV_DATA CI_END="1.9359632829410933" CI_START="0.5518367170589068" EFFECT_SIZE="1.2439" ESTIMABLE="YES" ESTIMATE="1.2439" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-08 14:25:16 +0000" MODIFIED_BY="[Empty name]" ORDER="280" SE="0.3531" STUDY_ID="STD-Poewe-1998" TOTAL_1="19" TOTAL_2="20" WEIGHT="5.091553030710462"><FOOTNOTE>Tsui (computed from baseline value and % of change), week 4, appropriated SD from Wissel 2001</FOOTNOTE></IV_DATA></IV_SUBGROUP><IV_SUBGROUP CHI2="4.11231516609134" CI_END="0.9355330742109845" CI_START="0.5860483465620324" DF="5" EFFECT_SIZE="0.7607907103865085" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="-0.0289408541357359" LOG_CI_START="-0.2320665550074764" LOG_EFFECT_SIZE="-0.1187347989787779" MODIFIED="2017-11-14 17:08:20 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5333614753457858" P_Z="1.422778436429126E-17" STUDIES="6" TAU2="0.0" TOTAL_1="267" TOTAL_2="278" WEIGHT="71.56044098942303" Z="8.533262109398908"><NAME>Medium 
dose</NAME><IV_DATA CI_END="1.1813098917779932" CI_START="0.5164901082220068" EFFECT_SIZE="0.8489" ESTIMABLE="YES" ESTIMATE="0.8489" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-10-15 16:29:51 +0100" MODIFIED_BY="[Empty name]" ORDER="276" SE="0.1696" STUDY_ID="STD-Comella-2011" TOTAL_1="78" TOTAL_2="74" WEIGHT="18.525033351579964"><FOOTNOTE>TWSTRS</FOOTNOTE></IV_DATA><IV_DATA CI_END="2.0732945014056123" CI_START="0.6041054985943877" EFFECT_SIZE="1.3387" ESTIMABLE="YES" ESTIMATE="1.3387" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-08 14:25:25 +0000" MODIFIED_BY="[Empty name]" ORDER="275" SE="0.3748" STUDY_ID="STD-Poewe-1998" TOTAL_1="16" TOTAL_2="20" WEIGHT="4.5483900865002855"><FOOTNOTE>Tsui (computed from baseline value and % of change), week 4, appropriated SD from Wissel 2001</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.0868563143008476" CI_START="0.2503436856991524" EFFECT_SIZE="0.6686" ESTIMABLE="YES" ESTIMATE="0.6686" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-10-21 16:32:39 +0100" MODIFIED_BY="[Empty name]" ORDER="324" SE="0.2134" STUDY_ID="STD-Poewe-2016" TOTAL_1="46" TOTAL_2="47" WEIGHT="12.675809046618399"><FOOTNOTE>TWSTRS, week 4, appropriated SD from Truong 2010</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.1149676948349365" CI_START="0.2110323051650635" EFFECT_SIZE="0.663" ESTIMABLE="YES" ESTIMATE="0.663" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-08 13:40:31 +0000" MODIFIED_BY="[Empty name]" ORDER="279" SE="0.2306" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" WEIGHT="11.08277093147716"><FOOTNOTE>TWSTRS, week 4, appropriated SD from Truong 2010</FOOTNOTE></IV_DATA><IV_DATA CI_END="0.9518971606641563" CI_START="0.20750283933584368" EFFECT_SIZE="0.5797" ESTIMABLE="YES" ESTIMATE="0.5797" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-10-15 16:29:44 +0100" MODIFIED_BY="[Empty name]" ORDER="278" SE="0.1899" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" WEIGHT="15.427950208133455"><FOOTNOTE>TWSTRS</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.3705068304638979" CI_START="0.37249316953610223" EFFECT_SIZE="0.8715" ESTIMABLE="YES" ESTIMATE="0.8715" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-23 18:49:54 +0000" MODIFIED_BY="[Empty name]" ORDER="277" SE="0.2546" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" WEIGHT="9.300487365113765"><FOOTNOTE>Tsui, week 4, pooled SD</FOOTNOTE></IV_DATA></IV_SUBGROUP><IV_SUBGROUP CHI2="2.103682154226702" CI_END="1.6316724143867924" CI_START="0.5323707258571103" DF="1" EFFECT_SIZE="1.0820215701219513" ESTIMABLE="YES" I2="52.46430179621919" ID="CMP-001.05.03" LOG_CI_END="0.21263297126550293" LOG_CI_START="-0.27378583364113107" LOG_EFFECT_SIZE="0.03423591852615445" MODIFIED="2017-11-13 15:08:32 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.14694494887978982" P_Z="1.1417381006404414E-4" STUDIES="2" TAU2="0.09143797500000005" TOTAL_1="99" TOTAL_2="94" WEIGHT="23.348005979866503" Z="3.858309925405421"><NAME>High 
dose</NAME><IV_DATA CI_END="1.2094499277934532" CI_START="0.5485500722065468" EFFECT_SIZE="0.879" ESTIMABLE="YES" ESTIMATE="0.879" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-10-15 16:29:59 +0100" MODIFIED_BY="[Empty name]" ORDER="281" SE="0.1686" STUDY_ID="STD-Comella-2011" TOTAL_1="81" TOTAL_2="74" WEIGHT="18.69899017153248"><FOOTNOTE>TWSTRS</FOOTNOTE></IV_DATA><IV_DATA CI_END="2.1955666562720904" CI_START="0.74323334372791" EFFECT_SIZE="1.4694" ESTIMABLE="YES" ESTIMATE="1.4694" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-08 14:25:35 +0000" MODIFIED_BY="[Empty name]" ORDER="282" SE="0.3705" STUDY_ID="STD-Poewe-1998" TOTAL_1="18" TOTAL_2="20" WEIGHT="4.649015808334023"><FOOTNOTE>Tsui (computed from baseline value and % of change), week 4, appropriated SD from Wissel 2001</FOOTNOTE></IV_DATA></IV_SUBGROUP></IV_OUTCOME><IV_OUTCOME CHI2="9.3217921989242" CI_END="0.8857653334258756" CI_START="0.5154830498277688" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.7006241916268222" ESTIMABLE="YES" I2="35.63469478870767" I2_Q="59.873651649927545" ID="CMP-001.06" LOG_CI_END="-0.052681320886281136" LOG_CI_START="-0.28778561066619623" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.1545148711452877" MODIFIED="2016-10-23 08:41:02 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.15627316722463136" P_Q="0.08273378048945956" P_Z="1.1977201890563075E-13" Q="4.984256186362865" RANDOM="YES" SCALE="2.12" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.021710642099560428" TOTALS="YES" TOTAL_1="473" TOTAL_2="360" WEIGHT="100.00000000000001" Z="7.417034209373564"><NAME>Cervical dystonia-specific improvement - BtA formulation subgroup analysis</NAME><GROUP_LABEL_1>Placebo</GROUP_LABEL_1><GROUP_LABEL_2>BtA</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="0.0" CI_END="0.6878984212052544" CI_START="0.08070157879474554" DF="0" EFFECT_SIZE="0.3843" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-0.16247568729793893" LOG_CI_START="-1.0931179689317205" LOG_EFFECT_SIZE="-0.4153296155356513" MODIFIED="2014-12-26 11:46:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.013103074659585675" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="82" WEIGHT="19.52312280197658" Z="2.480955455132343"><NAME>Botox</NAME><IV_DATA CI_END="0.6878984212052544" CI_START="0.08070157879474554" EFFECT_SIZE="0.3843" ESTIMABLE="YES" ESTIMATE="0.3843" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-23 19:09:10 +0000" MODIFIED_BY="[Empty name]" ORDER="283" SE="0.1549" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" WEIGHT="19.52312280197658"><FOOTNOTE>CDSS, week 4, mean and SD obtained from graph</FOOTNOTE></IV_DATA></IV_SUBGROUP><IV_SUBGROUP CHI2="4.350384516905888" CI_END="0.9617981094398497" CI_START="0.5439735557916804" DF="4" EFFECT_SIZE="0.752885832615765" ESTIMABLE="YES" I2="8.054104540512913" ID="CMP-001.06.02" LOG_CI_END="-0.016916080933086938" LOG_CI_START="-0.2644222121637631" LOG_EFFECT_SIZE="-0.12327087509294689" MODIFIED="2016-10-22 10:47:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3606584644999634" P_Z="1.6248755403912572E-12" STUDIES="5" TAU2="0.004629556947696417" TOTAL_1="226" TOTAL_2="204" WEIGHT="59.7104538745631" Z="7.063391098072758"><NAME>Dysport</NAME><IV_DATA CI_END="1.7969738112263811" CI_START="0.6880261887736187" EFFECT_SIZE="1.2425" ESTIMABLE="YES" ESTIMATE="1.2425" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-08 14:25:48 +0000" MODIFIED_BY="[Empty name]" ORDER="287" SE="0.2829" STUDY_ID="STD-Poewe-1998" TOTAL_1="53" TOTAL_2="20" WEIGHT="8.770107807343733"><FOOTNOTE>Tsui (computed from baseline value and % of change), week 4, appropriated SD from Wissel 2001</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.0868563143008476" CI_START="0.2503436856991524" EFFECT_SIZE="0.6686" ESTIMABLE="YES" ESTIMATE="0.6686" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-10-22 10:47:05 +0100" MODIFIED_BY="[Empty name]" ORDER="324" SE="0.2134" STUDY_ID="STD-Poewe-2016" TOTAL_1="46" TOTAL_2="47" WEIGHT="13.26832496711809"><FOOTNOTE>TWSTRS, week 4, appropriated SD from Truong 2010</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.1149676948349365" CI_START="0.2110323051650635" EFFECT_SIZE="0.663" ESTIMABLE="YES" ESTIMATE="0.663" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-08 13:42:11 +0000" MODIFIED_BY="[Empty name]" ORDER="286" SE="0.2306" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" WEIGHT="11.915252454291698"><FOOTNOTE>TWSTRS, week 4, appropriated SD from Truong 2010</FOOTNOTE></IV_DATA><IV_DATA CI_END="0.9518971606641563" CI_START="0.20750283933584368" EFFECT_SIZE="0.5797" ESTIMABLE="YES" ESTIMATE="0.5797" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-23 19:11:05 +0000" MODIFIED_BY="[Empty name]" ORDER="284" SE="0.1899" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" WEIGHT="15.44498137325643"><FOOTNOTE>TWSTRS, week 4</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.3705068304638979" CI_START="0.37249316953610223" EFFECT_SIZE="0.8715" ESTIMABLE="YES" ESTIMATE="0.8715" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-23 19:10:53 +0000" MODIFIED_BY="[Empty name]" ORDER="285" SE="0.2546" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" WEIGHT="10.311787272553147"><FOOTNOTE>Tsui, week 4, pooled SD</FOOTNOTE></IV_DATA></IV_SUBGROUP><IV_SUBGROUP CHI2="0.0" CI_END="1.10206274894594" CI_START="0.53053725105406" DF="0" EFFECT_SIZE="0.8163" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.042206322959625106" LOG_CI_START="-0.2752841172117397" LOG_EFFECT_SIZE="-0.08815020350057985" MODIFIED="2016-10-21 15:36:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="2.1588366695823764E-8" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="74" WEIGHT="20.766423323460334" Z="5.598765432098765"><NAME>Xeomin</NAME><IV_DATA CI_END="1.10206274894594" CI_START="0.53053725105406" EFFECT_SIZE="0.8163" ESTIMABLE="YES" ESTIMATE="0.8163" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-23 19:11:26 +0000" MODIFIED_BY="[Empty name]" ORDER="288" SE="0.1458" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" WEIGHT="20.766423323460334"><FOOTNOTE>TWSTRS, week 4, combined groups method</FOOTNOTE></IV_DATA></IV_SUBGROUP></IV_OUTCOME><IV_OUTCOME CHI2="9.321792198924202" CI_END="0.8857653334258755" CI_START="0.5154830498277687" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.7006241916268221" ESTIMABLE="YES" I2="35.634694788707684" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.05268132088628119" LOG_CI_START="-0.2877856106661963" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.15451487114528778" MODIFIED="2016-10-23 08:41:11 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.15627316722463136" P_Q="0.7595036762716012" P_Z="1.197720189056325E-13" Q="0.09371719323581597" RANDOM="YES" SCALE="1.63" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.021710642099560435" TOTALS="YES" TOTAL_1="473" TOTAL_2="360" WEIGHT="100.0" Z="7.417034209373562"><NAME>Cervical dystonia-specific improvement - EMG-guided versus non-EMG-guided subgroup analysis</NAME><GROUP_LABEL_1>Placebo</GROUP_LABEL_1><GROUP_LABEL_2>BtA</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="1.0801153914692048" CI_END="0.8888322475273491" CI_START="0.5241462880578829" DF="3" EFFECT_SIZE="0.706489267792616" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-0.051180197238740434" LOG_CI_START="-0.28054748547877545" LOG_EFFECT_SIZE="-0.15089443108909173" MODIFIED="2016-10-22 16:50:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.781876372967665" P_Z="3.104289467972256E-14" STUDIES="4" TAU2="0.0" TOTAL_1="297" TOTAL_2="225" WEIGHT="61.39498211812654" Z="7.593895429108431"><NAME>EMG-guided injection</NAME><IV_DATA CI_END="1.10206274894594" CI_START="0.53053725105406" EFFECT_SIZE="0.8163" ESTIMABLE="YES" ESTIMATE="0.8163" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 12:00:44 +0000" MODIFIED_BY="[Empty name]" ORDER="288" SE="0.1458" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" WEIGHT="20.76642332346033"><FOOTNOTE>TWSTRS, week 4, combined groups method</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.0868563143008476" CI_START="0.2503436856991524" EFFECT_SIZE="0.6686" ESTIMABLE="YES" ESTIMATE="0.6686" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-10-22 10:49:22 +0100" MODIFIED_BY="[Empty name]" ORDER="324" SE="0.2134" STUDY_ID="STD-Poewe-2016" TOTAL_1="46" TOTAL_2="47" WEIGHT="13.268324967118087"><FOOTNOTE>TWSTRS, week 4, appropriated SD from Truong 2010</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.1149676948349365" CI_START="0.2110323051650635" EFFECT_SIZE="0.663" ESTIMABLE="YES" ESTIMATE="0.663" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-08 13:43:53 +0000" MODIFIED_BY="[Empty name]" ORDER="286" SE="0.2306" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" WEIGHT="11.915252454291696"><FOOTNOTE>TWSTRS, week 4, appropriated SD from Truong 2010</FOOTNOTE></IV_DATA><IV_DATA CI_END="0.9518971606641563" CI_START="0.20750283933584368" EFFECT_SIZE="0.5797" ESTIMABLE="YES" ESTIMATE="0.5797" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 12:00:51 +0000" MODIFIED_BY="[Empty name]" ORDER="284" SE="0.1899" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" WEIGHT="15.44498137325643"><FOOTNOTE>TWSTRS, week 4</FOOTNOTE></IV_DATA></IV_SUBGROUP><IV_SUBGROUP CHI2="8.084645642972397" CI_END="1.3103121974977563" CI_START="0.27422762164836345" DF="2" EFFECT_SIZE="0.7922699095730599" ESTIMABLE="YES" I2="75.26174815418773" ID="CMP-001.07.02" LOG_CI_END="0.11737478382126654" LOG_CI_START="-0.5618888029188677" LOG_EFFECT_SIZE="-0.10112683827326022" MODIFIED="2016-10-22 16:50:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.01755670461822878" P_Z="0.002722232861505972" STUDIES="3" TAU2="0.156098743067091" TOTAL_1="176" TOTAL_2="135" WEIGHT="38.60501788187345" Z="2.9974782464548992"><NAME>Non-EMG-guided injection</NAME><IV_DATA CI_END="0.6878984212052544" CI_START="0.08070157879474554" EFFECT_SIZE="0.3843" ESTIMABLE="YES" ESTIMATE="0.3843" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 12:00:47 +0000" MODIFIED_BY="[Empty name]" ORDER="283" SE="0.1549" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" WEIGHT="19.523122801976573"><FOOTNOTE>CDSS, week 4, mean and SD obtained from graph</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.7969738112263811" CI_START="0.6880261887736187" EFFECT_SIZE="1.2425" ESTIMABLE="YES" ESTIMATE="1.2425" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-08 13:43:22 +0000" MODIFIED_BY="[Empty name]" ORDER="287" SE="0.2829" STUDY_ID="STD-Poewe-1998" TOTAL_1="53" TOTAL_2="20" WEIGHT="8.770107807343733"><FOOTNOTE>Tsui (computed from baseline value and % of change), week 4, appropriated SD from Wissel 2001</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.3705068304638979" CI_START="0.37249316953610223" EFFECT_SIZE="0.8715" ESTIMABLE="YES" ESTIMATE="0.8715" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 11:56:57 +0000" MODIFIED_BY="[Empty name]" ORDER="285" SE="0.2546" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" WEIGHT="10.311787272553147"><FOOTNOTE>Tsui, week 4, pooled SD</FOOTNOTE></IV_DATA></IV_SUBGROUP></IV_OUTCOME><DICH_OUTCOME CHI2="7.162522928848108" CI_END="1.3598403996704125" CI_START="1.0330983378044056" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1852632013940119" ESTIMABLE="YES" EVENTS_1="308" EVENTS_2="171" I2="16.230634657599165" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.13348793953944513" LOG_CI_START="0.01414166279081436" LOG_EFFECT_SIZE="0.07381480116512977" METHOD="MH" MODIFIED="2016-10-22 16:42:56 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.3060787264622086" P_Q="1.0" P_Z="0.015331727785281931" Q="0.0" RANDOM="YES" SCALE="7.413862024569745" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.005622757897027089" TOTALS="YES" TOTAL_1="584" TOTAL_2="368" WEIGHT="100.00000000000001" Z="2.424446840756587"><NAME>Adverse events</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_DATA CI_END="1.2985234892808313" CI_START="0.7847598272284366" EFFECT_SIZE="1.009469696969697" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="48" LOG_CI_END="0.11344981008606227" LOG_CI_START="-0.10526323710054225" LOG_EFFECT_SIZE="0.004093286492760025" MODIFIED="2014-12-26 17:42:06 +0000" MODIFIED_BY="[Empty name]" ORDER="631" O_E="0.0" SE="0.1284731265644558" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" VAR="0.016505344249246684" WEIGHT="22.210011642056877"/><DICH_DATA CI_END="1.6167398409304412" CI_START="0.9180180690555235" EFFECT_SIZE="1.2182759896411395" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="34" LOG_CI_END="0.20864014066185577" LOG_CI_START="-0.037148770635491005" LOG_EFFECT_SIZE="0.08574568501318237" MODIFIED="2014-12-26 17:44:10 +0000" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.14437762317079467" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" VAR="0.020844898072447986" WEIGHT="18.56852782324839"/><DICH_DATA CI_END="5.377175952747422" CI_START="1.1112354690424957" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="5" LOG_CI_END="0.7305542477579506" LOG_CI_START="0.045806095007812145" LOG_EFFECT_SIZE="0.3881801713828814" MODIFIED="2014-12-28 23:08:50 +0000" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.40222445448345356" STUDY_ID="STD-Poewe-1998" TOTAL_1="54" TOTAL_2="20" VAR="0.1617845117845118" WEIGHT="2.9357470987985503"/><DICH_DATA CI_END="2.4374740742844163" CI_START="0.9056995023231782" EFFECT_SIZE="1.4858058608058609" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="14" LOG_CI_END="0.38694000510694515" LOG_CI_START="-0.043015870899568265" LOG_EFFECT_SIZE="0.17196206710368842" MODIFIED="2016-10-21 22:19:04 +0100" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="0.2525582098821373" STUDY_ID="STD-Poewe-2016" TOTAL_1="156" TOTAL_2="55" VAR="0.06378564937886971" WEIGHT="7.0807763147741"/><DICH_DATA CI_END="1.3929362526370597" CI_START="0.9696214658815017" EFFECT_SIZE="1.162162162162162" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="34" LOG_CI_END="0.1439312415054764" LOG_CI_START="-0.01339777848029338" LOG_EFFECT_SIZE="0.06526673151259149" MODIFIED="2014-10-19 12:08:44 +0100" MODIFIED_BY="Ana Raquel Marques" ORDER="330" O_E="0.0" SE="0.09241584513085029" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.008540688431249305" WEIGHT="34.69956357332225"/><DICH_DATA CI_END="1.587708046535028" CI_START="0.7184272765685642" EFFECT_SIZE="1.068013468013468" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.2007706458015665" LOG_CI_START="-0.14361718714485872" LOG_EFFECT_SIZE="0.028576729328353867" MODIFIED="2014-11-03 23:47:23 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="343" O_E="0.0" SE="0.2022951178199971" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" VAR="0.0409233146938065" WEIGHT="10.55868688655269"/><DICH_DATA CI_END="3.0889368540311075" CI_START="0.7994296652194277" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.4898090302742084" LOG_CI_START="-0.09721973998627205" LOG_EFFECT_SIZE="0.1962946451439682" MODIFIED="2014-11-16 01:06:05 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="328" O_E="0.0" SE="0.3448236054902838" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" VAR="0.11890331890331887" WEIGHT="3.9466866612471563"/></DICH_OUTCOME><DICH_OUTCOME CHI2="12.283781816418834" CI_END="1.4585157409258764" CI_START="1.0760617627854527" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2527781205109823" ESTIMABLE="YES" EVENTS_1="256" EVENTS_2="167" I2="34.873476918102014" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.16391112057489818" LOG_CI_START="0.031837199273778226" LOG_EFFECT_SIZE="0.09787415992433819" METHOD="MH" MODIFIED="2017-11-14 15:22:05 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.13898441181749766" P_Q="0.6550781224172182" P_Z="0.0036738713369283238" Q="0.8460016125249157" RANDOM="YES" SCALE="10.3" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.022476902138696044" TOTALS="SUB" TOTAL_1="496" TOTAL_2="400" WEIGHT="300.0" Z="2.9048857878832406"><NAME>Adverse events - doses subgroup analysis</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="3.8512546326178128" CI_START="0.5639058851007135" DF="0" EFFECT_SIZE="1.4736842105263157" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.5856022337317852" LOG_CI_START="-0.2487933729530046" LOG_EFFECT_SIZE="0.16840443038939024" MODIFIED="2017-11-13 15:09:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4288556657883439" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="0.7911513813252303"><NAME>Low 
dose</NAME><DICH_DATA CI_END="3.8512546326178128" CI_START="0.5639058851007135" EFFECT_SIZE="1.4736842105263157" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5856022337317852" LOG_CI_START="-0.2487933729530046" LOG_EFFECT_SIZE="0.16840443038939024" MODIFIED="2014-11-16 21:50:03 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="1112" O_E="0.0" SE="0.4901281096915116" STUDY_ID="STD-Poewe-1998" TOTAL_1="19" TOTAL_2="20" VAR="0.24022556390977445" WEIGHT="100.0"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="5.6171647278571015" CI_END="1.442480898572569" CI_START="1.0559440457497693" DF="5" EFFECT_SIZE="1.2341714289171828" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="123" I2="10.98712175550786" ID="CMP-001.09.02" LOG_CI_END="0.1591100709096025" LOG_CI_START="0.0236409056353453" LOG_EFFECT_SIZE="0.09137548827247384" MODIFIED="2017-11-13 15:09:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.345269427583638" P_Z="0.008192397408830444" STUDIES="6" TAU2="0.004672141975864205" TOTAL_1="378" TOTAL_2="286" WEIGHT="100.0" Z="2.6440358692878627"><NAME>Medium 
dose</NAME><DICH_DATA CI_END="1.6491356267553643" CI_START="0.872965211861795" EFFECT_SIZE="1.1998491704374057" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="34" LOG_CI_END="0.2172563739764203" LOG_CI_START="-0.05900306282076594" LOG_EFFECT_SIZE="0.07912665557782718" MODIFIED="2014-12-26 17:52:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1110" O_E="0.0" SE="0.16227616068093423" STUDY_ID="STD-Comella-2011" TOTAL_1="78" TOTAL_2="74" VAR="0.026333552325344387" WEIGHT="20.422770303000355"/><DICH_DATA CI_END="5.973434311698179" CI_START="1.1214590448575343" EFFECT_SIZE="2.588235294117647" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7762240922318858" LOG_CI_START="0.049783417983941224" LOG_EFFECT_SIZE="0.41300375510791354" MODIFIED="2014-11-16 21:50:15 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="1113" O_E="0.0" SE="0.42671484799257475" STUDY_ID="STD-Poewe-1998" TOTAL_1="17" TOTAL_2="20" VAR="0.1820855614973262" WEIGHT="3.3906080500156235"/><DICH_DATA CI_END="2.4374740742844163" CI_START="0.9056995023231782" EFFECT_SIZE="1.4858058608058609" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="14" LOG_CI_END="0.38694000510694515" LOG_CI_START="-0.043015870899568265" LOG_EFFECT_SIZE="0.17196206710368842" MODIFIED="2016-10-22 09:09:55 +0100" MODIFIED_BY="[Empty name]" ORDER="772" O_E="0.0" SE="0.2525582098821373" STUDY_ID="STD-Poewe-2016" TOTAL_1="156" TOTAL_2="55" VAR="0.06378564937886971" WEIGHT="9.249818906914564"/><DICH_DATA CI_END="1.3929362526370597" CI_START="0.9696214658815017" EFFECT_SIZE="1.162162162162162" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="34" LOG_CI_END="0.1439312415054764" LOG_CI_START="-0.01339777848029338" LOG_EFFECT_SIZE="0.06526673151259149" MODIFIED="2014-12-26 17:51:06 +0000" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="0.09241584513085029" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.008540688431249305" WEIGHT="47.92479380176685"/><DICH_DATA CI_END="1.587708046535028" CI_START="0.7184272765685642" EFFECT_SIZE="1.068013468013468" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.2007706458015665" LOG_CI_START="-0.14361718714485872" LOG_EFFECT_SIZE="0.028576729328353867" MODIFIED="2014-12-26 17:51:06 +0000" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.2022951178199971" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" VAR="0.0409233146938065" WEIGHT="13.887834864473204"/><DICH_DATA CI_END="3.0889368540311075" CI_START="0.7994296652194277" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.4898090302742084" LOG_CI_START="-0.09721973998627205" LOG_EFFECT_SIZE="0.1962946451439682" MODIFIED="2014-12-26 17:51:06 +0000" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="0.3448236054902838" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" VAR="0.11890331890331887" WEIGHT="5.1241740738294075"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="5.382668636902823" CI_END="5.019709138434379" CI_START="0.717633422140276" DF="1" EFFECT_SIZE="1.8979755127934288" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="39" I2="81.4218547070845" ID="CMP-001.09.03" LOG_CI_END="0.7006785531544614" LOG_CI_START="-0.14409734321774453" LOG_EFFECT_SIZE="0.27829060496835833" MODIFIED="2017-11-13 15:09:15 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.02033781757296904" P_Z="0.19659146001072064" STUDIES="2" TAU2="0.40847088277350785" TOTAL_1="99" TOTAL_2="94" WEIGHT="100.0" Z="1.2913236878944443"><NAME>High 
dose</NAME><DICH_DATA CI_END="1.6880888677450319" CI_START="0.9050153077838026" EFFECT_SIZE="1.2360203340595497" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="34" LOG_CI_END="0.22739530588879336" LOG_CI_START="-0.04334407490550261" LOG_EFFECT_SIZE="0.09202561549164538" MODIFIED="2014-12-26 17:52:54 +0000" MODIFIED_BY="[Empty name]" ORDER="1111" O_E="0.0" SE="0.15903365246011855" STUDY_ID="STD-Comella-2011" TOTAL_1="81" TOTAL_2="74" VAR="0.025291702614805768" WEIGHT="56.768333197889305"/><DICH_DATA CI_END="7.320479715191451" CI_START="1.517811884384209" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8645395415548591" LOG_CI_START="0.18121794900581606" LOG_EFFECT_SIZE="0.5228787452803376" MODIFIED="2014-12-26 17:53:05 +0000" MODIFIED_BY="[Empty name]" ORDER="1114" O_E="0.0" SE="0.4013864859597432" STUDY_ID="STD-Poewe-1998" TOTAL_1="18" TOTAL_2="20" VAR="0.1611111111111111" WEIGHT="43.2316668021107"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="7.16252292884811" CI_END="1.3598403996704125" CI_START="1.0330983378044056" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1852632013940119" ESTIMABLE="YES" EVENTS_1="308" EVENTS_2="171" I2="16.230634657599186" I2_Q="6.989364319001569" ID="CMP-001.10" LOG_CI_END="0.13348793953944513" LOG_CI_START="0.01414166279081436" LOG_EFFECT_SIZE="0.07381480116512977" METHOD="MH" MODIFIED="2016-10-22 16:42:32 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.3060787264622087" P_Q="0.34124819173265253" P_Z="0.015331727785281954" Q="2.15029172239986" RANDOM="YES" SCALE="3.0174483629767144" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0056227578970270975" TOTALS="YES" TOTAL_1="584" TOTAL_2="368" WEIGHT="100.0" Z="2.4244468407565867"><NAME>Adverse events - BtA formulation subgroup analysis</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="1.2985234892808313" CI_START="0.7847598272284366" DF="0" EFFECT_SIZE="1.009469696969697" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="48" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.11344981008606227" LOG_CI_START="-0.10526323710054225" LOG_EFFECT_SIZE="0.004093286492760025" MODIFIED="2014-12-26 17:56:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9415174675935335" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="82" WEIGHT="22.210011642056877" Z="0.07336273905387099"><NAME>Botox</NAME><DICH_DATA CI_END="1.2985234892808313" CI_START="0.7847598272284366" EFFECT_SIZE="1.009469696969697" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="48" LOG_CI_END="0.11344981008606227" LOG_CI_START="-0.10526323710054225" LOG_EFFECT_SIZE="0.004093286492760025" MODIFIED="2014-12-26 17:56:22 +0000" MODIFIED_BY="[Empty name]" ORDER="631" O_E="0.0" SE="0.1284731265644558" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" VAR="0.016505344249246684" WEIGHT="22.210011642056877"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="6.413853638339463" CI_END="1.6617351895785086" CI_START="1.0216485452087152" DF="4" EFFECT_SIZE="1.3029617565205096" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="89" I2="37.63499721774764" ID="CMP-001.10.02" LOG_CI_END="0.2205618167598587" LOG_CI_START="0.009301520918794897" LOG_EFFECT_SIZE="0.11493166883932679" MODIFIED="2016-10-22 09:18:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.17029993310173164" P_Z="0.03296137911027426" STUDIES="5" TAU2="0.02792236322211995" TOTAL_1="337" TOTAL_2="212" WEIGHT="59.221460534694735" Z="2.1325534049013632"><NAME>Dysport</NAME><DICH_DATA CI_END="5.377175952747422" CI_START="1.1112354690424957" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="5" LOG_CI_END="0.7305542477579506" LOG_CI_START="0.045806095007812145" LOG_EFFECT_SIZE="0.3881801713828814" MODIFIED="2014-12-26 17:56:56 +0000" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.40222445448345356" STUDY_ID="STD-Poewe-1998" TOTAL_1="54" TOTAL_2="20" VAR="0.1617845117845118" WEIGHT="2.935747098798551"/><DICH_DATA CI_END="2.4374740742844163" CI_START="0.9056995023231782" EFFECT_SIZE="1.4858058608058609" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="14" LOG_CI_END="0.38694000510694515" LOG_CI_START="-0.043015870899568265" LOG_EFFECT_SIZE="0.17196206710368842" MODIFIED="2016-10-22 09:18:03 +0100" MODIFIED_BY="[Empty name]" ORDER="772" O_E="0.0" SE="0.2525582098821373" STUDY_ID="STD-Poewe-2016" TOTAL_1="156" TOTAL_2="55" VAR="0.06378564937886971" WEIGHT="7.0807763147741"/><DICH_DATA CI_END="1.3929362526370597" CI_START="0.9696214658815017" EFFECT_SIZE="1.162162162162162" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="34" LOG_CI_END="0.1439312415054764" LOG_CI_START="-0.01339777848029338" LOG_EFFECT_SIZE="0.06526673151259149" MODIFIED="2014-12-26 17:56:36 +0000" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="0.09241584513085029" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.008540688431249305" WEIGHT="34.69956357332224"/><DICH_DATA CI_END="1.587708046535028" CI_START="0.7184272765685642" EFFECT_SIZE="1.068013468013468" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.2007706458015665" LOG_CI_START="-0.14361718714485872" LOG_EFFECT_SIZE="0.028576729328353867" MODIFIED="2014-12-26 17:56:36 +0000" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.2022951178199971" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" VAR="0.0409233146938065" WEIGHT="10.558686886552694"/><DICH_DATA CI_END="3.0889368540311075" CI_START="0.7994296652194277" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.4898090302742084" LOG_CI_START="-0.09721973998627205" LOG_EFFECT_SIZE="0.1962946451439682" MODIFIED="2014-12-26 17:56:36 +0000" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="0.3448236054902838" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" VAR="0.11890331890331887" WEIGHT="3.946686661247157"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.0" CI_END="1.6167398409304412" CI_START="0.9180180690555235" DF="0" EFFECT_SIZE="1.2182759896411395" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="34" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="0.20864014066185577" LOG_CI_START="-0.037148770635491005" LOG_EFFECT_SIZE="0.08574568501318237" MODIFIED="2014-12-26 17:56:56 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.17146790741878834" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="74" WEIGHT="18.56852782324839" Z="1.3675023300969193"><NAME>Xeomin</NAME><DICH_DATA CI_END="1.6167398409304412" CI_START="0.9180180690555235" EFFECT_SIZE="1.2182759896411395" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="34" LOG_CI_END="0.20864014066185577" LOG_CI_START="-0.037148770635491005" LOG_EFFECT_SIZE="0.08574568501318237" MODIFIED="2014-12-26 17:53:39 +0000" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.14437762317079467" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" VAR="0.020844898072447986" WEIGHT="18.56852782324839"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="7.16252292884811" CI_END="1.3598403996704125" CI_START="1.0330983378044056" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1852632013940119" ESTIMABLE="YES" EVENTS_1="308" EVENTS_2="171" I2="16.230634657599186" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.13348793953944513" LOG_CI_START="0.01414166279081436" LOG_EFFECT_SIZE="0.07381480116512977" METHOD="MH" MODIFIED="2016-10-22 16:57:24 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.3060787264622087" P_Q="0.516138676870892" P_Z="0.015331727785281954" Q="0.42160219898332474" RANDOM="YES" SCALE="2.47" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0056227578970270975" TOTALS="YES" TOTAL_1="584" TOTAL_2="368" WEIGHT="100.00000000000001" Z="2.4244468407565867"><NAME>Adverse events - EMG-guided vs non-EMG-guided subgroup analysis</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="1.29619466303496" CI_END="1.3591375624054605" CI_START="1.0337432391867343" DF="3" EFFECT_SIZE="1.1853266496039745" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="109" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.13326341520942067" LOG_CI_START="0.014412682228321613" LOG_EFFECT_SIZE="0.0738380487188712" MODIFIED="2016-10-22 16:57:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7300370069191708" P_Z="0.01487853335195756" STUDIES="4" TAU2="0.0" TOTAL_1="407" TOTAL_2="233" WEIGHT="70.90755459789743" Z="2.435322232311623"><NAME>EMG-guided injection</NAME><DICH_DATA CI_END="1.6167398409304412" CI_START="0.9180180690555235" EFFECT_SIZE="1.2182759896411395" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="34" LOG_CI_END="0.20864014066185577" LOG_CI_START="-0.037148770635491005" LOG_EFFECT_SIZE="0.08574568501318237" MODIFIED="2014-12-26 17:58:33 +0000" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.14437762317079467" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" VAR="0.020844898072447986" WEIGHT="18.56852782324839"/><DICH_DATA CI_END="2.4374740742844163" CI_START="0.9056995023231782" EFFECT_SIZE="1.4858058608058609" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="14" LOG_CI_END="0.38694000510694515" LOG_CI_START="-0.043015870899568265" LOG_EFFECT_SIZE="0.17196206710368842" MODIFIED="2016-10-22 11:05:18 +0100" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="0.2525582098821373" STUDY_ID="STD-Poewe-2016" TOTAL_1="156" TOTAL_2="55" VAR="0.06378564937886971" WEIGHT="7.080776314774101"/><DICH_DATA CI_END="1.3929362526370597" CI_START="0.9696214658815017" EFFECT_SIZE="1.162162162162162" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="34" LOG_CI_END="0.1439312415054764" LOG_CI_START="-0.01339777848029338" LOG_EFFECT_SIZE="0.06526673151259149" MODIFIED="2014-12-26 17:58:33 +0000" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="0.09241584513085029" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.008540688431249305" WEIGHT="34.699563573322244"/><DICH_DATA CI_END="1.587708046535028" CI_START="0.7184272765685642" EFFECT_SIZE="1.068013468013468" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.2007706458015665" LOG_CI_START="-0.14361718714485872" LOG_EFFECT_SIZE="0.028576729328353867" MODIFIED="2014-12-26 17:58:33 +0000" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.2022951178199971" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" VAR="0.0409233146938065" WEIGHT="10.558686886552694"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="5.945698916043918" CI_END="2.497264942178222" CI_START="0.8219899793680461" DF="2" EFFECT_SIZE="1.4327340151952912" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="62" I2="66.36223885129493" ID="CMP-001.11.02" LOG_CI_END="0.3974646203738257" LOG_CI_START="-0.0851334767807392" LOG_EFFECT_SIZE="0.1561655717965432" MODIFIED="2016-10-22 16:51:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.05115744180891291" P_Z="0.20463270871523587" STUDIES="3" TAU2="0.15845268900675702" TOTAL_1="177" TOTAL_2="135" WEIGHT="29.092445402102584" Z="1.2684629224648551"><NAME>Non-EMG-guided injection</NAME><DICH_DATA CI_END="1.2985234892808313" CI_START="0.7847598272284366" EFFECT_SIZE="1.009469696969697" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="48" LOG_CI_END="0.11344981008606227" LOG_CI_START="-0.10526323710054225" LOG_EFFECT_SIZE="0.004093286492760025" MODIFIED="2014-12-26 17:53:43 +0000" MODIFIED_BY="[Empty name]" ORDER="631" O_E="0.0" SE="0.1284731265644558" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" VAR="0.016505344249246684" WEIGHT="22.210011642056877"/><DICH_DATA CI_END="5.377175952747422" CI_START="1.1112354690424957" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="5" LOG_CI_END="0.7305542477579506" LOG_CI_START="0.045806095007812145" LOG_EFFECT_SIZE="0.3881801713828814" MODIFIED="2014-12-26 17:53:43 +0000" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.40222445448345356" STUDY_ID="STD-Poewe-1998" TOTAL_1="54" TOTAL_2="20" VAR="0.1617845117845118" WEIGHT="2.9357470987985512"/><DICH_DATA CI_END="3.0889368540311075" CI_START="0.7994296652194277" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.4898090302742084" LOG_CI_START="-0.09721973998627205" LOG_EFFECT_SIZE="0.1962946451439682" MODIFIED="2014-12-26 17:53:43 +0000" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="0.3448236054902838" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" VAR="0.11890331890331887" WEIGHT="3.9466866612471576"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="4.008356673943554" CI_END="5.496018353337819" CI_START="1.6815382778146826" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="3.040027176968911" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.7400481743317033" LOG_CI_START="0.22570675785611707" LOG_EFFECT_SIZE="0.48287746609391025" METHOD="MH" MODIFIED="2016-10-22 13:12:08 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.7788144601081888" P_Q="1.0" P_Z="2.3311222223690843E-4" Q="0.0" RANDOM="YES" SCALE="564.8720620492264" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="612" TOTAL_2="395" WEIGHT="99.99999999999999" Z="3.680133126261467"><NAME>Dysphagia</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_DATA CI_END="124.97947216785441" CI_START="0.36549165102318226" EFFECT_SIZE="6.758620689655173" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0968386861573434" LOG_CI_START="-0.4371225392423035" LOG_EFFECT_SIZE="0.8298580734575199" MODIFIED="2014-12-26 18:37:24 +0000" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="1.4884613671101143" STUDY_ID="STD-Greene-1990" TOTAL_1="28" TOTAL_2="27" VAR="2.2155172413793105" WEIGHT="4.120055468949261"/><DICH_DATA CI_END="11.74851973292894" CI_START="0.7472558006847378" EFFECT_SIZE="2.962962962962963" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.0699831506657416" LOG_CI_START="-0.12653070499982919" LOG_EFFECT_SIZE="0.47172622283295623" MODIFIED="2014-10-13 17:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.7028381616570643" STUDY_ID="STD-Poewe-1998" TOTAL_1="54" TOTAL_2="20" VAR="0.4939814814814815" WEIGHT="18.478534659883604"/><DICH_DATA CI_END="25.852648054715573" CI_START="0.30947763299130393" EFFECT_SIZE="2.8285714285714287" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.412505033954154" LOG_CI_START="-0.5093707334596054" LOG_EFFECT_SIZE="0.4515671502472743" MODIFIED="2014-10-13 17:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="1.1289193392173218" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" VAR="1.2744588744588745" WEIGHT="7.1622977483458685"/><DICH_DATA CI_END="5.709358137169165" CI_START="0.5322659626708894" EFFECT_SIZE="1.7432432432432432" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7565872863273977" LOG_CI_START="-0.2738713051908521" LOG_EFFECT_SIZE="0.24135799056827276" MODIFIED="2014-10-19 12:09:52 +0100" MODIFIED_BY="Ana Raquel Marques" ORDER="338" O_E="0.0" SE="0.6052964775101134" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.36638382568615124" WEIGHT="24.913910732280545"/><DICH_DATA CI_END="215.3145490514283" CI_START="0.6888415236881666" EFFECT_SIZE="12.178571428571429" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3330733765920466" LOG_CI_START="-0.1618806812914894" LOG_EFFECT_SIZE="1.0855963476502786" MODIFIED="2014-11-03 23:47:54 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="344" O_E="0.0" SE="1.4655483638225573" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" VAR="2.1478320067029744" WEIGHT="4.249891936803852"/><DICH_DATA CI_END="23.01044749268027" CI_START="1.355522149025442" EFFECT_SIZE="5.584905660377358" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="2" LOG_CI_END="1.3619250646361352" LOG_CI_START="0.13210661828016387" LOG_EFFECT_SIZE="0.7470158414581495" MODIFIED="2014-10-15 23:42:09 +0100" MODIFIED_BY="Ana Raquel Marques" ORDER="331" O_E="0.0" SE="0.7224014430889881" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" VAR="0.5218638449770525" WEIGHT="17.491255649828716"/><DICH_DATA CI_END="7.209425946558435" CI_START="0.4817499370425938" EFFECT_SIZE="1.8636363636363635" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8579006852232626" LOG_CI_START="-0.3171783334282041" LOG_EFFECT_SIZE="0.2703611758975292" MODIFIED="2014-11-30 23:24:45 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="331" O_E="0.0" SE="0.690247232290825" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" VAR="0.4764412416851441" WEIGHT="19.158824065294656"/><DICH_DATA CI_END="136.93974113607436" CI_START="0.4914766831449843" EFFECT_SIZE="8.203821656050955" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.1365295025638638" LOG_CI_START="-0.30849708133474485" LOG_EFFECT_SIZE="0.9140162106145595" MODIFIED="2016-10-22 12:59:34 +0100" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="1.436220718458829" STUDY_ID="STD-Poewe-2016" TOTAL_1="156" TOTAL_2="55" VAR="2.062729952130395" WEIGHT="4.425229738613491"/></DICH_OUTCOME><DICH_OUTCOME CHI2="4.9952214500140455" CI_END="2.938552511561349" CI_START="1.0801383123405717" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7815844494612159" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.4681334559071687" LOG_CI_START="0.03347937070939016" LOG_EFFECT_SIZE="0.25080641330827946" METHOD="MH" MODIFIED="2016-10-22 13:12:13 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.4164638169446304" P_Q="1.0" P_Z="0.02370372469386668" Q="0.0" RANDOM="YES" SCALE="33.31" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="522" TOTAL_2="301" WEIGHT="99.99999999999999" Z="2.261897697118008"><NAME>Diffuse weakness/tiredness</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_DATA CI_END="67.72263949570383" CI_START="0.11558056269648315" EFFECT_SIZE="2.797752808988764" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.830733876431581" LOG_CI_START="-0.9371151955299338" LOG_EFFECT_SIZE="0.44680934045082354" MODIFIED="2014-12-26 19:04:57 +0000" MODIFIED_BY="[Empty name]" ORDER="371" O_E="0.0" SE="1.625848245944068" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" VAR="2.6433825188394025" WEIGHT="2.466054793648683"/><DICH_DATA CI_END="55.09829174408515" CI_START="1.0064009124376756" EFFECT_SIZE="7.446540880503145" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="1" LOG_CI_END="1.7411381342852148" LOG_CI_START="0.0027710218476841263" LOG_EFFECT_SIZE="0.8719545780664495" MODIFIED="2014-12-26 19:00:58 +0000" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="1.0211254469017927" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" VAR="1.0426971783103858" WEIGHT="6.251792243836465"/><DICH_DATA CI_END="32.346603578074834" CI_START="0.4599416746954066" EFFECT_SIZE="3.857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5098286860947272" LOG_CI_START="-0.3372972378052661" LOG_EFFECT_SIZE="0.5862657241447304" MODIFIED="2014-12-26 18:42:05 +0000" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="1.0850109111196427" STUDY_ID="STD-Greene-1990" TOTAL_1="28" TOTAL_2="27" VAR="1.1772486772486772" WEIGHT="5.53725500653423"/><DICH_DATA CI_END="22.214480172999473" CI_START="0.39519941279386106" EFFECT_SIZE="2.962962962962963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.3466361550453" LOG_CI_START="-0.4031837093793876" LOG_EFFECT_SIZE="0.47172622283295623" MODIFIED="2014-10-13 17:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="376" O_E="0.0" SE="1.0278528501110853" STUDY_ID="STD-Poewe-1998" TOTAL_1="54" TOTAL_2="20" VAR="1.0564814814814814" WEIGHT="6.170222806830431"/><DICH_DATA CI_END="5.541088670832125" CI_START="0.0224326759236221" EFFECT_SIZE="0.3525641025641026" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.7435950999785242" LOG_CI_START="-1.6491189176989598" LOG_EFFECT_SIZE="-0.4527619088602177" MODIFIED="2016-10-22 13:00:39 +0100" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="1.4054920581091612" STUDY_ID="STD-Poewe-2016" TOTAL_1="156" TOTAL_2="55" VAR="1.9754079254079255" WEIGHT="3.2999392420099296"/><DICH_DATA CI_END="2.6953436602430454" CI_START="0.8569006158100481" EFFECT_SIZE="1.5197505197505197" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.43061414623222677" LOG_CI_START="-0.06706954506416946" LOG_EFFECT_SIZE="0.18177230058402866" MODIFIED="2014-12-26 18:50:41 +0000" MODIFIED_BY="[Empty name]" ORDER="377" O_E="0.0" SE="0.29234186384150707" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.08546376535432625" WEIGHT="76.27473590714025"/></DICH_OUTCOME><DICH_OUTCOME CHI2="3.8933778072174112" CI_END="10.912227773389525" CI_START="0.9544447667461108" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="3.227246301702613" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="5" I2="22.946085672993203" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="1.0379134225336089" LOG_CI_START="-0.020249198953332385" LOG_EFFECT_SIZE="0.5088321117901382" METHOD="MH" MODIFIED="2016-10-22 13:17:32 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.2732100137740401" P_Q="1.0" P_Z="0.05943638535972474" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.39830005863815365" TOTALS="YES" TOTAL_1="154" TOTAL_2="123" WEIGHT="100.00000000000001" Z="1.884951505629113"><NAME>Neck weakness</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_DATA CI_END="124.97947216785441" CI_START="0.36549165102318226" EFFECT_SIZE="6.758620689655173" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0968386861573434" LOG_CI_START="-0.4371225392423035" LOG_EFFECT_SIZE="0.8298580734575199" MODIFIED="2014-12-26 18:37:59 +0000" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="1.4884613671101143" STUDY_ID="STD-Greene-1990" TOTAL_1="28" TOTAL_2="27" VAR="2.2155172413793105" WEIGHT="14.781033757513448"/><DICH_DATA CI_END="177.41379263454849" CI_START="0.6910696594415902" EFFECT_SIZE="11.072727272727272" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.248987380051667" LOG_CI_START="-0.16047817377440432" LOG_EFFECT_SIZE="1.0442546031386315" MODIFIED="2014-10-13 17:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="1.4153319933642827" STUDY_ID="STD-Poewe-1998" TOTAL_1="54" TOTAL_2="20" VAR="2.003164651440514" WEIGHT="16.088065581553014"/><DICH_DATA CI_END="4.199831615906619" CI_START="0.46308858572002937" EFFECT_SIZE="1.3945945945945946" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6232318785530089" LOG_CI_START="-0.33433592343257623" LOG_EFFECT_SIZE="0.14444797756021635" MODIFIED="2014-10-19 12:10:33 +0100" MODIFIED_BY="Ana Raquel Marques" ORDER="347" O_E="0.0" SE="0.5624800669233989" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.3163838256861513" WEIGHT="54.05875603877374"/><DICH_DATA CI_END="152.0131414434293" CI_START="0.47528785547062297" EFFECT_SIZE="8.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1818811340609834" LOG_CI_START="-0.32304328263239807" LOG_EFFECT_SIZE="0.9294189257142927" MODIFIED="2014-10-13 17:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="1.4714050019415328" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" VAR="2.1650326797385624" WEIGHT="15.072144622159808"/></DICH_OUTCOME><DICH_OUTCOME CHI2="1.3528241498312576" CI_END="8.945388660681456" CI_START="0.3735180005415" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8279123848271128" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="26.080562641882654" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.9515992146096365" LOG_CI_START="-0.4276884638687411" LOG_EFFECT_SIZE="0.26195537537044766" METHOD="MH" MODIFIED="2016-10-22 13:17:42 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.24478516661036875" P_Q="1.0" P_Z="0.4565887240906351" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.44130598146665084" TOTALS="YES" TOTAL_1="91" TOTAL_2="63" WEIGHT="100.0" Z="0.7444757309064831"><NAME>Voice change/hoarseness</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_DATA CI_END="107.54477790201798" CI_START="0.39176147506512937" EFFECT_SIZE="6.490909090909091" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.0315893270117282" LOG_CI_START="-0.40697827377582946" LOG_EFFECT_SIZE="0.8123055266179494" MODIFIED="2014-10-13 17:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="393" O_E="0.0" SE="1.4324266798069156" STUDY_ID="STD-Poewe-1998" TOTAL_1="54" TOTAL_2="20" VAR="2.051846193022664" WEIGHT="26.32910702182695"/><DICH_DATA CI_END="4.326040782597279" CI_START="0.3122071563898994" EFFECT_SIZE="1.162162162162162" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6360906093179293" LOG_CI_START="-0.5055571462927463" LOG_EFFECT_SIZE="0.06526673151259149" MODIFIED="2014-10-19 12:16:49 +0100" MODIFIED_BY="Ana Raquel Marques" ORDER="394" O_E="0.0" SE="0.6706095428932433" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.4497171590194846" WEIGHT="73.67089297817306"/></DICH_OUTCOME><DICH_OUTCOME CHI2="2.110170247652881" CI_END="3.5101794480634583" CI_START="0.7830170488324147" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6578692205040915" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="11" I2="5.220917495895041" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.5453293191187168" LOG_CI_START="-0.10622878183320207" LOG_EFFECT_SIZE="0.21955026864275742" METHOD="MH" MODIFIED="2016-10-22 13:17:42 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.3481629703517666" P_Q="1.0" P_Z="0.1865458967118507" Q="0.0" RANDOM="YES" SCALE="14.64" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02907156559164449" TOTALS="YES" TOTAL_1="126" TOTAL_2="96" WEIGHT="100.0" Z="1.3208664544488642"><NAME>Sore throat/dry mouth</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_DATA CI_END="34.46280586379055" CI_START="0.6726800421470496" EFFECT_SIZE="4.814814814814815" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="1.5373506335749685" LOG_CI_START="-0.17219145727926966" LOG_EFFECT_SIZE="0.6825795881478495" MODIFIED="2014-10-13 17:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="389" O_E="0.0" SE="1.0041934865376085" STUDY_ID="STD-Poewe-1998" TOTAL_1="54" TOTAL_2="20" VAR="1.0084045584045582" WEIGHT="14.11898220425407"/><DICH_DATA CI_END="2.7903993815729535" CI_START="0.484024222511146" EFFECT_SIZE="1.162162162162162" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.4456663670012248" LOG_CI_START="-0.3151329039760418" LOG_EFFECT_SIZE="0.06526673151259149" MODIFIED="2014-10-19 12:16:17 +0100" MODIFIED_BY="Ana Raquel Marques" ORDER="390" O_E="0.0" SE="0.44689725778917533" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.1997171590194846" WEIGHT="64.0246015486042"/><DICH_DATA CI_END="11.32258695620298" CI_START="0.49071139576770645" EFFECT_SIZE="2.357142857142857" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0539456647009084" LOG_CI_START="-0.3091738563016096" LOG_EFFECT_SIZE="0.37238590419964945" MODIFIED="2014-10-13 17:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="392" O_E="0.0" SE="0.8007031541873312" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" VAR="0.6411255411255411" WEIGHT="21.85641624714173"/></DICH_OUTCOME><DICH_OUTCOME CHI2="0.0990620742534428" CI_END="5.734853240214581" CI_START="0.3754988171268369" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4674571912313432" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.7585223084133096" LOG_CI_START="-0.4253914267452899" LOG_EFFECT_SIZE="0.16656544083400984" METHOD="MH" MODIFIED="2016-10-22 13:42:46 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.7529581224886066" P_Q="1.0" P_Z="0.58129322366263" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="91" TOTAL_2="63" WEIGHT="100.0" Z="0.551496710290236"><NAME>Vertigo/dizziness</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_DATA CI_END="10.07053805653701" CI_START="0.12259204963067315" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.003052674996754" LOG_CI_START="-0.9115376938754038" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2014-11-15 22:19:36 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="363" O_E="0.0" SE="1.1246398600506806" STUDY_ID="STD-Poewe-1998" TOTAL_1="54" TOTAL_2="20" VAR="1.2648148148148146" WEIGHT="38.23740211878689"/><DICH_DATA CI_END="9.87614437506069" CI_START="0.3077007473470178" EFFECT_SIZE="1.7432432432432432" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9945874300685094" LOG_CI_START="-0.5118714489319639" LOG_EFFECT_SIZE="0.24135799056827276" MODIFIED="2014-10-19 12:12:23 +0100" MODIFIED_BY="Ana Raquel Marques" ORDER="341" O_E="0.0" SE="0.8849014026165954" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.7830504923528179" WEIGHT="61.76259788121311"/></DICH_OUTCOME><DICH_OUTCOME CHI2="10.967592783655244" CI_END="2.6350486650234055" CI_START="0.6286926494530171" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.287103619236307" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="32" I2="45.29337368413546" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.42078864032881647" LOG_CI_START="-0.2015616173031535" LOG_EFFECT_SIZE="0.10961351151283148" METHOD="MH" MODIFIED="2016-10-22 13:18:23 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.08938328320222155" P_Q="1.0" P_Z="0.4899361640860739" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3606383020615656" TOTALS="YES" TOTAL_1="584" TOTAL_2="368" WEIGHT="100.00000000000003" Z="0.6904103666689962"><NAME>Malaise/upper respiratory infection</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_DATA CI_END="1.8148090582748244" CI_START="0.5906720259530096" EFFECT_SIZE="1.0353535353535352" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.25883093829783294" LOG_CI_START="-0.2286535967093867" LOG_EFFECT_SIZE="0.015088670794223144" MODIFIED="2014-12-26 19:06:53 +0000" MODIFIED_BY="[Empty name]" ORDER="366" O_E="0.0" SE="0.2863508289506068" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" VAR="0.08199679724069968" WEIGHT="30.192501912844907"/><DICH_DATA CI_END="1.1375375763149425" CI_START="0.06854976021178785" EFFECT_SIZE="0.2792452830188679" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.055965751629537444" LOG_CI_START="-1.1639940600412009" LOG_EFFECT_SIZE="-0.5540141542058317" MODIFIED="2014-12-26 19:01:38 +0000" MODIFIED_BY="[Empty name]" ORDER="329" O_E="0.0" SE="0.7166104322738536" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" VAR="0.5135305116437192" WEIGHT="15.28796368944996"/><DICH_DATA CI_END="27.022629910890238" CI_START="0.04855434574758807" EFFECT_SIZE="1.1454545454545455" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.4317276133835313" LOG_CI_START="-1.3137718934648555" LOG_EFFECT_SIZE="0.05897785995933788" MODIFIED="2014-10-13 17:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="368" O_E="0.0" SE="1.612720000764485" STUDY_ID="STD-Poewe-1998" TOTAL_1="54" TOTAL_2="20" VAR="2.600865800865801" WEIGHT="4.512659992321379"/><DICH_DATA CI_END="12.347027032992097" CI_START="0.16107708660190226" EFFECT_SIZE="1.4102564102564104" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.0915623990048124" LOG_CI_START="-0.7929662340693232" LOG_EFFECT_SIZE="0.14929808246774467" MODIFIED="2016-10-22 13:02:35 +0100" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="1.1069814476349302" STUDY_ID="STD-Poewe-2016" TOTAL_1="156" TOTAL_2="55" VAR="1.2254079254079255" WEIGHT="8.426148526388404"/><DICH_DATA CI_END="9.173604472930958" CI_START="1.5076252705578306" EFFECT_SIZE="3.718918918918919" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.9625400112563315" LOG_CI_START="0.17829340840866348" LOG_EFFECT_SIZE="0.5704167098324975" MODIFIED="2014-12-26 18:51:36 +0000" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.46067033659601375" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.21221715901948462" WEIGHT="23.329202548153948"/><DICH_DATA CI_END="7.6089369859835605" CI_START="0.1616628770738984" EFFECT_SIZE="1.1090909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8813239874711728" LOG_CI_START="-0.7913896964381264" LOG_EFFECT_SIZE="0.0449671455165232" MODIFIED="2014-11-03 23:49:20 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="346" O_E="0.0" SE="0.9825602979945969" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" VAR="0.965424739195231" WEIGHT="10.07814912759333"/><DICH_DATA CI_END="25.852648054715573" CI_START="0.30947763299130393" EFFECT_SIZE="2.8285714285714287" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.412505033954154" LOG_CI_START="-0.5093707334596054" LOG_EFFECT_SIZE="0.4515671502472743" MODIFIED="2014-10-13 17:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="370" O_E="0.0" SE="1.1289193392173218" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" VAR="1.2744588744588745" WEIGHT="8.173374203248084"/></DICH_OUTCOME><DICH_OUTCOME CHI2="1.3237705910311433" CI_END="2.0225682847634756" CI_START="0.8757826598011081" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3309133074920854" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.30590319292725715" LOG_CI_START="-0.05760365794184546" LOG_EFFECT_SIZE="0.1241497674927059" METHOD="MH" MODIFIED="2016-10-22 13:18:23 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.970330804100753" P_Q="1.0" P_Z="0.18064011402112987" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="524" TOTAL_2="313" WEIGHT="100.0" Z="1.3387867237877555"><NAME>Local pain (injection site)</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_DATA CI_END="3.5883824659385404" CI_START="0.37726844521321456" EFFECT_SIZE="1.1635220125786163" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.5548987258977834" LOG_CI_START="-0.4233495177326587" LOG_EFFECT_SIZE="0.0657746040825623" MODIFIED="2014-10-15 23:43:46 +0100" MODIFIED_BY="Ana Raquel Marques" ORDER="332" O_E="0.0" SE="0.574627860715425" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" VAR="0.33019717831038586" WEIGHT="13.807881359637292"/><DICH_DATA CI_END="2.2007430730840025" CI_START="0.422514990572013" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.3425693435733556" LOG_CI_START="-0.3741578779398194" LOG_EFFECT_SIZE="-0.015794267183231903" MODIFIED="2014-12-26 18:38:46 +0000" MODIFIED_BY="[Empty name]" ORDER="327" O_E="0.0" SE="0.4210091177738046" STUDY_ID="STD-Greene-1990" TOTAL_1="28" TOTAL_2="27" VAR="0.17724867724867727" WEIGHT="25.72275028602975"/><DICH_DATA CI_END="7.060758156888239" CI_START="0.3934106955735159" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.8488513364165111" LOG_CI_START="-0.4051538371837983" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2014-10-13 17:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="357" O_E="0.0" SE="0.7366088463985432" STUDY_ID="STD-Poewe-1998" TOTAL_1="54" TOTAL_2="20" VAR="0.5425925925925926" WEIGHT="8.40284870387125"/><DICH_DATA CI_END="14.758721280999406" CI_START="0.21055592156357492" EFFECT_SIZE="1.7628205128205128" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.1690487311548436" LOG_CI_START="-0.6766325402032417" LOG_EFFECT_SIZE="0.24620809547580105" MODIFIED="2016-10-22 13:01:04 +0100" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="1.0841623150653805" STUDY_ID="STD-Poewe-2016" TOTAL_1="156" TOTAL_2="55" VAR="1.1754079254079255" WEIGHT="3.8789286381700157"/><DICH_DATA CI_END="3.2185772393842513" CI_START="0.8224804781080375" EFFECT_SIZE="1.627027027027027" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.507663935784659" LOG_CI_START="-0.08487440140299977" LOG_EFFECT_SIZE="0.21139476719082956" MODIFIED="2014-10-19 12:11:36 +0100" MODIFIED_BY="Ana Raquel Marques" ORDER="358" O_E="0.0" SE="0.3480599523761044" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.12114573044805603" WEIGHT="37.635032175993366"/><DICH_DATA CI_END="9.589700115982193" CI_START="0.2886102711179256" EFFECT_SIZE="1.6636363636363636" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9818050263562226" LOG_CI_START="-0.5396882172118137" LOG_EFFECT_SIZE="0.2210584045722044" MODIFIED="2014-11-03 23:48:44 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="345" O_E="0.0" SE="0.8937326627848868" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" VAR="0.7987580725285642" WEIGHT="5.7080155058260935"/><DICH_DATA CI_END="6.3126301577105135" CI_START="0.14082554650392395" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8002103457711055" LOG_CI_START="-0.8513185547158818" LOG_EFFECT_SIZE="-0.025554104472388168" MODIFIED="2014-10-13 17:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="360" O_E="0.0" SE="0.9701162513459617" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" VAR="0.9411255411255411" WEIGHT="4.844543330472229"/></DICH_OUTCOME><DICH_OUTCOME CHI2="1.8784010393567094" CI_END="1.8643498868455026" CI_START="0.5946583746652658" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0529251034707638" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.2705274207146515" LOG_CI_START="-0.2257324605016879" LOG_EFFECT_SIZE="0.022397480106481786" METHOD="MH" MODIFIED="2016-10-22 13:18:11 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.865701762823758" P_Q="1.0" P_Z="0.8595740612187794" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="418" TOTAL_2="288" WEIGHT="100.0" Z="0.17691639406982299"><NAME>Headache</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_DATA CI_END="2.4476243160370785" CI_START="0.2463514423279101" EFFECT_SIZE="0.7765151515151515" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3887447590646785" LOG_CI_START="-0.608444890692832" LOG_EFFECT_SIZE="-0.10985006581407677" MODIFIED="2014-11-30 23:27:03 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="379" O_E="0.0" SE="0.5857541364359374" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" VAR="0.3431079083518108" WEIGHT="24.766395856999534"/><DICH_DATA CI_END="124.97947216785441" CI_START="0.36549165102318226" EFFECT_SIZE="6.758620689655173" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0968386861573434" LOG_CI_START="-0.4371225392423035" LOG_EFFECT_SIZE="0.8298580734575199" MODIFIED="2014-12-26 18:42:23 +0000" MODIFIED_BY="[Empty name]" ORDER="381" O_E="0.0" SE="1.4884613671101143" STUDY_ID="STD-Greene-1990" TOTAL_1="28" TOTAL_2="27" VAR="2.2155172413793105" WEIGHT="3.8354683598028605"/><DICH_DATA CI_END="27.022629910890238" CI_START="0.04855434574758807" EFFECT_SIZE="1.1454545454545455" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.4317276133835313" LOG_CI_START="-1.3137718934648555" LOG_EFFECT_SIZE="0.05897785995933788" MODIFIED="2014-10-13 17:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="382" O_E="0.0" SE="1.612720000764485" STUDY_ID="STD-Poewe-1998" TOTAL_1="54" TOTAL_2="20" VAR="2.600865800865801" WEIGHT="3.2671990523614554"/><DICH_DATA CI_END="9.957168756025343" CI_START="0.11235252160153628" EFFECT_SIZE="1.0576923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.9981358676976674" LOG_CI_START="-0.949417175978778" LOG_EFFECT_SIZE="0.024359345859444693" MODIFIED="2016-10-22 13:01:43 +0100" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="1.144002298398591" STUDY_ID="STD-Poewe-2016" TOTAL_1="156" TOTAL_2="55" VAR="1.3087412587412588" WEIGHT="6.492915404899027"/><DICH_DATA CI_END="2.2954614396930118" CI_START="0.4765939008703489" EFFECT_SIZE="1.045945945945946" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.36087000166784095" LOG_CI_START="-0.32185151976400816" LOG_EFFECT_SIZE="0.019509240951916394" MODIFIED="2014-10-19 12:15:18 +0100" MODIFIED_BY="Ana Raquel Marques" ORDER="383" O_E="0.0" SE="0.4010340012151036" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.1608282701305957" WEIGHT="52.836147979505654"/><DICH_DATA CI_END="7.6089369859835605" CI_START="0.1616628770738984" EFFECT_SIZE="1.1090909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8813239874711728" LOG_CI_START="-0.7913896964381264" LOG_EFFECT_SIZE="0.0449671455165232" MODIFIED="2014-11-03 23:50:19 +0000" MODIFIED_BY="Ana Raquel Marques" ORDER="348" O_E="0.0" SE="0.9825602979945969" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" VAR="0.965424739195231" WEIGHT="8.801873346431476"/></DICH_OUTCOME><DICH_OUTCOME CHI2="4.164215152523357" CI_END="2.4938741605498014" CI_START="1.4650091260391505" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9114257517357782" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="69" I2="27.957612896583566" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="0.3968745354465967" LOG_CI_START="0.16584033006630575" LOG_EFFECT_SIZE="0.2813574327564512" METHOD="MH" MODIFIED="2016-10-22 10:53:28 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.24426926207236666" P_Q="1.0" P_Z="1.8082165176677942E-6" Q="0.0" RANDOM="YES" SCALE="12.84" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.020663104667058788" TOTALS="YES" TOTAL_1="335" TOTAL_2="209" WEIGHT="100.0" Z="4.773755765537716"><NAME>Any improvement by subjective clinician assessment</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_DATA CI_END="2.1844840473828224" CI_START="1.1858651724985532" EFFECT_SIZE="1.609504132231405" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="33" LOG_CI_END="0.33934887753773235" LOG_CI_START="0.07403531451857169" LOG_EFFECT_SIZE="0.206692096028152" MODIFIED="2014-12-26 13:11:53 +0000" MODIFIED_BY="[Empty name]" ORDER="529" O_E="0.0" SE="0.1558465002407729" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" VAR="0.02428813163729723" WEIGHT="40.97190245391631"><FOOTNOTE>Global Assessment Scale, week 4</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="2.6561940300063993" CI_START="1.2461230672433699" EFFECT_SIZE="1.819325328759291" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="22" LOG_CI_END="0.4242597962544457" LOG_CI_START="0.09556093540932664" LOG_EFFECT_SIZE="0.2599103658318862" MODIFIED="2014-12-26 13:29:17 +0000" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.19307933794602544" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" VAR="0.0372796307416755" WEIGHT="31.78548019960053"><FOOTNOTE>final visit (between 8-20 weeks)</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="19.476214252081135" CI_START="1.3325123586603647" EFFECT_SIZE="5.09433962264151" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="2" LOG_CI_END="1.2895045434454717" LOG_CI_START="0.12467124567092504" LOG_EFFECT_SIZE="0.7070878945581983" MODIFIED="2014-12-26 12:40:41 +0000" MODIFIED_BY="[Empty name]" ORDER="365" O_E="0.0" SE="0.6842288451305858" STUDY_ID="STD-Poewe-1998" TOTAL_1="53" TOTAL_2="20" VAR="0.4681691125087351" WEIGHT="3.767627427843387"><FOOTNOTE>Clinical Global Rating assessing efficacy and adverse events together, week 8</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="3.775850927499504" CI_START="1.4714888261383359" EFFECT_SIZE="2.357142857142857" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="12" LOG_CI_END="0.5770148397991344" LOG_CI_START="0.16775696860016454" LOG_EFFECT_SIZE="0.37238590419964945" MODIFIED="2014-12-26 12:51:24 +0000" MODIFIED_BY="[Empty name]" ORDER="531" O_E="0.0" SE="0.24040009940140997" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" VAR="0.0577922077922078" WEIGHT="23.47498991863977"><FOOTNOTE>week 4</FOOTNOTE></DICH_DATA></DICH_OUTCOME><DICH_OUTCOME CHI2="3.2535469432255177" CI_END="2.895821791618138" CI_START="1.8268312101514752" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3000386144508043" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.4617718319386943" LOG_CI_START="0.26169842262008486" LOG_EFFECT_SIZE="0.36173512727938956" METHOD="MH" MODIFIED="2017-11-14 15:21:33 +0000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.5163260238553239" P_Q="1.0" P_Z="1.3677659143553047E-12" Q="0.0" RANDOM="YES" SCALE="10.21" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="372" TOTAL_2="252" WEIGHT="99.99999999999999" Z="7.087276853283179"><NAME>Any improvement by subjective participant assessment</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_DATA CI_END="2.9426295027097975" CI_START="1.3392549603982693" EFFECT_SIZE="1.9851778656126482" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="23" LOG_CI_END="0.46873558487983913" LOG_CI_START="0.12686326360909847" LOG_EFFECT_SIZE="0.2977994242444688" MODIFIED="2014-12-26 13:53:01 +0000" MODIFIED_BY="[Empty name]" ORDER="630" O_E="0.0" SE="0.20081749380971634" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" VAR="0.04032766582001546" WEIGHT="34.24923408922989"><FOOTNOTE>Subjective Global Assessment Scale, week 4</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="5.14123883712675" CI_START="2.0252823212121203" EFFECT_SIZE="3.2268343815513627" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="15" LOG_CI_END="0.7110677795598733" LOG_CI_START="0.30648557174737434" LOG_EFFECT_SIZE="0.5087766756536238" MODIFIED="2014-12-26 13:09:10 +0000" MODIFIED_BY="[Empty name]" ORDER="520" O_E="0.0" SE="0.23765359158328989" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" VAR="0.05647922959243715" WEIGHT="24.45486025409406"><FOOTNOTE>final visit (between 8-20 weeks)</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="11.281825951131008" CI_START="0.7099886130866213" EFFECT_SIZE="2.830188679245283" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" LOG_CI_END="1.0523793954207126" LOG_CI_START="-0.1487486165109284" LOG_EFFECT_SIZE="0.4518153894548922" MODIFIED="2014-12-26 13:53:01 +0000" MODIFIED_BY="[Empty name]" ORDER="523" O_E="0.0" SE="0.7055485398881957" STUDY_ID="STD-Poewe-1998" TOTAL_1="53" TOTAL_2="20" VAR="0.4977987421383648" WEIGHT="2.7745985476155295"><FOOTNOTE>&gt;50% improvement (underestimate), week 4</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="5.140556054309161" CI_START="1.0509531473967686" EFFECT_SIZE="2.324324324324324" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.711010099200834" LOG_CI_START="0.0215833551523114" LOG_EFFECT_SIZE="0.3662967271765727" MODIFIED="2014-12-26 13:06:04 +0000" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.4049726821715248" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.16400287330519886" WEIGHT="8.421752857778504"><FOOTNOTE>&gt;50% improvement (underestimate), week 4</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="3.074524942463411" CI_START="1.3277007741294868" EFFECT_SIZE="2.020408163265306" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.48777802066259424" LOG_CI_START="0.12310020847547815" LOG_EFFECT_SIZE="0.3054391145690362" MODIFIED="2014-12-26 12:51:42 +0000" MODIFIED_BY="[Empty name]" ORDER="521" O_E="0.0" SE="0.21421355206299597" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" VAR="0.04588744588744588" WEIGHT="30.099554251282"><FOOTNOTE>week 4</FOOTNOTE></DICH_DATA></DICH_OUTCOME><DICH_OUTCOME CHI2="4.057392926784197" CI_END="3.374723300123443" CI_START="2.0843793529209766" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="2.652207301211322" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="0.5282381700097556" LOG_CI_START="0.3189767625580038" LOG_EFFECT_SIZE="0.42360746628387963" METHOD="MH" MODIFIED="2017-11-14 15:21:44 +0000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.6689096922164961" P_Q="0.3990931983116245" P_Z="2.1032124835215296E-15" Q="1.8371208762724844" RANDOM="YES" SCALE="30.4" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="284" TOTAL_2="284" WEIGHT="300.0" Z="7.935102679552575"><NAME>Any improvement by subjective participant assessment - doses subgroup analysis</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="8.433037870854212" CI_START="0.29563187435220595" DF="0" EFFECT_SIZE="1.5789473684210527" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.23.01" LOG_CI_END="0.9259840506491807" LOG_CI_START="-0.5292487431155137" LOG_EFFECT_SIZE="0.1983676537668335" MODIFIED="2017-11-13 15:09:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5931073595032175" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="0.5343385041164366"><NAME>Low 
dose</NAME><DICH_DATA CI_END="8.433037870854212" CI_START="0.29563187435220595" EFFECT_SIZE="1.5789473684210527" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9259840506491807" LOG_CI_START="-0.5292487431155137" LOG_EFFECT_SIZE="0.1983676537668335" MODIFIED="2014-12-26 13:43:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1120" O_E="0.0" SE="0.8548109465758875" STUDY_ID="STD-Poewe-1998" TOTAL_1="19" TOTAL_2="20" VAR="0.7307017543859649" WEIGHT="100.0"><FOOTNOTE>&gt;50% improvement (underestimate), week 4</FOOTNOTE></DICH_DATA></DICH_SUBGROUP><DICH_SUBGROUP CHI2="2.0127160205617707" CI_END="3.2521383536877226" CI_START="1.8249635902947012" DF="3" EFFECT_SIZE="2.436192538795127" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="38" I2="0.0" ID="CMP-001.23.02" LOG_CI_END="0.5121690132335327" LOG_CI_START="0.2612542043038167" LOG_EFFECT_SIZE="0.3867116087686747" MODIFIED="2017-11-13 15:10:03 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5697716821980241" P_Z="1.527641009315023E-9" STUDIES="4" TAU2="0.0" TOTAL_1="166" TOTAL_2="170" WEIGHT="99.99999999999999" Z="6.041419626232211"><NAME>Medium 
dose</NAME><DICH_DATA CI_END="5.117925663489517" CI_START="1.9540593535569841" EFFECT_SIZE="3.1623931623931623" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="15" LOG_CI_END="0.7090939735850151" LOG_CI_START="0.2909377510566515" LOG_EFFECT_SIZE="0.5000158623208333" MODIFIED="2014-12-26 13:43:59 +0000" MODIFIED_BY="[Empty name]" ORDER="1118" O_E="0.0" SE="0.24562703501984537" STUDY_ID="STD-Comella-2011" TOTAL_1="78" TOTAL_2="74" VAR="0.06033264033264034" WEIGHT="36.00604835133207"><FOOTNOTE>final visit (between 8-20 weeks)</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="11.955560443773642" CI_START="0.5227693029861222" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.077569939459181" LOG_CI_START="-0.2816899221151056" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2014-12-26 13:43:23 +0000" MODIFIED_BY="[Empty name]" ORDER="1121" O_E="0.0" SE="0.7984359711335656" STUDY_ID="STD-Poewe-1998" TOTAL_1="16" TOTAL_2="20" VAR="0.6375" WEIGHT="3.407592101930315"><FOOTNOTE>&gt;50% improvement (underestimate), week 4</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="5.140556054309161" CI_START="1.0509531473967686" EFFECT_SIZE="2.324324324324324" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.711010099200834" LOG_CI_START="0.0215833551523114" LOG_EFFECT_SIZE="0.3662967271765727" MODIFIED="2014-12-26 13:41:17 +0000" MODIFIED_BY="[Empty name]" ORDER="1123" O_E="0.0" SE="0.4049726821715248" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.16400287330519886" WEIGHT="13.245743328764672"><FOOTNOTE>&gt;50% improvement (underestimate), week 4</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="3.074524942463411" CI_START="1.3277007741294868" EFFECT_SIZE="2.020408163265306" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.48777802066259424" LOG_CI_START="0.12310020847547815" LOG_EFFECT_SIZE="0.3054391145690362" MODIFIED="2014-12-26 13:41:34 +0000" MODIFIED_BY="[Empty name]" ORDER="1124" O_E="0.0" SE="0.21421355206299597" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" VAR="0.04588744588744588" WEIGHT="47.34061621797293"><FOOTNOTE>week 4</FOOTNOTE></DICH_DATA></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.15740009203823832" CI_END="5.331714527046797" CI_START="2.157942789228551" DF="1" EFFECT_SIZE="3.3919809725093906" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="17" I2="0.0" ID="CMP-001.23.03" LOG_CI_END="0.7268668881823079" LOG_CI_START="0.3340399266065295" LOG_EFFECT_SIZE="0.5304534073944187" MODIFIED="2017-11-13 15:10:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6915617495249979" P_Z="1.201483644292173E-7" STUDIES="2" TAU2="0.0" TOTAL_1="99" TOTAL_2="94" WEIGHT="100.0" Z="5.293269941549343"><NAME>High 
dose</NAME><DICH_DATA CI_END="5.3012190020425844" CI_START="2.0404344961581535" EFFECT_SIZE="3.2888888888888888" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="15" LOG_CI_END="0.7243757460136345" LOG_CI_START="0.30972265722559295" LOG_EFFECT_SIZE="0.5170492016196137" MODIFIED="2014-12-26 13:44:02 +0000" MODIFIED_BY="[Empty name]" ORDER="1119" O_E="0.0" SE="0.2435692769199884" STUDY_ID="STD-Comella-2011" TOTAL_1="81" TOTAL_2="74" VAR="0.05932599265932599" WEIGHT="89.74965049075422"><FOOTNOTE>final visit (between 8-20 weeks)</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="18.251546372028297" CI_START="1.0822691961063635" EFFECT_SIZE="4.444444444444445" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2612996661836187" LOG_CI_START="0.03433529759365632" LOG_EFFECT_SIZE="0.6478174818886375" MODIFIED="2014-12-26 13:43:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1122" O_E="0.0" SE="0.7207249436813217" STUDY_ID="STD-Poewe-1998" TOTAL_1="18" TOTAL_2="20" VAR="0.5194444444444444" WEIGHT="10.250349509245783"><FOOTNOTE>&gt;50% improvement (underestimate), week 4</FOOTNOTE></DICH_DATA></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="3.2535469432255177" CI_END="2.895821791618138" CI_START="1.8268312101514752" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3000386144508043" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="61" I2="0.0" I2_Q="27.29571122829697" ID="CMP-001.24" LOG_CI_END="0.4617718319386943" LOG_CI_START="0.26169842262008486" LOG_EFFECT_SIZE="0.36173512727938956" METHOD="MH" MODIFIED="2017-11-14 15:21:21 +0000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.5163260238553239" P_Q="0.25272995398502085" P_Z="1.3677659143553047E-12" Q="2.7508693555618864" RANDOM="YES" SCALE="11.26" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="372" TOTAL_2="252" WEIGHT="300.0" Z="7.087276853283179"><NAME>Any improvement by subjective participant assessment - BtA formulation subgroup analysis</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="2.9426295027097975" CI_START="1.3392549603982693" DF="0" EFFECT_SIZE="1.9851778656126482" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="23" I2="0.0" ID="CMP-001.24.01" LOG_CI_END="0.46873558487983913" LOG_CI_START="0.12686326360909847" LOG_EFFECT_SIZE="0.2977994242444688" MODIFIED="2014-12-26 13:52:29 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="6.387912669182868E-4" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="82" WEIGHT="100.0" Z="3.414585562039049"><NAME>Botox</NAME><DICH_DATA CI_END="2.9426295027097975" CI_START="1.3392549603982693" EFFECT_SIZE="1.9851778656126482" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="23" LOG_CI_END="0.46873558487983913" LOG_CI_START="0.12686326360909847" LOG_EFFECT_SIZE="0.2977994242444688" MODIFIED="2014-12-26 13:52:29 +0000" MODIFIED_BY="[Empty name]" ORDER="630" O_E="0.0" SE="0.20081749380971634" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" VAR="0.04032766582001546" WEIGHT="100.0"><FOOTNOTE>Subjective Global Assessment Scale, week 4</FOOTNOTE></DICH_DATA></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.3057574918478645" CI_END="3.043373973742666" CI_START="1.485985727972953" DF="2" EFFECT_SIZE="2.126595939492487" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="23" I2="0.0" ID="CMP-001.24.02" LOG_CI_END="0.48335532230675116" LOG_CI_START="0.17201463829914776" LOG_EFFECT_SIZE="0.3276849803029494" MODIFIED="2014-12-26 13:53:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8582337954033159" P_Z="3.6959200303662345E-5" STUDIES="3" TAU2="0.0" TOTAL_1="125" TOTAL_2="96" WEIGHT="100.0" Z="4.125710468682683"><NAME>Dysport</NAME><DICH_DATA CI_END="11.281825951131008" CI_START="0.7099886130866213" EFFECT_SIZE="2.830188679245283" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" LOG_CI_END="1.0523793954207126" LOG_CI_START="-0.1487486165109284" LOG_EFFECT_SIZE="0.4518153894548922" MODIFIED="2014-12-26 13:52:49 +0000" MODIFIED_BY="[Empty name]" ORDER="523" O_E="0.0" SE="0.7055485398881957" STUDY_ID="STD-Poewe-1998" TOTAL_1="53" TOTAL_2="20" VAR="0.4977987421383648" WEIGHT="6.71882237111557"><FOOTNOTE>&gt;50% improvement (underestimate), week 4</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="5.140556054309161" CI_START="1.0509531473967686" EFFECT_SIZE="2.324324324324324" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.711010099200834" LOG_CI_START="0.0215833551523114" LOG_EFFECT_SIZE="0.3662967271765727" MODIFIED="2014-12-26 13:48:13 +0000" MODIFIED_BY="[Empty name]" ORDER="1123" O_E="0.0" SE="0.4049726821715248" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.16400287330519886" WEIGHT="20.39367516914359"><FOOTNOTE>&gt;50% improvement (underestimate), week 4</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="3.074524942463411" CI_START="1.3277007741294868" EFFECT_SIZE="2.020408163265306" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.48777802066259424" LOG_CI_START="0.12310020847547815" LOG_EFFECT_SIZE="0.3054391145690362" MODIFIED="2014-12-26 13:48:13 +0000" MODIFIED_BY="[Empty name]" ORDER="1124" O_E="0.0" SE="0.21421355206299597" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" VAR="0.04588744588744588" WEIGHT="72.88750245974084"><FOOTNOTE>week 4</FOOTNOTE></DICH_DATA></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.0" CI_END="5.14123883712675" CI_START="2.0252823212121203" DF="0" EFFECT_SIZE="3.2268343815513627" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="15" I2="0.0" ID="CMP-001.24.03" LOG_CI_END="0.7110677795598733" LOG_CI_START="0.30648557174737434" LOG_EFFECT_SIZE="0.5087766756536238" MODIFIED="2014-12-26 13:53:20 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="8.246127273881287E-7" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="74" WEIGHT="100.0" Z="4.929450387087996"><NAME>Xeomin</NAME><DICH_DATA CI_END="5.14123883712675" CI_START="2.0252823212121203" EFFECT_SIZE="3.2268343815513627" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="15" LOG_CI_END="0.7110677795598733" LOG_CI_START="0.30648557174737434" LOG_EFFECT_SIZE="0.5087766756536238" MODIFIED="2014-12-26 13:53:20 +0000" MODIFIED_BY="[Empty name]" ORDER="520" O_E="0.0" SE="0.23765359158328989" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" VAR="0.05647922959243715" WEIGHT="100.0"><FOOTNOTE>final visit (between 8-20 weeks)</FOOTNOTE></DICH_DATA></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="3.253546943225518" CI_END="2.895821791618138" CI_START="1.8268312101514752" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3000386144508043" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="61" I2="0.0" I2_Q="56.47461415782883" ID="CMP-001.25" LOG_CI_END="0.4617718319386943" LOG_CI_START="0.26169842262008486" LOG_EFFECT_SIZE="0.36173512727938956" METHOD="MH" MODIFIED="2017-11-14 15:21:07 +0000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.5163260238553239" P_Q="0.12958172782029664" P_Z="1.3677659143553047E-12" Q="2.2975097880260797" RANDOM="YES" SCALE="4.52" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="372" TOTAL_2="252" WEIGHT="200.0" Z="7.087276853283179"><NAME>Any improvement by subjective participant assessment - EMG guided vs non-EMG-guided subgroup analysis</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.4931474627267501" CI_END="4.433499773297555" CI_START="1.9852291485774614" DF="1" EFFECT_SIZE="2.966734396632411" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="22" I2="0.0" ID="CMP-001.25.01" LOG_CI_END="0.6467466905935566" LOG_CI_START="0.29781064319937983" LOG_EFFECT_SIZE="0.4722786668964683" MODIFIED="2016-10-22 16:53:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4825266909979651" P_Z="1.1233251828240787E-7" STUDIES="2" TAU2="0.0" TOTAL_1="196" TOTAL_2="117" WEIGHT="100.0" Z="5.305552032794158"><NAME>EMG-guided injection</NAME><DICH_DATA CI_END="5.14123883712675" CI_START="2.0252823212121203" EFFECT_SIZE="3.2268343815513627" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="15" LOG_CI_END="0.7110677795598733" LOG_CI_START="0.30648557174737434" LOG_EFFECT_SIZE="0.5087766756536238" MODIFIED="2014-12-26 13:58:23 +0000" MODIFIED_BY="[Empty name]" ORDER="520" O_E="0.0" SE="0.23765359158328989" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" VAR="0.05647922959243715" WEIGHT="74.3837577516852"><FOOTNOTE>final visit (between 8-20 weeks)</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="5.140556054309161" CI_START="1.0509531473967686" EFFECT_SIZE="2.324324324324324" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.711010099200834" LOG_CI_START="0.0215833551523114" LOG_EFFECT_SIZE="0.3662967271765727" MODIFIED="2014-12-26 13:55:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1123" O_E="0.0" SE="0.4049726821715248" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" VAR="0.16400287330519886" WEIGHT="25.616242248314805"><FOOTNOTE>&gt;50% improvement (underestimate), week 4</FOOTNOTE></DICH_DATA></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.24300292948246235" CI_END="2.689635962594184" CI_START="1.5328148153339844" DF="2" EFFECT_SIZE="2.030446712258031" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="39" I2="0.0" ID="CMP-001.25.02" LOG_CI_END="0.429693503000435" LOG_CI_START="0.18548968940324667" LOG_EFFECT_SIZE="0.3075915962018409" MODIFIED="2016-10-22 16:53:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8855897602150423" P_Z="7.916268427687326E-7" STUDIES="3" TAU2="0.0" TOTAL_1="176" TOTAL_2="135" WEIGHT="100.0" Z="4.937420440920884"><NAME>Non-EMG-guided injection</NAME><DICH_DATA CI_END="2.9426295027097975" CI_START="1.3392549603982693" EFFECT_SIZE="1.9851778656126482" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="23" LOG_CI_END="0.46873558487983913" LOG_CI_START="0.12686326360909847" LOG_EFFECT_SIZE="0.2977994242444688" MODIFIED="2014-12-26 13:55:07 +0000" MODIFIED_BY="[Empty name]" ORDER="630" O_E="0.0" SE="0.20081749380971634" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" VAR="0.04032766582001546" WEIGHT="51.024293732841706"><FOOTNOTE>Subjective Global Assessment Scale, week 4</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="11.281825951131008" CI_START="0.7099886130866213" EFFECT_SIZE="2.830188679245283" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" LOG_CI_END="1.0523793954207126" LOG_CI_START="-0.1487486165109284" LOG_EFFECT_SIZE="0.4518153894548922" MODIFIED="2014-12-26 13:58:13 +0000" MODIFIED_BY="[Empty name]" ORDER="523" O_E="0.0" SE="0.7055485398881957" STUDY_ID="STD-Poewe-1998" TOTAL_1="53" TOTAL_2="20" VAR="0.4977987421383648" WEIGHT="4.133579481380865"><FOOTNOTE>&gt;50% improvement (underestimate), week 4</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="3.074524942463411" CI_START="1.3277007741294868" EFFECT_SIZE="2.020408163265306" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.48777802066259424" LOG_CI_START="0.12310020847547815" LOG_EFFECT_SIZE="0.3054391145690362" MODIFIED="2014-12-26 13:58:19 +0000" MODIFIED_BY="[Empty name]" ORDER="1124" O_E="0.0" SE="0.21421355206299597" STUDY_ID="STD-Wissel-2001" TOTAL_1="35" TOTAL_2="33" VAR="0.04588744588744588" WEIGHT="44.84212678577743"><FOOTNOTE>week 4</FOOTNOTE></DICH_DATA></DICH_SUBGROUP></DICH_OUTCOME><IV_OUTCOME CHI2="3.265810274080318" CI_END="0.6510210487603025" CI_START="0.34761951884360387" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.4993202838019532" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="-0.1864049696304719" LOG_CI_START="-0.4588958458940384" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.3016207913165472" MODIFIED="2016-10-23 08:41:59 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.6590801006754822" P_Q="1.0" P_Z="1.1097856863382429E-10" Q="0.0" RANDOM="YES" SCALE="1.53" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="367" TOTAL_2="287" WEIGHT="100.00000000000001" Z="6.451185485260032"><NAME>Cervical dystonia-specific pain</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE><IV_DATA CI_END="0.6056184392129844" CI_START="3.8156078701556684E-4" EFFECT_SIZE="0.303" ESTIMABLE="YES" ESTIMATE="0.303" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 16:05:06 +0000" MODIFIED_BY="[Empty name]" ORDER="299" SE="0.1544" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" WEIGHT="25.129553227835203"><FOOTNOTE>pain intensity scale, week 4, pooled SD from p-value</FOOTNOTE></IV_DATA><IV_DATA CI_END="0.8297748497892277" CI_START="0.26922515021077226" EFFECT_SIZE="0.5495" ESTIMABLE="YES" ESTIMATE="0.5495" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 16:05:06 +0000" MODIFIED_BY="[Empty name]" ORDER="300" SE="0.143" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" WEIGHT="29.295929680547978"><FOOTNOTE>TWSTRS pain, week 4, combined groups method</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.3831098436402953" CI_START="0.27769015635970473" EFFECT_SIZE="0.8304" ESTIMABLE="YES" ESTIMATE="0.8304" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-28 20:36:01 +0000" MODIFIED_BY="[Empty name]" ORDER="297" SE="0.282" STUDY_ID="STD-Greene-1990" TOTAL_1="28" TOTAL_2="27" WEIGHT="7.53322853525383"><FOOTNOTE>% of difference from baseline, week 6, pooled SD from p-value</FOOTNOTE></IV_DATA><IV_DATA CI_END="0.9122958100844083" CI_START="0.020904189915591675" EFFECT_SIZE="0.4666" ESTIMABLE="YES" ESTIMATE="0.4666" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-07 20:59:03 +0000" MODIFIED_BY="[Empty name]" ORDER="298" SE="0.2274" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" WEIGHT="11.585064037688204"><FOOTNOTE>TWSTRS pain, week 4, SD appropriated from Truong 2010</FOOTNOTE></IV_DATA><IV_DATA CI_END="0.9088171786718863" CI_START="0.16638282132811366" EFFECT_SIZE="0.5376" ESTIMABLE="YES" ESTIMATE="0.5376" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 16:05:06 +0000" MODIFIED_BY="[Empty name]" ORDER="296" SE="0.1894" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" WEIGHT="16.70011301284681"><FOOTNOTE>TWSTRS pain, week 4</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.0576790753690255" CI_START="0.08632092463097452" EFFECT_SIZE="0.572" ESTIMABLE="YES" ESTIMATE="0.572" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 16:05:06 +0000" MODIFIED_BY="[Empty name]" ORDER="301" SE="0.2478" STUDY_ID="STD-Wissel-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.75611150582797"><FOOTNOTE>Pain scale, week 4, pooled SD from p-value</FOOTNOTE></IV_DATA></IV_OUTCOME><IV_OUTCOME CHI2="0.5749059371981755" CI_END="2.8332250697035466" CI_START="1.381934536370152" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="2.1075798030368493" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.4522810759845135" LOG_CI_START="0.14048747055873806" LOG_DATA="NO" LOG_EFFECT_SIZE="0.32378402807133533" MODIFIED="2017-11-13 15:07:39 +0000" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.7501718726078753" P_Q="1.0" P_Z="1.2514729544058852E-8" Q="0.0" RANDOM="YES" SCALE="5.11" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="251" TOTAL_2="178" WEIGHT="100.0" Z="5.692561776736003"><NAME>Cervical dystonia-specific pain - TWSTRS pain subscale subgroup analysis</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE><IV_DATA CI_END="3.223850053496309" CI_START="1.270549946503691" EFFECT_SIZE="2.2472" ESTIMABLE="YES" ESTIMATE="2.2472" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-07 19:58:59 +0000" MODIFIED_BY="[Empty name]" ORDER="300" SE="0.4983" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" WEIGHT="55.204029220861834"><FOOTNOTE>TWSTRS pain, week 4, combined groups method</FOOTNOTE></IV_DATA><IV_DATA CI_END="3.1025083905484054" CI_START="0.09749160945159452" EFFECT_SIZE="1.6" ESTIMABLE="YES" ESTIMATE="1.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-08 13:47:12 +0000" MODIFIED_BY="[Empty name]" ORDER="298" SE="0.7666" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" WEIGHT="23.32463850493365"><FOOTNOTE>TWSTRS pain, week 4, SD appropriated from Truong 2010</FOOTNOTE></IV_DATA><IV_DATA CI_END="3.8660112236475035" CI_START="0.7339887763524964" EFFECT_SIZE="2.3" ESTIMABLE="YES" ESTIMATE="2.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-07 19:56:25 +0000" MODIFIED_BY="[Empty name]" ORDER="296" SE="0.799" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" WEIGHT="21.47133227420452"><FOOTNOTE>TWSTRS pain, week 4</FOOTNOTE></IV_DATA></IV_OUTCOME><IV_OUTCOME CHI2="3.2658102740803177" CI_END="0.6510210487603025" CI_START="0.3476195188436039" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.49932028380195326" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="-0.1864049696304719" LOG_CI_START="-0.45889584589403837" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.3016207913165471" MODIFIED="2016-10-23 08:42:40 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.6590801006754823" P_Q="0.9885441851928665" P_Z="1.109785686338235E-10" Q="0.023043877744826566" RANDOM="YES" SCALE="1.53" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="367" TOTAL_2="287" WEIGHT="99.99999999999999" Z="6.451185485260033"><NAME>Cervical dystonia-specific pain - BtA formulation subgroup analysis</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="2.6909995959883664" CI_END="1.0202878290933386" CI_START="0.007528856534268602" DF="1" EFFECT_SIZE="0.5139083428138036" ESTIMABLE="YES" I2="62.839087694745125" ID="CMP-001.28.01" LOG_CI_END="0.008722706029891863" LOG_CI_START="-2.123270978456244" LOG_EFFECT_SIZE="-0.2891143318992046" MODIFIED="2014-12-26 16:21:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10091655250754028" P_Z="0.0466896417687672" STUDIES="2" TAU2="0.08739370000000003" TOTAL_1="116" TOTAL_2="109" WEIGHT="32.66278176308903" Z="1.9891047535715027"><NAME>Botox</NAME><IV_DATA CI_END="0.6056184392129844" CI_START="3.8156078701556684E-4" EFFECT_SIZE="0.303" ESTIMABLE="YES" ESTIMATE="0.303" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 16:08:01 +0000" MODIFIED_BY="[Empty name]" ORDER="299" SE="0.1544" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" WEIGHT="25.129553227835203"><FOOTNOTE>pain intensity scale, week 4, pooled SD from p-value</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.3831098436402953" CI_START="0.27769015635970473" EFFECT_SIZE="0.8304" ESTIMABLE="YES" ESTIMATE="0.8304" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 16:08:01 +0000" MODIFIED_BY="[Empty name]" ORDER="297" SE="0.282" STUDY_ID="STD-Greene-1990" TOTAL_1="28" TOTAL_2="27" WEIGHT="7.53322853525383"><FOOTNOTE>% of difference from baseline, week 6, pooled SD from p-value</FOOTNOTE></IV_DATA></IV_SUBGROUP><IV_SUBGROUP CHI2="0.1063520657285208" CI_END="0.7707575300955711" CI_START="0.27884242693249134" DF="2" EFFECT_SIZE="0.5247999785140313" ESTIMABLE="YES" I2="0.0" ID="CMP-001.28.02" LOG_CI_END="-0.11308222363943037" LOG_CI_START="-0.554641145994338" LOG_EFFECT_SIZE="-0.2800061914129561" MODIFIED="2015-01-07 21:03:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.948213084515161" P_Z="2.8898400384069063E-5" STUDIES="3" TAU2="0.0" TOTAL_1="92" TOTAL_2="104" WEIGHT="38.041288556362986" Z="4.181977948474972"><NAME>Dysport</NAME><IV_DATA CI_END="0.9122958100844083" CI_START="0.020904189915591675" EFFECT_SIZE="0.4666" ESTIMABLE="YES" ESTIMATE="0.4666" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-07 21:03:17 +0000" MODIFIED_BY="[Empty name]" ORDER="298" SE="0.2274" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" WEIGHT="11.585064037688204"><FOOTNOTE>TWSTRS pain, week 4, SD appropriated from Truong 2010</FOOTNOTE></IV_DATA><IV_DATA CI_END="0.9088171786718863" CI_START="0.16638282132811366" EFFECT_SIZE="0.5376" ESTIMABLE="YES" ESTIMATE="0.5376" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 16:21:48 +0000" MODIFIED_BY="[Empty name]" ORDER="296" SE="0.1894" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" WEIGHT="16.70011301284681"><FOOTNOTE>TWSTRS pain, week 4</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.0576790753690255" CI_START="0.08632092463097452" EFFECT_SIZE="0.572" ESTIMABLE="YES" ESTIMATE="0.572" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 16:21:48 +0000" MODIFIED_BY="[Empty name]" ORDER="301" SE="0.2478" STUDY_ID="STD-Wissel-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.75611150582797"><FOOTNOTE>Pain scale, week 4, pooled SD from p-value</FOOTNOTE></IV_DATA></IV_SUBGROUP><IV_SUBGROUP CHI2="0.0" CI_END="0.8297748497892277" CI_START="0.26922515021077226" DF="0" EFFECT_SIZE="0.5495" ESTIMABLE="YES" I2="0.0" ID="CMP-001.28.03" LOG_CI_END="-0.08103973263464964" LOG_CI_START="-0.5698843720574108" LOG_EFFECT_SIZE="-0.26003230324049065" MODIFIED="2014-12-26 16:21:44 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.217093379875221E-4" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="74" WEIGHT="29.295929680547978" Z="3.842657342657343"><NAME>Xeomin</NAME><IV_DATA CI_END="0.8297748497892277" CI_START="0.26922515021077226" EFFECT_SIZE="0.5495" ESTIMABLE="YES" ESTIMATE="0.5495" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 16:21:44 +0000" MODIFIED_BY="[Empty name]" ORDER="300" SE="0.143" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" WEIGHT="29.295929680547978"><FOOTNOTE>TWSTRS pain, week 4, combined groups method</FOOTNOTE></IV_DATA></IV_SUBGROUP></IV_OUTCOME><IV_OUTCOME CHI2="3.2658102740803177" CI_END="0.6510210487603025" CI_START="0.3476195188436039" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.49932028380195326" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="-0.1864049696304719" LOG_CI_START="-0.45889584589403837" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.3016207913165471" MODIFIED="2016-10-23 08:42:47 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.6590801006754823" P_Q="0.8656420543777824" P_Z="1.109785686338235E-10" Q="0.02862748063010516" RANDOM="YES" SCALE="1.24" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="367" TOTAL_2="287" WEIGHT="100.0" Z="6.451185485260033"><NAME>Cervical dystonia-specific pain - EMG-guided vs non-EMG-guided subgroup analysis</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2><EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE><IV_SUBGROUP CHI2="0.09789859001327048" CI_END="0.7292856556796649" CI_START="0.32945345947869276" DF="2" EFFECT_SIZE="0.5293695575791788" ESTIMABLE="YES" I2="0.0" ID="CMP-001.29.01" LOG_CI_END="-0.1371023284916205" LOG_CI_START="-0.4822059277139004" LOG_EFFECT_SIZE="-0.2762410372611912" MODIFIED="2016-10-22 16:56:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9522294135086732" P_Z="2.1040303585771414E-7" STUDIES="3" TAU2="0.0" TOTAL_1="251" TOTAL_2="178" WEIGHT="57.58110673108299" Z="5.18990355066644"><NAME>EMG-guided injection</NAME><IV_DATA CI_END="0.8297748497892277" CI_START="0.26922515021077226" EFFECT_SIZE="0.5495" ESTIMABLE="YES" ESTIMATE="0.5495" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 16:08:18 +0000" MODIFIED_BY="[Empty name]" ORDER="300" SE="0.143" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" WEIGHT="29.295929680547978"><FOOTNOTE>TWSTRS pain, week 4, combined groups method</FOOTNOTE></IV_DATA><IV_DATA CI_END="0.9122958100844083" CI_START="0.020904189915591675" EFFECT_SIZE="0.4666" ESTIMABLE="YES" ESTIMATE="0.4666" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-07 21:03:55 +0000" MODIFIED_BY="[Empty name]" ORDER="298" SE="0.2274" STUDY_ID="STD-Truong-2005" TOTAL_1="37" TOTAL_2="43" WEIGHT="11.585064037688204"><FOOTNOTE>TWSTRS pain, week 4, SD appropriated from Truong 2010</FOOTNOTE></IV_DATA><IV_DATA CI_END="0.9088171786718863" CI_START="0.16638282132811366" EFFECT_SIZE="0.5376" ESTIMABLE="YES" ESTIMATE="0.5376" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 16:08:18 +0000" MODIFIED_BY="[Empty name]" ORDER="296" SE="0.1894" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" WEIGHT="16.70011301284681"><FOOTNOTE>TWSTRS pain, week 4</FOOTNOTE></IV_DATA></IV_SUBGROUP><IV_SUBGROUP CHI2="2.96330996599344" CI_END="0.7998096703241555" CI_START="0.19644471248016376" DF="2" EFFECT_SIZE="0.49812719140215966" ESTIMABLE="YES" I2="32.507904237095005" ID="CMP-001.29.02" LOG_CI_END="-0.09701334921096226" LOG_CI_START="-0.7067596561959867" LOG_EFFECT_SIZE="-0.3026597506715622" MODIFIED="2016-10-22 16:56:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2272613233247689" P_Z="0.0012112331316656024" STUDIES="3" TAU2="0.024095616752247095" TOTAL_1="116" TOTAL_2="109" WEIGHT="42.418893268917" Z="3.2362216007936"><NAME>Non-EMG-guided injection</NAME><IV_DATA CI_END="0.6056184392129844" CI_START="3.8156078701556684E-4" EFFECT_SIZE="0.303" ESTIMABLE="YES" ESTIMATE="0.303" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 16:24:52 +0000" MODIFIED_BY="[Empty name]" ORDER="299" SE="0.1544" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" WEIGHT="25.129553227835203"><FOOTNOTE>pain intensity scale, week 4, pooled SD from p-value</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.3831098436402953" CI_START="0.27769015635970473" EFFECT_SIZE="0.8304" ESTIMABLE="YES" ESTIMATE="0.8304" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 16:24:51 +0000" MODIFIED_BY="[Empty name]" ORDER="297" SE="0.282" STUDY_ID="STD-Greene-1990" TOTAL_1="28" TOTAL_2="27" WEIGHT="7.53322853525383"><FOOTNOTE>% of difference from baseline, week 6, pooled SD from p-value</FOOTNOTE></IV_DATA><IV_DATA CI_END="1.0576790753690255" CI_START="0.08632092463097452" EFFECT_SIZE="0.572" ESTIMABLE="YES" ESTIMATE="0.572" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-26 16:24:51 +0000" MODIFIED_BY="[Empty name]" ORDER="301" SE="0.2478" STUDY_ID="STD-Wissel-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.75611150582797"><FOOTNOTE>Pain scale, week 4, pooled SD from p-value</FOOTNOTE></IV_DATA></IV_SUBGROUP></IV_OUTCOME><DICH_OUTCOME CHI2="2.768251518701618" CI_END="0.6209044029980427" CI_START="0.232254859927517" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.379747370164283" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-001.30" LOG_CI_END="-0.20697526044557127" LOG_CI_START="-0.6340351896373545" LOG_EFFECT_SIZE="-0.42050522504146287" METHOD="IV" MODIFIED="2017-11-14 16:55:51 +0000" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.428753070175102" P_Q="1.0" P_Z="1.1349696094955727E-4" Q="0.0" RANDOM="YES" SCALE="410.36" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="330" TOTAL_2="244" WEIGHT="100.00000000000001" Z="3.859763185705296"><NAME>Tolerability - withdrawals</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours BtA</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2><DICH_DATA CI_END="0.8157554543983425" CI_START="0.2235966338044772" EFFECT_SIZE="0.4270833333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.08844001370045167" LOG_CI_START="-0.6505347389392142" LOG_EFFECT_SIZE="-0.3694873763198329" MODIFIED="2017-11-14 16:55:51 +0000" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="0.3301772240190133" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" VAR="0.10901699926090169" WEIGHT="57.72429370569753"><FOOTNOTE>BtA: 8 due to therapeutic failure, 3 due to other reasons; Placebo: 19 due to therapeutic failure, 5 due to other reasons</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="2.251322250964856" CI_START="0.0962125060985684" EFFECT_SIZE="0.46540880503144655" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.35243766372513047" LOG_CI_START="-1.0167684729040811" LOG_EFFECT_SIZE="-0.3321654045894753" MODIFIED="2014-12-26 17:05:10 +0000" MODIFIED_BY="[Empty name]" ORDER="360" O_E="0.0" SE="0.8042784623356841" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" VAR="0.6468638449770525" WEIGHT="9.72836762035037"><FOOTNOTE>BtA: 3 adverse events (1 pain, muscle and neck weakness, 1 nausea and dizziness, 1 muscle weakness); Placebo: 3 due to therapeutic failure</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="68.15071061090849" CI_START="0.12310967582579363" EFFECT_SIZE="2.896551724137931" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.833470388604843" LOG_CI_START="-0.9097078122789919" LOG_EFFECT_SIZE="0.46188128816292556" MODIFIED="2014-12-26 17:05:28 +0000" MODIFIED_BY="[Empty name]" ORDER="353" O_E="0.0" SE="1.6113564541502576" STUDY_ID="STD-Greene-1990" TOTAL_1="28" TOTAL_2="27" VAR="2.5964696223316914" WEIGHT="2.4236483377760063"><FOOTNOTE>BtA: 1 dysphagia</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="0.5905527629058265" CI_START="0.09843735187717928" EFFECT_SIZE="0.24110671936758893" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="23" LOG_CI_END="-0.22874129429912765" LOG_CI_START="-1.0068400780309743" LOG_EFFECT_SIZE="-0.6177906861650508" MODIFIED="2014-12-26 17:06:01 +0000" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="0.45705907721518474" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" VAR="0.20890300006479623" WEIGHT="30.12369033617611"><FOOTNOTE>BtA: 5 due to therapeutic failure; Placebo: 23 due to therapeutic failure</FOOTNOTE></DICH_DATA></DICH_OUTCOME><DICH_OUTCOME CHI2="1.688327139892973" CI_END="0.5333708466504016" CI_START="0.1697160563094371" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3008680718253961" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-001.31" LOG_CI_END="-0.2729707259631166" LOG_CI_START="-0.7702770684853706" LOG_EFFECT_SIZE="-0.5216238972242435" METHOD="IV" MODIFIED="2016-10-22 18:15:00 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.42991708467273293" P_Q="1.0" P_Z="3.929151666729207E-5" Q="0.0" RANDOM="YES" SCALE="410.36" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="302" TOTAL_2="217" WEIGHT="99.99999999999999" Z="4.111606728559633"><NAME>Tolerability - withdrawals due lack of efficacy subgroup analysis</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours BtA</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2><DICH_DATA CI_END="0.8468025157522618" CI_START="0.18178288554829727" EFFECT_SIZE="0.3923444976076555" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.07221786041207036" LOG_CI_START="-0.7404470070426042" LOG_EFFECT_SIZE="-0.4063324337273373" MODIFIED="2014-12-26 17:12:52 +0000" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="0.3925211085183987" STUDY_ID="STD-Charles-2012" TOTAL_1="88" TOTAL_2="82" VAR="0.15407282063251254" WEIGHT="55.385638534309685"><FOOTNOTE>BtA: 8 due to therapeutic failure; Placebo: 19 due to therapeutic failure</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="1.2800127001833603" CI_START="0.003503258647810391" EFFECT_SIZE="0.06696428571428571" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.10721427870426656" LOG_CI_START="-2.45552779726123" LOG_EFFECT_SIZE="-1.1741567592784816" MODIFIED="2014-12-26 17:16:06 +0000" MODIFIED_BY="[Empty name]" ORDER="360" O_E="0.0" SE="1.5053673812000021" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" VAR="2.2661309523809523" WEIGHT="3.7656347893523425"><FOOTNOTE>Placebo: 3 due to therapeutic failure</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="0.5905527629058265" CI_START="0.09843735187717928" EFFECT_SIZE="0.24110671936758893" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="23" LOG_CI_END="-0.22874129429912765" LOG_CI_START="-1.0068400780309743" LOG_EFFECT_SIZE="-0.6177906861650508" MODIFIED="2014-12-26 17:12:52 +0000" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="0.45705907721518474" STUDY_ID="STD-Truong-2010" TOTAL_1="55" TOTAL_2="61" VAR="0.20890300006479623" WEIGHT="40.84872667633796"><FOOTNOTE>BtA: 5 due to therapeutic failure; Placebo: 23 due to therapeutic failure</FOOTNOTE></DICH_DATA></DICH_OUTCOME><DICH_OUTCOME CHI2="0.0031980742220756335" CI_END="26.738497419968937" CI_START="0.35847825198432826" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.095992541302052" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.32" LOG_CI_END="1.4271369982681026" LOG_CI_START="-0.44553718680147214" LOG_EFFECT_SIZE="0.4907999057333153" METHOD="IV" MODIFIED="2016-10-22 18:14:47 +0100" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.9549024862182589" P_Q="1.0" P_Z="0.3042535758739583" Q="0.0" RANDOM="YES" SCALE="205.21" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="187" TOTAL_2="101" WEIGHT="100.0" Z="1.027354514226096"><NAME>Tolerability - withdrawals due to adverse events subgroup analysis</NAME><GROUP_LABEL_1>BtA</GROUP_LABEL_1><GROUP_LABEL_2>Placebo</GROUP_LABEL_2><GRAPH_LABEL_1>Favours BtA</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2><DICH_DATA CI_END="62.72062230898465" CI_START="0.17165967374270924" EFFECT_SIZE="3.28125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.79741035873278" LOG_CI_START="-0.7653317172327162" LOG_EFFECT_SIZE="0.5160393207500321" MODIFIED="2014-12-26 17:26:09 +0000" MODIFIED_BY="[Empty name]" ORDER="360" O_E="0.0" SE="1.5053673812000021" STUDY_ID="STD-Comella-2011" TOTAL_1="159" TOTAL_2="74" VAR="2.2661309523809523" WEIGHT="53.39672840566656"><FOOTNOTE>BtA: 3 adverse events (1 pain, muscle and neck weakness, 1 nausea and dizziness, 1 muscle weakness)</FOOTNOTE></DICH_DATA><DICH_DATA CI_END="68.15071061090849" CI_START="0.12310967582579363" EFFECT_SIZE="2.896551724137931" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.833470388604843" LOG_CI_START="-0.9097078122789919" LOG_EFFECT_SIZE="0.46188128816292556" MODIFIED="2014-12-26 17:25:27 +0000" MODIFIED_BY="[Empty name]" ORDER="353" O_E="0.0" SE="1.6113564541502576" STUDY_ID="STD-Greene-1990" TOTAL_1="28" TOTAL_2="27" VAR="2.5964696223316914" WEIGHT="46.60327159433345"><FOOTNOTE>BtA: 1 dysphagia</FOOTNOTE></DICH_DATA></DICH_OUTCOME></COMPARISON></ANALYSES_AND_DATA><FIGURES MODIFIED="2017-11-14 17:46:33 +0000" MODIFIED_BY="[Empty name]"><FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-11-14 15:20:23 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Study flow diagram</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-11-14 17:46:33 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT"><CAPTION><P>Risk of bias of included studies: review authors' judgements about each risk of bias item presented as percentages across all included studies</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-11-14 17:46:33 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT"><CAPTION><P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study</P></CAPTION><FILE>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</FILE></FIGURE></FIGURES><FEEDBACK/><APPENDICES MODIFIED="2016-10-15 09:15:57 +0100" MODIFIED_BY="[Empty name]"><APPENDIX ID="APP-01" MODIFIED="2016-10-15 09:15:57 +0100" MODIFIED_BY="[Empty name]" NO="1"><TITLE MODIFIED="2015-04-09 21:27:28 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE><APPENDIX_BODY MODIFIED="2016-10-15 09:15:57 +0100" MODIFIED_BY="[Empty name]"><P>#1 MeSH descriptor: [Botulinum Toxins] explode all trees</P><P>#2 Botulinum Toxins, Type A</P><P>#3 (botul* near/2 tox*):ti,ab</P><P>#4 (botox or dysport or xeomin or myobloc or rimabotulinum* or abobotuli* or onabotulinum* or oculinum or purtox or CNBTX or Neuronox):ti,ab</P><P>#5 {or #1-#4}</P><P>#6 MeSH descriptor: [Dystonic Disorders] explode all trees</P><P>#7 MeSH descriptor: [Dystonia] explode all trees</P><P>#8 MeSH descriptor: [Torticollis] explode all trees</P><P>#9 MeSH descriptor: [Blepharospasm] explode all trees</P><P>#10 MeSH descriptor: [Meige Syndrome] explode all trees</P><P>#11 MeSH descriptor: [Hemifacial Spasm] explode all trees</P><P>#12 (cervic* near/2 dysto*):ti,ab</P><P>#13 blepharosp*:ti,ab</P><P>#14 (hem* near/2 spasm*):ti,ab</P><P>#15 (meige and (dysto* or syndrom*)):ti,ab</P><P>#16 (crani* near/2 dysto*):ti,ab</P><P>#17 (foca* near/2 dysto*):ti,ab</P><P>#18 (write* and (cramp* or dysto*)):ti,ab</P><P>#19 torticol*:ti,ab</P><P>#20 {or #6-#19}</P><P>#21 #5 and #20</P><P>#22 MeSH descriptor: [Animals] explode all trees</P><P>#23 MeSH descriptor: [Humans] explode all trees</P><P>#24 #22 not #23</P><P>#25 #21 not #24 in Trials</P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-02" MODIFIED="2016-10-15 09:15:26 +0100" MODIFIED_BY="[Empty name]" NO="2"><TITLE MODIFIED="2015-04-09 21:26:52 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE><APPENDIX_BODY MODIFIED="2016-10-15 09:15:26 +0100" MODIFIED_BY="[Empty name]"><P>#1 randomized controlled trial.pt.</P><P>#2 controlled clinical trial.pt.</P><P>#3 randomized.ab.</P><P>#4 placebo.ab.</P><P>#5 clinical trials as topic.sh.</P><P>#6 randomly.ab.</P><P>#7 trial.ti.</P><P>#8 1 or 2 or 3 or 4 or 5 or 6 or 7</P><P>#9 exp botulinum toxins/</P><P>#10 exp botulinum toxins, type A/</P><P>#11 (botul$ adj2 tox$).ti,ab.</P><P>#12 (botox or dysport or xeomin or myobloc or rimabotulinum$ or abobotuli$ or onabotulinum$ or oculinum or purtox or CNBTX or Neuronox).ti,ab.</P><P>#13 9 or 10 or 11 or 12</P><P>#14 (cervic$ adj2 dysto$).ti,ab.</P><P>#15 blepharosp$.ti,ab.</P><P>#16 (hem$ adj2 spasm$).ti,ab.</P><P>#17 (meige and (dysto$ or syndrom$)).ti,ab.</P><P>#18 (crani$ adj2 dysto$).ti,ab.</P><P>#19 (foca$ adj2 dysto$).ti,ab.</P><P>#20 (write$ and (cramp$ or dysto$)).ti,ab.</P><P>#21 torticol$.ti,ab.</P><P>#22 exp dystonic disorders/</P><P>#23 exp dystonia/</P><P>#24 exp torticollis/</P><P>#25 exp blepharospasm/</P><P>#26 exp meige syndrome/</P><P>#27 exp hemifacial spasm/</P><P>#28 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27</P><P>#29 8 and 3 and 28</P><P>#30 exp animals/ not humans/</P><P>#31 29 not 30</P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-03" MODIFIED="2016-10-15 09:13:46 +0100" MODIFIED_BY="[Empty name]" NO="3"><TITLE MODIFIED="2016-10-15 09:13:46 +0100" MODIFIED_BY="[Empty name]">Embase search strategy</TITLE><APPENDIX_BODY MODIFIED="2016-10-15 09:13:37 +0100" MODIFIED_BY="[Empty name]"><P>#1 random$.tw.</P><P>#2 clinical trial:.mp.</P><P>#3 placebo$.mp.</P><P>#4 double-blind$.tw.</P><P>#5 1 or 2 or 3 or 4</P><P>#6 exp Hemifacial Spasm/</P><P>#7 exp Meige Syndrome/</P><P>#8 exp blepharospasm/</P><P>#9 exp torticollis/</P><P>#10 exp Dystonia/</P><P>#11 exp Dystonic Disorders/</P><P>#12 (cervic$ adj2 dysto$).ti,ab.</P><P>#13 blepharosp$.ti,ab.</P><P>#14 (hem$ adj2 spasm$).ti,ab.</P><P>#15 (meige and (dysto$ or syndrom$)).ti,ab.</P><P>#16 (crani$ adj2 dysto$).ti,ab.</P><P>#17 (foca$ adj2 dysto$).ti,ab.</P><P>#18 (write$ and (cramp$ or dysto$)).ti,ab.</P><P>#19 torticol$.ti,ab.</P><P>#20 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18</P><P>#21 exp Botulinum Toxins, Type A/</P><P>#22 exp Botulinum Toxins/</P><P>#23 (botul$ adj2 tox$).ti,ab.</P><P>#24 (botox or dysport or xeomin or myobloc or rimabotulinum$ or abobotuli$ or onabotulinum$ or oculinum or purtox or CNBTX or Neuronox).ti,ab.</P><P>#25 21 or 22 or 23 or 24</P><P>#26 19 and 20 and 25</P><P>#27 limit 26 to human</P></APPENDIX_BODY></APPENDIX></APPENDICES><EXTENSIONS><EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART"><ALIAS ALIAS_ID="1"><FLOWCHARTBOX TEXT="&lt;p&gt;8 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120"><FLOWCHARTBOX TEXT="&lt;p&gt;8 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="148"><FLOWCHARTBOX TEXT="&lt;p&gt;23 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120"><FLOWCHARTBOX TEXT="&lt;p&gt;1599 records screened&lt;/p&gt;" WIDTH="120"><FLOWCHARTBOX TEXT="&lt;p&gt;1599 records after duplicates removed&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;1646 records identified in total&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;208 records identified through CENTRAL database search&lt;/p&gt;&lt;p&gt;182 records identified through MEDLINE database search&lt;/p&gt;&lt;p&gt;1256 records identified through Embase database search&lt;/p&gt;" WIDTH="207"/><FLOWCHARTBOX TEXT="&lt;p&gt;0 additional studies identified through other sources&lt;/p&gt;"/></FLOWCHARTBOX></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;1576 records excluded&lt;/p&gt;" WIDTH="120"/></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;15 full-text articles excluded:&lt;/p&gt;&lt;p&gt;-Cross-over design: 9&lt;/p&gt;&lt;p&gt;-Not randomised: 2&lt;/p&gt;&lt;p&gt;-Wrong population: 2&lt;/p&gt;&lt;p&gt;-Wrong outcomes: 2&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="170"/></FLOWCHARTBOX></FLOWCHARTBOX></FLOWCHARTBOX></ALIAS></EXTENSION></EXTENSIONS></COCHRANE_REVIEW>